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ABSTRACT 
 
The Na+-K+ pump is a highly conserved glycoprotein complex present in all eukaryotic cells. 
Utilizing the energy from adenosine triphosphate (ATP) hydrolysis, it extrudes 3 Na+ ions in 
exchange for the uptake of 2 K+ ions against their electrochemical gradients with each 
catalytic cycle and maintains ionic electrochemical gradients which are essential for the 
maintenance of cellular homeostasis and multiple cellular functions. These include the 
generation of action potentials in cardiac myocytes. Thus, regulation of Na+-K+ pump has 
important implications in the pathophysiology of cardiac myocytes. The pump is regulated 
by multiple receptor-coupled signalling pathways. Our Laboratory has previously shown that 
angiotensin II (Ang II) and forskolin induces oxidative inhibition of the Na+-K+ pump. We 
have also previously demonstrated that stimulation of soluble guanylyl cyclase (sGC) results 
in increased Na+-K+ pump activity as measured by the pump current (Ip). With the heart 
failure phenotype characterised by elevated intracellular Na+, increased Ang II levels and 
increased reactive oxygen species (ROS), the oxidative inhibition of the pump, which is the 
only export route for elevated intracellular Na+, is deleterious. Modulation of the redox-
dependent regulation of the Na+-K+ pump is thus a potential therapeutic strategy in heart 
failure. We examined if the stimulation of soluble guanylyl cyclase (sGC) is able to modulate 
oxidative signalling to the Na+-K+ pump and the mechanisms by which this may occur.  
Rabbit cardiac myocytes were voltage clamped to identify the electrogenic Na+-K+ pump 
current normalised for membrane capacitance and hence cell size (Ip), measured by the shift 
in membrane current induced by 100 μM ouabain. Stimulation of sGC with 3-(5’-
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hydroxymethyl-2’-furyl)-1-benzylindazole (YC-1) attenuated the Ang II-induced inhibition of 
the Na+-K+ pump. 
Since we have previously shown that Ang II induced inhibition of the Na+-K+ pump is via 
protein kinase C (PKC)-dependent activation of nicotinamide adenine dinucleotide 
phosphate hydrogen (NADPH) oxidase, we studied if the effects of sGC occur via attenuation 
of NADPH oxidase activity. Stimulation of sGC decreased Ang II-induced O2
-sensitive 
fluorescence, serine phosphorylation of p47phox  (necessary for NADPH oxidase activation) 
and the co-localisation of p47phox with the Na+-K+ pump (α1 subunit).  
We have previously demonstrated that the oxidative modification, glutathionylation, of the 
β1 subunit of the pump is causally related to receptor-coupled inhibition of Na
+-K+ pump. 
Consistent with the effects on Ang II-induced pump inhibition and NADPH oxidase activity, 
stimulation of sGC decreased both baseline and Ang II-induced glutathionylation of the β1 
subunit, while increasing the α1/β1 subunits’ interaction, necessary for Na
+-K+ pump 
function, as evident by increased co-immunoprecipitation. 
The role of protein phosphatase 2A (PP2A) in the effects of sGC modulation of oxidative 
inhibition of the pump was demonstrated by the okadaic acid-sensitive nature of the effects 
of YC-1 on Ang II-induced pump inhibition, Ang II-induced O2
-sensitive fluorescence and 
Ang II-induced glutathionylation of the β1 subunit of the Na
+-K+ pump. Further, the effects of 
YC-1 on both Ang II-induced O2
-sensitive fluorescence and the functional correlate of Ang 
II-induced decrease in Ip were paralleled by the effect of a PP2A activator C6 ceramide.  
We also used forskolin, an adenylyl cyclase activator, in place of Ang II as the oxidant 
stimulant in a separate set of experiments. Forskolin-induced NADPH oxidase activity as 
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assessed by O2
-sensitive fluorescence and the downstream inhibitory functional effects on 
Na+-K+ pump activity as assessed by Ip, were similarly attenuated by sGC. 
We conclude that stimulation of sGC attenuates receptor-coupled oxidative inhibition of the 
cardiac Na+-K+ pump by attenuation of NADPH oxidase activation, cellular O2
 levels and 
glutathionylation of the β1 subunit of the pump. This allows for increased α1/β1 subunit 
interaction and hence Na+-K+ pump activity. The signalling pathway from sGC is via PP2A 
which attenuated NADPH oxidase activity. These results have important therapeutic 
implications in cardiovascular diseases associated with increased oxidative stress, such as 
heart failure, where sGC may act as a brake to, or potentially reverse, the oxidant signal and 
its consequences. The demonstration of a phosphatase-dependent step in the regulation of 
the Na+-K+ pump that is upstream from the pump also contributes to our understanding of 
the mechanisms of pump regulation, shifting it from the traditional paradigm of direct 
phosphorylation/dephosphorylation of the pump to a more biologically plausible paradigm 
of oxidative modification.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background 
The Na+-K+ pump is a highly conserved glycoprotein complex active in the cell membrane of 
eukaryotic cells. It is responsible for the coupled extrusion and uptake of Na+ and K+ ions by 
cells. This membrane pump utilizes the energy released by hydrolysis of adenosine-5'-
triphosphate (ATP) to transport 3 Na+ ions out and 2 K+ ions into the cell against the 
electrochemical gradient of each ion. (Albers 1967; Post, Hegyvary et al. 1972). The Na+-K+ 
pump is primarily a sodium pump as the K+ can be substituted with other monovalent metal 
and inorganic cations (Ratheal, Virgin et al. 2010). It was the first of the P-type ATPases that 
was discovered. The transmembrane gradients of Na+ and K+ it maintains are crucial for 
many essential cellular processes including the osmotic regulation of cell volume, secondary 
active co- and counter-transporters for other ions and organic compounds. In excitable cells, 
such as cardiac myocytes, the Na+ and K+ transmembrane ion gradients are critical for the 
generation of action potentials (Fuller, Tulloch et al. 2012). 
Na+-K+ pump activity maintains a low intracellular Na+ concentration and high intracellular 
K+ concentration, while maintaining the converse in the extracellular space. Disruption of 
sodium homeostasis is increasingly recognised in various pathological states. Cardiac 
myocytes obtained from failing hearts from animals (Despa and Bers 2003) and humans 
have been found to have elevated intracellular sodium (Pieske, Maier et al. 2002; Pieske and 
Houser 2003). Raised intracellular Na+ has adverse effects which contribute to the 
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electromechanical phenotype of heart failure because the associated increase in Ca2+ causes 
diastolic Ca2+ release from the sarcoplasmic reticulum and hence a reduced amount of 
stored Ca2+ available for release in systole (Bers, Barry et al. 2003; Pieske and Houser 2003). 
A decrease in Na+-K+ pump activity measured as electrogenic pump current (Ip) precedes a 
reduction in sarcoplasmic Ca2+ content and systolic cytoplasmic Ca2+ transients in myocytes 
from guinea pigs with heart failure (Ke H-Y 2012). Raised intracellular Na+ in failing myocytes 
resulting from enhanced Na+ influx (Despa, Islam et al. 2002)  and the reduced Na+-K+ pump 
activity (Fry, Garcia et al. 2012; Ke H-Y 2012) is now also thought to contribute to the heart 
failure phenotype by reducing mitochondrial Ca2+ uptake which in turn increases production 
of reactive oxygen species (Kohlhaas, Liu et al. 2010). Since the Na+-K+ pump effectively is 
the only export route for the excess of intracellular Na+, Na+-K+ pump activity is a logical 
therapeutic target. As recently reviewed by our Laboratory, many evidence-based 
efficacious therapies for heart failure, which were developed based on their inhibition of the 
renin-angiotensin-aldosterone system and effects to block the beta adrenergic system, 
actually result in stimulation of the Na+-K+ pump with an increase in the measured 
electrogenic pump current ( Ip) (Galougahi, Liu et al. 2012).  
Na+-K+ pump activity is determined by membrane voltages, transmembrane ionic 
concentrations and regulation by hormones via receptors and incompletely understood 
cellular messengers that include protein kinases and protein phosphatases. While these 
have previously been thought to directly phosphorylate and dephosphorylate the pump 
subunits, this idea has serious flaws, including non-integer phosphate: pump molecule 
ratios, poor access for kinases to putative phosphorylation sites (Sweadner and Feschenko 
2001; Galougahi, Liu et al. 2012) and the need to denature isolated Na+-K+ ATPase before 
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phosphorylation can occur (Cornelius and Mahmmoud 2003). A new paradigm for pump 
regulation that invokes oxidative signalling has recently been developed by our Laboratory. 
According to this, angiotensin II (Ang II) and forskolin-induced activation of adenylyl cyclase, 
physiologically coupled to β1 adreno-receptors (AR), result in pump inhibition via activation 
of nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase and the downstream 
oxidative modification of glutathionylation of the β1 subunit of the Na
+-K+ pump (White, 
Figtree et al. 2009; Rasmussen, Hamilton et al. 2010). 
Nitric oxide (NO) donors and other activators and stimulators of soluble guanylyl cyclase 
(sGC) are being increasingly studied as therapeutic compounds in cardiovascular disease, 
particularly pulmonary hypertension, arterial hypertension, atherosclerosis and thrombosis 
and protection against ischaemia and reperfusion injury (Stasch, Pacher et al. 2011). Our 
Laboratory has previously demonstrated that the nitric oxide donor, sodium nitroprusside, 
and sGC stimulator, 3-(5’-hydroxymethyl-2’-furyl)-l-benzylindazol (YC-1), increases Na+-K+ 
pump activity via cyclic guanosine 3’,5’ monophosphate (cGMP), cGMP-dependent protein 
kinases, that are also referred to as protein kinase G (PKG), and protein phosphatases, as 
demonstrated by increased Ip (William, Vien et al. 2005). 
Understanding the physiology and pharmacology of Na+–K+ pump regulation is of particular 
importance for heart failure. NO donors are not widely used in heart failure but are 
nevertheless of proven benefit (Cohn, Archibald et al. 1986). Agonists of sGC may show 
benefits in heart failure by preventing the progression of and even reversing adverse left 
ventricular hypertrophy, fibrosis and remodelling (Masuyama, Tsuruda et al. 2006; Jones, 
Kemp-Harper et al. 2009; Masuyama, Tsuruda et al. 2009; Irvine, Ganthavee et al. 2012). 
The heart failure phenotype is characterised by an increase in Ang II levels and downstream 
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activation of protein kinase C (PKC) and production of reactive oxidant species (ROS). It is 
conceivable that the NO signalling pathway and the Ang II signalling pathway interact and 
that activation of sGC may be able to counterbalance and reduce inhibitory effects of Ang II-
dependent pathways on Na+-K+ pump activity. While it is theoretically possible that the 
pathways interact at the level of phosphorylation and dephosphorylation of the Na+–K+ 
pump, the biological plausibility of this is in doubt as detailed above. Instead, they may 
interact at the level of activation of NADPH oxidase and hence the downstream 
consequences of such activation: oxidative modification of the Na+-K+ pump. Understanding 
the role of sGC stimulation in oxidant signalling to the Na+-K+ pump is the focus of this 
thesis.  
1.2 The Na+-K+ pump 
1.2.1 The Role of the Na+-K+ pump 
The Na+-K+ pump is a heterodimeric membrane protein which is the first member of the P-
type ATPases to have been identified by Jens Christian Skou (Skou 1957) for which he was 
subsequently awarded the Nobel Prize in Chemistry 40 years later. It is present in the 
plasma membrane of all eukaryotic cells. With the hydrolysis of an ATP molecule and 
phosphorylation of a highly conserved aspartic acid residue (thus defining it as a P-type 
ATPase) (Lutsenko and Kaplan 1995), it pumps 3 Na+ ions out of and 2 K+ ions into the cell. 
The non-integer exchange ratio makes it electrogenic, generating a net outward pump 
current, Ip, from the cell. In addition, it maintains a steep electrochemical gradient across the 
cell membranes (Thomas 1972; Glynn 1984). These ionic gradients are necessary for co-
transport and counter-transport of ions including H+, Ca2 and Cl-,(Aronson 1985; Eisner and 
Lederer 1985) as well as organic molecules like amino acids and glucose (Glitsch 2001). The 
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range of mammalian cell surface translocators that are influenced by the transmembrane 
Na+ gradient is detailed in Table 1.1 (Fuller, Tulloch et al. 2012). In this manner, the Na+-K+ 
pump plays a critical role in cellular homeostasis of ions and organic solutes. As a 
consequence of this, it is also important for regulation of cell volume. 
Translocator Stoichiometry Charge flux 
 Na channel N/A −ve 
 Na/Ca exchanger 3:1 −1 
 Na/H exchanger 1:1 Neutral 
 Na/Mg exchanger 2:1 Neutral 
 Na/K/Cl co-transporter 1 + 1 + 2 Neutral 
 Na/HCO3 co-transporter 1 + 2 +1 
 Na/I co-transporter 2 + 1 −1 
 Na/glucose co-transporter 2 + 1 −2 
 Na/mannose co-transporter 1 + 1 −1 
 Na/Cl/creatine co-transporter 2 + 1 + 1 −1 
 Na/succinate co-transporter 3 + 1 −1 
 Na/Cl/taurine co-transporter 3 + 1 + 1 −2 
 Na/glutamate/K exchanger 3 + 1:1 −1 
 Na/Cl/glycine co-transporter 3 or 2 + 1 + 1 −2 or −1 
 Na/alanine co-transporter 1 + 1 −1 
 Na/Cl/GABA co-transporter 2 + 1 + 1 −1 
 Na/Cl/proline co-transporter 3 + 1 + 1 −1 
 Na/arginine co-transporter 1 + 1 −2 
 Na/glutamine/H exchanger 2 + 1:1 −1 
 Na/ascorbate co-transporter 2 + 1 −1 
 Na/citrate co-transporter 3 + 1 −1 
 Na/monocarboxylate co-transporter 2 + 1 −2 
 Na/Pi co-transporter 3 + 1 −1 
 Na/sulphate co-transporter 3 + 1 −1 
 Na/bile acid co-transporter 2 + 1 −1 
 Na/nucleoside co-transporters 1 + 1 Neutral 
 Na/inositol co-transporter 1 + 1 −1 
 Na/Cl/dopamine co-transporter 2 + 1 + 1 −2 
 Na/Cl/noradrenaline co-transporter 1 + 1 + 1 −1 
 Na/Cl/serotonin/K exchanger 2 + 1 + 1:1 −1 
 Na/carnitine co-transporter 1 + 1 −1 
Table 1.1 Mammalian cell surface translocators whose activity relies on the 
transmembrane Na gradient. 
By convention, inward positive charge movement results in a negative charge flux. 
Modified from (Fuller, Tulloch et al. 2012) 
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In addition to the critical role the Na+-K+ pump has in homeostatic control of the 
intracellular milieu, it has also been implicated in cell signalling as a receptor for signal 
transduction. On binding of cardiac glycosides to the Na + K + pump, the pump interacts with 
multiple proteins and hence is able to form large signal complexes. The interactions 
between the Na+-K+ pump and target proteins results in signal transduction that can be 
independent of Na+-K+ pump activity and intracellular ion concentrations (Xie 2003; Schoner 
and Scheiner-Bobis 2007; Prassas and Diamandis 2008). The Na+-K+ pump has an additional 
role as a cell adhesion molecule at cell-cell junctions by interacting with pump molecules of 
adjacent cells (Rajasekaran, Barwe et al. 2007; Vagin, Dada et al. 2012).  
Role in excitable cells 
Due to its role in intracellular sodium, and consequently calcium, homeostasis, the Na+-K+ 
pump plays an important role in the re-establishment of a hyperpolarised transmembrane 
potential following excitation-induced depolarization in excitable tissues like neurones, 
skeletal muscle cells and cardiac muscle. These pump generated transmembrane Na+ 
gradients are necessary for the generation and restoration of a resting potential as well as 
the propagation of action potentials necessary for cardiac contractile function. 
In cardiac myocytes, Ca2+enters the cell upon electrical depolarization via voltage-gated 
calcium channels. This rise in intracellular calcium triggers a further increase via calcium-
induced-calcium release from the sarcoplasmic reticulum which triggers contraction of the 
myofibril. Relaxation is dependent on a decrease in intracellular calcium largely via re-
uptake into the sarcoplasmic reticulum and efflux out of the cell through the Na+/Ca+ 
exchanger. Via this exchanger, 3 Na+ ions are transported, using the energy of the Na+ 
gradient, from the extracellular to intracellular compartment in exchange for a Ca2+ion that 
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is extruded from the cell. This transient rise in intracellular Na+ is restored to its resting, 
baseline state by the Na+-K+ pump that helps to maintain the steep transmembrane Na+ 
gradient. Dysregulation of the Na+-K+ pump and subsequent rise in intracellular Na+ would 
interfere with myocardial relaxation and contractile force via its alteration of calcium 
homeostasis, with a rise in diastolic intracellular calcium (Bers, Barry et al. 2003).  
The Na+-K+ pump in heart failure 
Elevated intracellular sodium levels are part of the pathophysiology of congestive heart 
failure (Pieske, Houser et al. 2003; Pogwizd 2003). Excitation-contraction coupling in cardiac 
myocytes is regulated by Ca2+levels which are intricately linked to Na+ levels via the Na+/Ca2+ 
exchanger.  Due to the stoichiometry of the exchanger, a small rise in intracellular Na+ levels 
can lead to a large increase in intracellular Ca2+ levels and hence increased myocardial 
contractility under physiological conditions. However, larger increases in Na+ levels and 
hence concomitant rises in Ca2+ can lead to Ca2+ induced Ca2+ release from the sarcoplasmic 
reticulum during diastole. As a result, there is less available Ca2+ stored in the sarcoplasmic 
reticulum for release during systole when triggered by channel-mediated Ca2+influx. This 
helps to account for the negative slope in the relationship between intracellular Na+ and 
myocardial contractility in heart failure (Bers, Barry et al. 2003), opposite of the 
characteristic for normal myocardium. In addition, disruption of calcium homeostasis, 
including via the reversal of the Na+-Ca2+ exchanger (Pogwizd 2003; Sipido, Varro et al. 2006) 
is potentially arrhythmogenic via triggering of delayed afterdepolarisations, further 
contributing to the heart failure phenotype. It is unclear if the elevation in intracellular Na+ 
seen in the heart failure phenotype is largely generated by increased influx such as via the 
late sodium current or by decreased efflux. However, with the Na+-K+ pump being effectively 
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the only export route for elevated intracellular Na+; it is likely to play a role both in 
pathogenesis as well as treatment of heart failure.  
1.2.2 Structure of the Na+-K+ pump 
The Na +-K+ pump is a oligomeric membrane protein composed of the two essential 
polypeptide units: a larger α subunit and β subunit present in 1:1 stoichiometry. There is 
also an accompanying FXYD protein, the first of which was identified as the γ subunit in 
renal Na+-K+ ATPase, which is not necessary to form the active enzyme in purified isolates.  
The α subunit is the catalytic unit responsible for ATP hydrolysis and ion transport, 
possessing the binding sites for ATP, Na+ and K+. It consists of 10 transmembrane spanning 
domains with both the amino (N)- and carboxyl (C)-terminus located on the cytosolic side. 
ATP binding and ion occlusion has been shown to occur at this subunit, the process of which 
is explained in greater detail in Section 1.2.3. It has a molecular weight of 110-116kDa 
(Kaplan 2002) depending on the tissue specific and cell-region specific (James, Grupp et al. 
1999) isoform. The transmembrane spanning domains are α helices numbered from the N 
terminus as M1 to M10 (see Figure1.1). 
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Figure 1.1  Tertiary structure of the Na+-K+ pump derived from renal tissue. 
The α-, β- and γ-subunits are coloured blue, wheat and red, respectively. Figure 
from (Morth, Pedersen et al. 2007) 
 
Four isoforms have been identified in humans. α1  is found in most tissues, α2/α3 is found in 
brain, heart and skeletal muscle while the α4 isoform is highly expressed in the testis and 
spermatozoa (Woo, James et al. 1999) though can be found in skeletal muscle too.  
There are 3 isoforms of the β subunit. It is a type II glycoprotein with a molecular mass of 
around 60 kDa, crossing the membrane only once, with the N terminus located on the 
cytosolic side of the membrane. It is close to the M7/M10 transmembrane domain of the α 
subunit. It functions as a molecular chaperone, assisting in the correct assembly and 
integration of the α subunit to the cellular membrane (Geering 2001). It also plays a role in 
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influencing the α subunit’s apparent sodium affinity as well as the processes relevant to cell 
polarity such as cell adhesion, motility, transition and transformation (Geering 2008). 
The FXYD proteins are small type I proteins which are adjacent to the M9 transmembrane 
domain of the α subunit, possessing an invariant FXYD signature sequence (Sweadner and 
Rael 2000). It was first identified in the kidney (Therien and Blostein 2000). While not 
required for isolated functioning Na+-K+ pump units, this family of proteins have been firmly 
established  to modulate Na+-K+ pump activity (Geering 2008) There are 7 members of the 
family with different tissue expression (see Table 1.2) with FXYD1, or phospholemman, 
being found in the heart. There is evidence that the FXYD proteins can stabilise the Na+-K+ 
pump, influence the enzyme’s binding affinity for Na+ ,K+ and ATP (Cornelius and 
Mahmmoud 2003; Geering 2005) and mediate reversal of oxidative inhibition of the Na+-K+ 
pump (Bibert, Liu et al. 2011).  
FXYD Protein Alternate Nomenclature Tissue Expression 
FXYD 1  Phospholemman Heart Skeletal Muscle 
FXYD 2 γ Subunit Kidney 
FXYD 3 Mat-8 Stomach, Colon 
FXYD 4 CHIF Kidney, Colon 
FXYD 5 RIC Intestine, Lung, Kidney 
FXYD 6 - Brain 
FXYD 7 - Brain 
Table 1.2 Tissue expression of FXYD proteins 
 
The first tertiary crystal structure of the Na+-K+ pump, depicted in Fig 1.1, was published in 
2007 (Morth, Pedersen et al. 2007) with higher resolution structures with different ion and 
phosphate bindings subsequently published(Ogawa, Shinoda et al. 2009; Shinoda, Ogawa et 
al. 2009; Yatime, Laursen et al. 2011). This has allowed for further insights into relationships 
between structure, function and regulation.  
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1.2.3 The catalytic cycle of the Na+-K+ pump  
The reaction cycle of the Na+-K+ pump is described by the Post-Albers Scheme (Albers, 1967; 
Post, 1972). This scheme is shown in simplified form in Figure 1.2. The pump molecule can 
exist in two principal alternating conformations, E1 and E2, which have different binding 
affinities for Na+ and K+  and their ion binding sites face intracellularly or extracellularly 
respectively, hence leading to the exchange of Na+ for K+ ions. The different intermediary 
forms have different binding affinity for ATP and ADP with resultant autophosphorylation 
and dephosphorylation of the catalytic aspartate during the reaction cycle with “occluded” 
states where the binding sites are inaccessible from either side of the membrane (Gadsby, 
2009). The E1 form has cation binding sites that face intracellularly and have a high affinity 
for Na+ and ATP which bind to the enzyme with phosphorylation of the aspartate residue 
utilizing magnesium as a co-factor. While phosphorylated, the cation gate is closed, 
occluding the 3 Na+ ions in the E1P(3Na) conformation. The enzyme progresses to the 
E2P(3Na) conformation where the affinity for Na
+ is reduced while the affinity for K+  
increased with the 3 Na+ ions released to the extracellular space and 2 K+ ions bind to the 
outer surface. The K+ ions dephosphorylate the enzyme which occludes the K+ ions to 
produce the E2(2K). ATP binds with low affinity to this conformation of the enzyme to 
catalyse the release of K+ into the cytoplasm with the enzyme returning from the E2 to the E1 
form and the cycle restarts.  
Like all P-Type ATPases, the Na +-K + pump hydrolyses ATP and occludes ions during the 
translocation of the transmembrane cation binding segments with the ionophore accessible 
only from either side of the membrane at any given time. Each step of the pump cycle is 
reversible with rates determined by forward and backward rate constants.  
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Figure 1.2 Post-Albers Scheme of the reaction cycle of the Na
+
-K
+
 pump. 
Na+-K+ ATPase binds ATP then Na+ in the E1 conformational state and is 
phosphorylated by ATP. This leads to the occlusion of three Na+ ions in the 
E1P(3Na) state and then to their sequential release to the extracellular side. This 
new conformational state (E2P) binds K+ with high affinity. Binding of K+ leads to 
dephosphorylation of the enzyme and to the occlusion of two K+ cations resulting 
in the E2(2K) state. K
+ ions are then released to the cytosol after ATP binds to the 
enzyme with low affinity. Adapted from (Kaplan 2002; Scheiner-Bobis 2002) 
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1.3 Determinants of the Na+-K+ pump activity 
1.3.1 Voltage dependence of the Na+-K+ pump 
Whole cell voltage-clamp techniques allows for assessment of pump activity by 
measurement of the outward electrogenic pump current, Ip, after minimizing the effects of 
passive ion currents. Gadsby et al (Gadsby, Kimura et al. 1985) were the first to study the 
voltage dependence of Ip. The Ip-V curve is sigmoid with the pump rate being less voltage 
dependent at positive membrane potentials. The voltage dependent steps in the pump 
cycling are largely those that result in charge translocation across the membrane field within 
the widely accepted external access channel or “ion-well” hypothesis. According to this 
hypothesis, charge translocation is a simple consequence of the location of Na+ and K+ 
binding sites within the membrane field. The channel can be a wide pore that allows a 
variety of ions to enter with low resistance. This is a “low field, high conductance” channel 
which would have a small voltage drop across the channel and hence low voltage 
dependence. In contrast, a channel may be narrow and highly selective in the ions it 
transports and would hence be considered to have low conductance and is known as a “high 
field, narrow access” channel. Such a channel would have a high voltage drop across the 
channel resulting in changes in and hence greater voltage dependence (Lauger 1991). The 
reverse rate coefficient for rebinding/ reocclusion step should be strongly voltage 
dependent whereas the rate coefficient for the forward rate coefficient for release/ 
deocclusion is relatively voltage independent. E1 to E2 conformational change may also be 
V-dependent.  
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1.3.2 Ligand concentrations 
The Na+-K+ pump can be considered an enzyme that in a single cycle, concomitantly 
catalyses 1) the hydrolysis of one ATP, 2) the translocation of 3 intracellular Na+ ions from 
the cytosol to the extracellular space and 3) the translocation of 2 K+ ions from the 
extracellular space to the cytosol. Thus the substrate or ligand concentrations will have an 
influence on the pump activity.  
Based on Michaelis-Menten enzyme kinetics, the Km (substrate concentration that leads to 
half maximal velocity) of the Na+-K+ pump for intracellular ATP has been estimated between 
0.21mM down to 95μM depending on the species. The physiological intracellular ATP levels, 
even with metabolic inhibition, are generally high enough to saturate the Na+-K+ pump and 
not limit its activity. In contrast, the Km of the Na+-K+ pump for intracellular Na+, depending 
on the species and tissue, is around 10-40mM which is close to the steady state intracellular 
Na+ concentration. Hence, small changes in intracellular Na+ concentrations can have large 
effects on Na+-K+ pump activity.(Therien and Blostein 2000; Fuller, Tulloch et al. 2012).  
Activation of the pump by extracellular potassium occurs at low milliomolar range. It 
competes with sodium for the same extracellular binding site and hence the K0.5 value for 
K+-dependent activation of the pump is lower in sodium-free rather than sodium containing 
superfusate. Of greater significance is the competition of intracellular K+ for the intracellular 
Na+ binding sites that can influence pump activity (Cornelius 1992).  
There is also an interplay between the effects of membrane voltage and ligand 
concentrations on Na+-K+ pump activity. There is some evidence that activation of the pump 
by intracellular sodium is voltage dependent and increases with depolarization although this 
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was obtained in cell-free Na+-K+ pump systems (Goldschlegger R 1987; Stürmer, Bühler et al. 
1991; Heyse S 1994; Hansen, Buhagiar et al. 2002). The activation of the pump by 
extracellular potassium is also influenced by membrane voltage. Extracellular potassium 
binding to the pump occurs at the bottom of a “high-field, narrow-access channel” and 
potassium ions have to migrate through this channel within the electrical field of the cell 
membrane to reach their binding sites. Depolarisation of the cell membrane decreases the 
concentration of potassium ions at the local binding site for the same extracellular 
potassium concentration while the converse occurs with hyperpolarisation of the cell 
membrane (Glitsch 2001).  
1.3.3 Hormonal regulation of the Na+-K+ pump 
The Na+-K+ pump is subject to regulation by various hormones via short term as well as long 
term effects. Short term regulation is via effects on pump kinetics or translocation of various 
pump components to the cellular membrane from intracellular stores. Longer term 
regulation is via effects on the synthesis and degradation of the pump subunits. Of the 
hormones known to affect Na+-K+ pump activity, the best understood are catecholamines, 
peptide hormones and steroid hormones, of which the most widely studied are 
corticosteroids and mineralocorticoids (Therien and Blostein 2000).  
Studies looking at the effects of catecholamines and AR blockers on Na+-K+ pump activity 
have reported both stimulation as well as inhibitory effects (Therien and Blostein 2000; 
Glitsch 2001; Fuller, Tulloch et al. 2012). These effects have appeared to be dependent on 
the adrenergic agent used and the downstream activation of different protein kinases. 
These differences have been attributed to the tissue-specificity of the effects of 
catecholamines on the Na+-K+ pump.  These varying results have also been attributed to 
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different intracellular calcium between experimental designs. (Gao, Mathias et al. 1996; 
Fuller, Tulloch et al. 2012) 
Importantly, the divergent results on the functional consequence of AR activation rests on 
the differing results of the downstream effects of activation of protein kinase A (PKA) and 
protein kinase C (PKC). There are 3 different  β ARs expressed in human cardiac myocytes, 
with the β1 AR the most abundant followed by β2 AR and β3 AR. The binding of 
catecholamines to the β1 AR and β2 AR which are coupled to stimulatory G proteins (Gs) 
activates adenylate cyclase leading to increased synthesis of cyclic adenosine 3’,5’-
monophosphate (cAMP). cAMP then activates PKA. The different reported downstream 
signalling pathways from PKA help account for the differences in reported effects of 
adrenergic stimulation on the Na+-K+ pump. PKA mediated pump stimulation has been 
attributed to phosphorylation of the Na+-K+ pump or the accompanying FXYD protein 
(Poulsen, Morth et al. 2010). The difficulties with this paradigm and the alternative 
signalling pathway from PKA to oxidative modification of the NAK Pump will be discussed 
further in section 1.3.4.  
Different catecholamines also have different relative effects on the different ARs. 
Stimulation of the β1 and β2 ARs has been shown to inhibit the pump in rabbit cardiac 
myocytes (White, Liu et al. 2010). In contrast, stimulation of the β3 AR in rabbit cardiac 
myocytes results in increased NO synthesis and pump stimulation (Bundgaard, Liu et al. 
2010). Depending on the concentration of catecholamine used, different adrenergic 
receptors may be have different relative stimulation with different downstream effects on 
the Na+-K+ pump with the final effect being a balance between the inhibitory and 
stimulatory pathways. 
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Steroid hormones exert their long-term effect on the sodium pump by influencing the 
intranuclear synthesis of mRNA of the pump subunits. This long-term increased expression 
of the Na+-K+ ATPase has been demonstrated by increased ouabain binding in various tissues 
including the kidney, heart and skeletal muscle (Dørup and Clausen 1997; Ramñrez-Gil, 
Trouvé et al. 1998; Therien and Blostein 2000). While the effects of steroids are primarily via 
their long term effects on enzyme expression, they may also have effects in the short term 
which may contrast with their long term effects. Acute short term exposure of isolated 
rabbit ventricular myocytes to aldosterone has been shown to result in pump stimulation 
indirectly via Na+ influx (Mihailidou, Buhagiar et al. 1998). In contrast, Na+-K+ ATPase was 
found to be inhibited in ventricular myocytes isolated from rabbits that had been subjected 
to longer term exposure of 7 days of aldosterone (Mihailidou, Bundgaard et al. 2000). 
Insulin is the best studied peptide hormone influencing the Na+-K+ pump and has the well-
known effect of stimulating the pump (Ewart and Klip 1995; Sweeney G 1998).The 
mechanisms of short term stimulation of the Na+-K+ pump include increased translocation of 
the sodium pump to the cellular membrane, increased cytoplasmic sodium concentration 
and increased apparent affinity of Na+ to the enzyme (Therien and Blostein 2000). In rabbit 
cardiac myocytes, insulin has been found to stimulate the pump and also flatten the Ip-V 
curve. It is likely that it facilitates the voltage-dependent binding of intracellular sodium to 
the Na+ binding site within a relatively shallow internal access channel of the sodium pump 
via activation of the insulin receptor tyrosine kinase, phosphatidyl inositol 3-kinase and 
protein phosphatase (Hansen, Buhagiar et al. 2000). 
Other peptide hormones known to regulate Na+-K+ pump activity include the parathyroid 
hormone which has been shown to down-regulate sodium pump activity (Derrickson and 
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Mandel 1997). Ang II, another peptide hormone, which is elevated in heart failure, inhibits 
the sodium pump via activation of PKC and subsequently NADPH oxidase which lead to 
downstream oxidative modifications of the pump (White, Figtree et al. 2009).  
1.3.4 Protein Kinases and Phosphorylation in pump regulation 
PKA and PKC have been implicated in Na+-K+ pump regulation with divergent effects on Na+-
K+ pump activity reported (Fuller, Tulloch et al. 2012). Most studies in non-cardiac cells have 
shown PKA to mediate inhibition of the Na+-K+ pump potentially by lowering Na+ affinity or 
the Vmax (maximum velocity of the enzyme) of the Na
+-K+ ATPase (Poulsen, Morth et al. 
2010). With respect to cardiac myocytes, results have been more conflicting, with most 
studies reporting stimulation of the pump by PKA dependent effects on the FXYD1 protein 
(Fuller, Tulloch et al. 2012), while our Laboratory has reported that PKA mediates Na+-K+ 
pump inhibition (White, Liu et al. 2010).  
With respect to PKC, similar to PKA, most studies in non-cardiac tissue have shown that PKC 
mediates a reduction in pump activity (Fuller, Tulloch et al. 2012). However, some groups 
have reported PKC mediated pump stimulation in cardiac myocytes (Gao, Mathias et al. 
1999; Han, Bossuyt et al. 2006) while others have reported pump inhibition (Buhagiar, 
Hansen et al. 2001; White, Figtree et al. 2009). 
The site of phosphorylation mediating the effects of PKA and PKC on the pump is still in 
question. Phosphorylation of amino acid residues on the α subunit of the α/β Na+-K+ pump 
heterodimer by PKA and PKC is widely implicated in mediating pump regulation. The 
phosphorylation target within a consensus recognition motif for PKA has been identified as 
Ser 943 on the α1 subunit of the Na
+-K+ pump. Its localisation close to the cytosolic 
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membrane interface makes it poorly accessible to protein kinases (Feschenko and Sweadner 
1994). The phosphorylation of this putative site does not always change activity. Further, 
the initial demonstration of phosphorylation of this residue occurred at low stoichiometry 
and required the denaturation of the peptide which was consequently of uncertain 
physiological relevance (Cornelius and Mahmmoud 2003). There are now studies that have 
demonstrated PKA-dependent phosphorylation of Na+-K+ pump derived from cells, although 
from cell lines not cell isolates (Poulsen, 2010).  
The PKC consensus recognition motif is a serine or threonine flanked by at least one basic 
residue not more than 2 residues away. There is no obvious conserved PKC site on the Na+-
K+ pump across the species with such a site present only in rats (Poulsen, Morth et al. 2010). 
Thus, while it has been reported, the regulatory role of PKC-dependent phosphorylation of 
the α subunit of Na+-K+ pump is uncertain.  
Phosphorylation of FXYD proteins by kinases has also been implicated as an alternative 
explanation for the role of kinases in pump regulation (Geering 2006). These proteins, 
abundantly expressed in a tissue-dependent manner, are named after a shared amino acid 
motif in their extracellular N-termini (Sweadner and Rael 2000). Their close association with 
the α/β pump heterodimer in the 3D structure (Morth, Pedersen et al. 2007; Shinoda, 
Ogawa et al. 2009) makes their role in regulation plausible with some evidence of their 
modulation of the Na+-K+ pump’s apparent affinities for sodium, potassium and ATP 
(Geering 2008). FXYD1, also known as phospholemman, has been shown to undergo PKA- 
and PKC-dependent phosphorylation with resultant stimulation of the pump (Fuller, Tulloch 
et al. 2012). However, only FXYD1, of the 7-member mammalian family, has functional 
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phosphorylation sites (Geering 2006), leaving kinase-mediated Na+-K+ pump regulation 
unaccounted for in tissues expressing FXYD2-7. 
Evidence for an alternative mechanism for pump regulation involving phosphorylation by 
protein kinases has been found (White, Figtree et al. 2009; White, Liu et al. 2010). This is via 
oxidative signalling as a result of phosphorylation, and hence activation, of subunits of 
NADPH oxidase by PKC. PKA is able to activate this PKC-dependent signalling pathway via 
phospholipase C. These changes in NADPH oxidase activity influence oxidative modification 
via glutathionylation of the β1 subunit of the Na
+-K+ pump (Rasmussen, Hamilton et al. 2010) 
which will be discussed in further detail in section 1.4. There is the potential for these 
changes to be attenuated or reversed by the activity of protein phosphatases allowing for 
fine-tuning of pump regulation.  
1.4 Glutathionylation: reversible oxidative modification of proteins  
1.4.1 Role of glutathionylation in redox signalling 
Redox (short for reduction/oxidation) reactions are the transfer of electrons from one 
substance (the reductant) to another (the oxidant). These are a key part of normal 
metabolic processes in the cell and involve smaller molecules like glucose to larger, more 
complex cellular molecules such as peptides and proteins undergoing redox modifications. 
While many of these modifications are irreversible and potentially disease causing (Fearon 
and Faux 2009), there are reversible oxidative modifications of proteins that are recognized 
as important to normal cell function including receptor-coupled cell signalling (Dalle-Donne, 
Rossi et al. 2009) and which may still contribute to disease phenotypes.  
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Important cellular oxidants in biological systems are derived from oxygen and NO and are 
referred to as reactive oxygen species (ROS) and reactive nitrogen species (RNS) with the 
presence of an overlap due to the interaction between the two. Sources of ROS include 
xanthine oxidases, the mitochondrial electron transport chain, cytochrome p450 and 
NADPH oxidase, the last of which is of particular interest in signal transduction as its activity 
is regulated by membrane receptors (Ushio-Fukai 2009). These cellular oxidants can modify 
amino acid side chains resulting in a change in the active site or a conformational change in 
the protein altering its tertiary structure, function and interaction with neighbouring 
peptides, all in a manner that can be reversed by enzymatic reduction. This process is 
analogous to the effects of phosphorylation on proteins (Ghezzi 2005; Pimentel, Haeussler 
et al. 2012). Methionine, tryptophan and cysteine residues are targets for oxidative 
modification, however, only the sulfhydryl group of the cysteine residue has been firmly 
implicated in signal transduction.  
Protein sulfhydryl groups (Protein-SH), also known as thiol groups, can undergo a large 
number of oxidative modifications induced by ROS/RNS when studied in pure chemical 
systems in vitro. (See Fig 1.3) These include the formation of sulfenic acid (Protein-S-OH), 
the formation of sulfinic acid (Protein S-O2H), formation of S-nitrosylates (Protein-S-NO) and 
the formation of disulphide bonds with glutathione (GSH) (Protein-S-SG) or other larger 
proteins (Protein-S-S-Protein). The formation of a disulphide bridge with GSH is also known 
as S-glutathionylation of proteins. This, unlike the others, is a stable yet reversible 
modification, making it suitable for signal transduction in vivo. The other products of protein 
oxidative modifications can also be further modified by enzymatically controlled, radical or 
nucleophillic attack-based mechanisms to be S glutathionylated (Gallogly and Mieyal 2007).   
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GSH is a tripeptide of glutamic acid linked via its γ-carboxyl group to a glycine residue and a 
cysteine residue which contributes a thiol group to the peptide. It is present in the cytosol of 
all cells in high concentrations and is a strong antioxidant in its reduced form. All cells have 
the necessary enzymes to synthesize GSH. Due to its ubiquity and high negative redox 
potential (Dalle-Donne, Rossi et al. 2007), it is considered the most abundant small molecule 
antioxidant in the cell (Pimentel, Haeussler et al. 2012). The thiol group on its cysteine 
residue is a strong electron donor and can be oxidised to form a disulphide bridge with the 
thiol group of the cysteine residue of another glutathione molecule, hence forming 
glutathione disulphide (GSSG). It can similarly form a disulphide bridge with the thiol group 
of protein cysteine residues, thus forming “mixed disulphide” bonds (Protein-S-SG) and 
resulting in S-glutathionylation of the target protein.  
GSH has a relatively high pKa (the pH at which 50% of the thiol group is deprotonated) of 8.5 
to 8.7 under intracellular conditions giving it a low reactivity at physiological pH. However, it 
is able to exert an antioxidant function by its high intracellular concentration and the 
lowering of its pKa by enzymes like GSH S-transferases. The steady state GSH:GSSG ratio in 
all cells is kept towards 100. 
The S-glutathionylation of a protein confers a large 305kD adduct that is negatively charged. 
This can change the tertiary protein structure and function. While it is a stable modification, 
it is reversible by changes in intracellular redox potential and enzymatic reduction by a thiol-
disulphide oxidoreductase called glutaredoxin (Shelton, Chock et al. 2005; Gallogly, Starke et 
al. 2009). Thus, while the process oxidises the protein involved in the mixed disulphide 
bond, it does so in a reversible manner and may function to protect key protein sulfhydryl 
groups from further irreversible oxidative modifications (Janssen-Heininger, Mossman et al. 
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2008). Many proteins have been found to be targets of S-glutathionylation in response to 
various stimuli. Examples of some such signalling proteins and their implications to 
cardiovascular physiology are listed in Table 1.3. These molecules form part of a signalling 
cascade, or are transcription factors or an enzyme that further generates signalling 
mediators (Zhang and Forman 2012).  
 
Figure 1.3 Oxidative modifications of protein sulfhydryl groups. 
Oxidative modifications of protein sulfhydryl groups induced by ROS/RNS include 
the formation of sulfenic acid ( Protein-S-OH), sulfinic acid (Protein S-O2H), S-
nitrosylates (Protein-S-NO), and the formation of disulphide bonds with 
glutathione (Protein-S-G)and other proteins (Protein-S-S-Protein) which is a 
stable reversible modification which may hence serve a signalling role. Modified 
from (Gallogly and Mieyal 2007; Rasmussen, Hamilton et al. 2010).  
  
Protein S Protein ProteinSS
Protein S H
Protein S SG
Protein S OH
Protein S O2H
Protein S NO
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Protein Effect of glutathionylation on 
function 
Stimuli for 
glutathionylation 
 
Actin ↓ Actin polymerization GSNO  
Activating transcription 
factor/cyclic-AMP-
responsive element binding 
protein (ATF/CREB) 
↑ ATF/CREB activity Disulfiram  
α4 VLA-4 ↑ Binding to VCAM, ↓ cell 
rolling 
H2O2  
β1 subunit of Na+-K+ pump ↓ Na+-K+ pump activity in 
cardiac myocytes 
Ang II, PKA 
(forskolin), ONOO− 
 
Caspase 3 Involved in increasing 
endothelial cell death in 
response to TNFα 
GSNO or SNAP+ 
GSH 
 
c-Jun ↓ c-Jun function ↑ GSSG:GSH ratio  
Creatine kinase ↓ Activity GSH + diamide, 
GSNO 
 
GADPH ↓ GAPDH activity I/R isolated heart  
Glutaredoxin N/A GSNO  
Mitochondrial complex I ↓ Rotenone-sensitive activity, 
↑O2 production 
GSSG  
Mitochondrial complex II ↑ Electron transfer efficiency 
↓ electron leak 
I/R in vivo  
P50 subunit of NF-κB ↓ DNA binding ↑ GSSG/GSH ratio  
Protein kinase A ↓ PKA activity Diamide  
Protein kinase C ↓ PKC activity Diamide  
PTP 1B ↓ Catalytic function GSSG, diamide, 
H2O2 
 
Ras (G protein) ↑ Protein synthesis, p38 and 
Akt activation in endothelial 
cells and smooth muscle cells 
Ang II and OxLDL  
Ryanodine receptor ↓ Mg2+ induced inhibition GSNO  
SERCA ↑ SERCA activity ONOO−, NO, NOS 
agonists 
 
Thioredoxin N/A GSNO  
Table 1.3 Examples of proteins susceptible to oxidative modification with 
relevance to cardiovascular physiology. Adapted from (Rasmussen, Hamilton et al. 
2010) 
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1.4.2 Glutathionylation in the regulation of the Na+-K+ ATPase 
Chemical oxidants have been shown to inhibit Na+-K+ ATPase in membrane fragments 
(Bogdanova, Petrushanko et al. 2006) and to reduce pump activity in cardiac myocytes 
(Shattock and Matsuura 1993). There is increasing evidence that a potential mechanism of 
alteration in pump activity by oxidative stress is the S-glutathionylation of Na+-K+ pump 
subunits (Figtree, Keyvan Karimi et al. 2012; Fuller, Tulloch et al. 2012).  
α- subunit 
Recently, glutathionylation of sites at the α-subunit’s actuator and nucleotide binding 
domains was found in purified enzyme preparations exposed to oxidised glutathione and 
chemical oxidants as well as from hypoxic rat heart. Glutathionylation of the α-subunit was 
inhibitory to pump activity and was competitive with ATP binding (Petrushanko, Yakushev et 
al. 2012). Our laboratory has been unable to detect glutathionylation of the pump’s α 
subunit from rabbit cardiac myocytes and the mutation of the β1 subunits reactive cysteine 
abolished the pump inhibition induced by ROS, suggesting a lack of functional significance of 
any undetected glutathionylation of the α1 subunit (Figtree, Liu et al. 2009). The role of 
glutathionylation of the α-subunit of the pump, no doubt, requires more study. It is of 
particular concern that no details were provided regarding the composition of solutions 
used to suspend Na-K ATPase-enriched membrane fragments in by Petrushanko et al 
(Petrushanko, Yakushev et al. 2012), making it impossible to try to reproduce their results.  
β1 subunit 
Our Laboratory has demonstrated reversible glutathionylation of the β1 subunit of the pump 
by chemical oxidants including peroxynitrite (ONOO) and hydrogen peroxide (H2O2) 
(Figtree, Liu et al. 2009). Receptor-coupled oxidant signalling using Ang II (Figtree, Liu et al. 
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2009) and forskolin (White, Figtree et al. 2009; White, Liu et al. 2010) was also associated 
with inhibition of the pump and glutathionylation of the β1 subunit, supporting an 
alternative role of protein kinases in PKA- and PKC- dependent regulation of the pump via 
NADPH oxidase activation rather than direct phosphorylation of the α subunit or FXYD1 
protein. 
White et al exposed rabbit myocytes to Ang II and demonstrated a decrease in Ip that was 
abolished by blocking εPKC activation. Ang II increased the co-immunoprecipitation of 
NADPH oxidase subunits in myocyte lysate consistent with the translocation of p47phox to 
the cell membrane that is required for activation of NADPH oxidase. It also increased co-
immunoprecipitation of the Na+-K+ pump molecular complex with p47phox (White, Figtree et 
al. 2009). These results are consistent with PKC-dependent phosphorylation of p47phox 
necessary for its translocation (Sumimoto 2008). The Ang II-induced activation of oxidative 
signalling was associated with glutathionylation of the β1 subunit of the Na
+-K+ pump 
(Figtree, Liu et al. 2009). 
The activation of adenylate cyclase using forskolin and the subsequent cAMP-dependent 
PKA stimulation has also been shown to cause downstream glutathionylation of the β1 
subunit of the Na+-K+ pump with associated decrease in Ip. Forskolin activated NADPH 
oxidase via PKA- and ultimately PKC-dependent pathways and inhibited Ip of cardiac 
myocytes. It also induced glutathionylation of the β1 subunit of the Na
+-K+ pump, and a 
decrease in Ip that was abolished by inhibition of PKA, εPKC or NADPH oxidase. It also 
resulted in a decrease in the coimmunoprecipiation of the α1  and β1 subunits of the pump 
indicating a decrease in their interaction necessary for pump activity (White, Liu et al. 2010).  
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Mutational studies of Na+-K+ pumps expressed in Xenopus oocytes identified cysteine 46 
(C46) as the reactive residue for glutathionylation in the β1 subunit (Figtree, Liu et al. 2009) , 
and, consistent with the NADPH oxidase-dependence of Ang II- and Forskolin- induced 
inhibition of Ip in cardiac myocytes, there was a causal relationship between β1 subunit 
glutathionylation and pump inhibition. While the location of this reactive cysteine in the 3-
dimensional crystal structure of the Na+-K+ pump indicates a location in the lipid bulk phase 
of the transmembrane segment that would be poorly accessible to the cytosolic, hydrophilic 
GSH, it is important to note that the crystal structure of the enzyme has been determined 
with the pump fixed in only one, the E2P2K, conformational state in the Albers-Post catalytic 
cycle scheme. Liu et al (Liu, Garcia et al. 2012) have shown that the susceptibility of the β1 
subunit of the Na+-K+ pump is dependent on the conformation of the enzyme with the E1 
conformational state being much more susceptible than the E2 state. The conformational 
change from E2 to E1 may shift C46 towards the cytosolic domain and hence facilitate 
glutathionylation (Rasmussen, Hamilton et al. 2010).  
In view of the above, attenuating the receptor-coupled, kinase-dependent activation of 
NADPH oxidase may decrease the glutathionylation of the β1 subunit and the inhibitory 
effects on pump function.  
FXYD proteins 
In contrast to serine residues susceptible to phosphorylation being present on FXYD1 only, 
there are two cytoplasmic cysteine residues that are highly conserved across the 7 member 
mammalian family of FXYD proteins that may potentially be glutathionylated. They are 
mostly flanked by basic amino acids making them good candidates to be glutathionylated 
because the basic residues are expected to lower the pKa values of their neighbouring 
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sulfhydryl groups. The cysteine residue closer to the C terminus (C2 as opposed to C1) was 
demonstrated, using mutational studies in Xenopus oocytes, to be susceptible to 
glutathionylation. Having a reactive cysteine in the C2 position of FXYD proteins was critical 
for reversal of the glutathionylation of the β1 subunit and reversal of pump inhibition 
induced by chemical oxidants or Ang II-dependent activation of NADPH oxidase (Bibert, Liu 
et al. 2011). Thus, by being susceptible to glutathionylation and facilitating the 
deglutathionylation of the β1 subunit of the Na
+-K+ pump, FXYD proteins play a role in 
regulating oxidative inhibition of the Na+-K+ pump (Figtree, Keyvan Karimi et al. 2012). 
1.5 NADPH Oxidase 
1.5.1 Reactive oxygen species 
Reactive oxygen species are small molecules derived from oxygen and include the following 
oxygen radicals: superoxide (O2
), hydroxyl (OH), peroxyl (RO2), and alkoxyl (RO). There 
are non-radicals also considered ROS which can be converted into radicals and/or are 
oxidizing agents and include hypochlorous acid (HOCL), ozone (O3), singlet oxygen (
1O2) and 
hydrogen peroxide (H2O2). These ROS interact with a large number of molecules including 
proteins, carbohydrates and nucleic acids, and with NO to form peroxynitrite (ONOO). 
Effects of ROS can range from participating in signal transduction in regulatory processes as 
a signalling molecule or by reversible oxidative modification of other peptides as previously 
discussed, to irreversibly destroying or altering the function of target molecules that may be 
pathological, or physiological (Cave, Brewer et al. 2006; Bedard and Krause 2007). The 
oxidative burst by phagocytes in host defence is an example of the latter (Babior, Kipnes et 
al. 1973). 
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The generation of ROS is generally a cascade of reactions and metabolites that starts with 
the production of O2
 (Lassegue and Griendling 2004). Sources of ROS include the 
mitochondrial electron transport chain, xanthine oxidases, peroxisomes, cytochrome p450 
and uncoupled eNOS. NADPH oxidase, however, is considered the major producer of O2
 in 
cardiomyocytes (Sawyer, Siwik et al. 2002; Cave, Grieve et al. 2005; Lin, Irvine et al. 2012), 
and was the first identified example of an enzyme system that generates ROS as a primary 
function, rather than as a by-product (Bedard and Krause 2007). NADPH oxidase is of further 
interest as a source of ROS modulating other enzymes as it is located in signalling platforms 
of cell membranes, including in caveolae, facilitating specificity of its signal transduction. It is 
also known to be regulated by membrane receptors including those for Ang II, endothelin 
and aldosterone (Lassègue, San Martín et al. 2012). The superoxide generated is highly 
reactive and short lived, hence subcellular localization of NADPH oxidase with its 
downstream effectors in its signalling cascade is important for its function in oxidant 
signalling (Winterbourn 2008; Lassègue, San Martín et al. 2012). NADPH oxidase has been 
found to be colocalised in caveolae with Ang II receptors, β1 and β2 ARs, and eNOS (Patel 
and Insel 2009). From co-immunoprecipitation experiments in rabbit cardiac myocytes, 
NADPH oxidase subunits have been found to colocalise with the α1 subunit of the Na
+-K+ 
ATPase (White, Figtree et al. 2009) further suggesting, along with NADPH oxidase being the 
main source of O2
 in cardiac myocytes (Hingtgen, Tian et al. 2006), its role in oxidant 
signalling to the Na+-K+ pump in cardiomyocytes.  
Poor permeability of O2
  through lipid membranes could limit its potential in signal 
transduction to intracellular targets. It is, however, rapidly converted by superoxide 
dismutase (SOD) to another ROS, H2O2, hydrogen peroxide, which is membrane permeable. 
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In addition, O2
 can combine with NO to form the highly oxidant species ONOO, which in 
its protonated form is readily lipid permeable (Marla, Lee et al. 1997). In this manner, O2
 
can bring about downstream oxidative modifications to intracellular targets.  
1.5.2 NADPH oxidase isoforms 
The NADPH oxidase (Nox) family is composed of 7 different catalytic units termed Nox 1-5 
and Duox (Dual oxidase) 1 and 2. There are also regulatory subunits p22phox, p47phox, p67phox, 
p40phox, Noxo1, Noxa 1 and the small GTPase, Rac. All Nox family members catalyse the 
transport of electrons from cytosolic NADPH or NADH across biological membranes to 
molecular O2 to form O2
, behaving like a transmembrane redox chain. There are structural 
properties conserved across the Nox enzyme catalytic subunits. The cytosolic carboxyl 
terminal moiety constitutes the dehydrogenase domain that has consensus binding sites for 
NADPH substrate and flavin adenine dinucleotide (FAD) cofactor. There are 6 
transmembrane domains with 4 haem-binding histidines. On activation, 2 electrons are 
transferred from NADPH to FAD in succession across the membrane via redox changes in 
the haem irons. Each electron then reduces a molecule of O2 to form O2
 which is released 
extracellularly or into a vesicle lumen, depending on whether the enzyme is located in the 
plasma membrane or intracellularly as part of an endosome (Bedard and Krause 2007; 
Sumimoto 2008; Lassègue, San Martín et al. 2012).  
Apart from differing in their defining catalytic units, the different members of the Nox 
families also differ in their regulatory units and mechanism of activation. Of the 7 Nox 
isoforms, Nox 1,2,4 and 5 are expressed in cardiovascular tissues with Nox 2 and Nox 4 
being the predominant isoforms expressed in cardiac myocytes (Bedard and Krause 2007; 
Lassègue, San Martín et al. 2012). Nox 2 is the predominant isoform in adult heart (Cave, 
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Brewer et al. 2006; Bedard and Krause 2007) while Nox 4 is the predominant form during 
development (Li, Stouffs et al. 2006). Nox 4 is constitutively active, not requiring cytosolic 
subunits with regulation mostly by effects on transcription (Martyn, Frederick et al. 2006), 
although it can respond to agonist stimulation (Mahadev, Motoshima et al. 2004; 
Anilkumar, Weber et al. 2008; Lassègue, San Martín et al. 2012). Nox 2 activity is tightly 
regulated with activation occurring through a complex series of protein/protein interactions 
requiring the phosphorylation and membrane translocation of cytosolic subunits which will 
be discussed in detail in Section 1.5.4. It has also been clearly demonstrated that Nox 2 can 
be activated by receptors in cardiovascular tissues, including by receptors for Ang II (Oudot, 
Vergely et al. 2003; Hingtgen, Tian et al. 2006; Zhou, Ziegler et al. 2006). The latter makes it 
a likely player in Ang II- and kinase-mediated signalling to the Na+-K+ pump.  
1.5.3 Nox 2 in cardiovascular disease 
There is accumulating evidence of the role Nox 2 plays in cardiac pathophysiology. It 
regulates endothelial and cardiac function and is upregulated in response to various 
vasoactive stimuli including Ang II, shear stress, pressure and activation of adenosine 
receptors (Lassègue, San Martín et al. 2012). Its effects are can be broadly divided into 
vascular and myocardial.  
Vascular 
As the O2
 produced in endothelium can rapidly inactivate NO, it is expected to impair NO-
mediated relaxation and hence cause vessel contraction. Consistent with this, a negative 
correlation between Nox 2 expression and endothelium dependent relaxation has been 
seen in isolated aorta (Zemse, Hilgers et al. 2007; Takenouchi, Kobayashi et al. 2009). 
Patients with chronic granulomatous disease who have Nox 2 mutations, have higher flow 
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mediated vasodilation with more bioactive NO (Violi, Sanguigni et al. 2009). Nox 2 is also 
upregulated in the renal and brain vasculature in hypertension, with NADPH oxidase 
subunits involved in the hypertensive response to Ang II and a reduction of hypertensive 
effect seen in Nox2- or p47phox-knockout mice(Rey, Cifuentes et al. 2001; Landmesser, Cai et 
al. 2002).  
There is also evidence supporting the contribution of Nox 2 to atherosclerosis with 
monocytes and macrophages being important for plaque development. High levels of Nox 2 
expression and activity have thus been found in atherosclerotic lesions (Azumi, Inoue et al. 
1999; Kalinina, Agrotis et al. 2002; Sorescu, Weiss et al. 2002; Guzik, Sadowski et al. 2006). 
Nox 2 expression is also increased by atherosclerotic risk factors like hypertension, shear 
stress and diabetes. However, experiments looking at the atherosclerotic burden in p47phox- 
or Nox2-knockout mice fed a high fat diet, or crossed with ApoE lipoprotein-knockout mice, 
have had conflicting results with respect to the contributions of Nox 2 to atherogenesis 
(Hsich, Segal et al. 2000; Kirk, Dinauer et al. 2000; Barry-Lane, Patterson et al. 2001; Chen, 
Keaney et al. 2004; Judkins, Diep et al. 2010). 
Myocardium 
Nox 2 in cardiomyocytes has been implicated in hypertrophy and remodelling after aging 
and injury, including myocardial infarction, with a clear link demonstrated in multiple 
murine models. The hypertrophic and fibrotic response to Ang II was reduced in mice with 
deletions in Nox 2 (Bendall, Cave et al. 2002) and other NADPH oxidase subunits (Satoh, 
Ogita et al. 2006) compared to wild-type mice. Nox 2-containing NADPH oxidase has 
similarly been shown to play a key role in Ang II-induced cardiomyocyte hypertrophy in rat 
neonatal cardiomyocytes (Hingtgen, Tian et al. 2006). This Nox 2-dependence is not seen, 
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however, in pressure-overload induced myocardial hypertrophy (Byrne, Grieve et al. 2003; 
Maytin, Siwik et al. 2004). Nox 2 is also implicated in the remodelling that occurs with 
myocardial infarction with increased levels seen in cardiomyocytes from patients with 
myocardial infarction (Krijnen, Meischl et al. 2003). While there is no decrease in infarct size 
compared to wild-type mice, in Nox 2- and p47phox-knockout mice, there is attenuation of 
cardiomyocyte hypertrophy, cardiomyocyte apoptosis and interstitial fibrosis (Hoffmeyer, 
Jones et al. 2000; Doerries, Grote et al. 2007; Looi, Grieve et al. 2008). Nox 2 in 
cardiomyocytes can also mediate non-deleterious outcomes in these cells. Ischaemic 
preconditioning, where the pre-exposure of the heart to mild stress reduces the damage 
from subsequent prolonged ischaemic insults, involves Nox 2-dependent generation of ROS 
(Bell, Cave et al. 2005; Kimura, Zhang et al. 2005).  
In view of this, modulating the activity of NADPH oxidase has therapeutic potential in 
multiple cardiovascular diseases. While regulation of its expression is an important arm of 
this therapeutic paradigm, modulating the activity of the enzyme is also important and will 
be considered here.  
1.5.4 Role of phosphorylation in Nox 2 activity 
The activation of Nox2 involves the assembly of a large number of subunits including Nox 2 
(gp91phox), p22phox, p47phox, p67phox, p40phox and Rac GTPase. In the resting state, p22phox and 
Nox 2 form an inactive membrane complex referred to as cytochrome b558 (Sumimoto, 
2008) (See Figure 1.4). A ternary complex of other dormant subunits, is present in the 
cytosol with p67phox linking p47phox and p40phox (Lapouge, Smith et al. 2002), while Rac is 
complexed with Rho GDP dissociation inhibitor. Activation of the enzyme requires 
translocation of the cytosolic subunits to the membrane to associate with cytochrome b588. 
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While this recruitment of cytosolic subunits has been shown to be promoted by PKC 
dependent phosphorylation of Nox 2 (Raad, Paclet et al. 2009), the dominant PKC-
dependent effector of cell stimulation is phosphorylation of p47phox (DeCoursey and Ligeti 
2005; Lassègue, San Martín et al. 2012). The p47phox functions as an “organizer” unit, while 
p67phox functions as an “activator” unit.  
The p47phox subunit is a 390amino acid protein that contains, from the N- terminus, a 
phagocyte oxidase (PX) domain, 2 central tandem SH3 (Src-homology-3) domains which are 
important for binding to p22phox , an autoinhibitory region (AIR) and a C-terminal proline-
rich region that binds p67phox. In the dormant state, intramolecular folding masks the PX 
domain and the SH3 tandem which binds to the AIR. On cell stimulation, p47phox undergoes 
PKC phosphorylation at multiple serine residues including Ser 303, 304 and 328 in the AIR. 
This results in unfolding of p47phox and unmasking of the PX and SH3 domains. Now that it is 
accessible after the phosphorylation-induced conformational change, the PX domain binds 
to phophoinositide 3-kinase (PI3K) lipid products and actin fibres while the SH3 domains 
then binds to the C-terminal proline rich region of p22phox. These two interactions allow the 
phosphorylated p47phox to be targeted to the membrane-bound cytochrome b558 and is 
crucial to oxidase activation (Ago, Kuribayashi et al. 2003). With the membrane 
translocation of p47phox to p22phox, the other units in the trimer, p67phox and p40phox, are 
brought to the Nox 2 subunit. The activation domain of the p67phox subunit directly interacts 
with Rac which is independently recruited to the cytochrome b558 on cell stimulation. This 
p67phox activation domain then triggers the oxidase activity of Nox 2 (Sumimoto 2008; 
Lassègue, San Martín et al. 2012). 
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Figure 1.4 Activation of Nox 2 
In the resting state, p22phox and Nox 2 form an inactive membrane complex 
referred to as cytochrome b558  as depicted on the left of the panel. A ternary 
complex of the dormant cytosolic subunits of p67phox linking p47phox and p40phox 
is present while Rac is complexed with Rho GDP dissociation inhibitor (Rho-GDI). 
Serine phosphorylation of p47 phox is necessary for translocation of the cytosolic 
subunits to the membrane to associate with cytochrome b588 and result in 
activation of the enzyme.  
In view of the critical nature of phosphorylation events in the assembly and activation of 
NADPH oxidase, it is logical to consider whether dephosphorylation plays a role in 
termination or attenuation of its activity. There is evidence that p47phox is continuously 
phosphorylated and dephosphorylated with phosphorylation being the dominating process 
in cells which are activated (Heyworth and Badwey 1990). Inactivation of the enzyme may 
result from assembled p47phox being dephosphorylated leading to disassembly of the 
activated Nox 2 complex or phosphatases acting on “free” phosphorylated p47phox, 
preventing assembly of the active membrane complex (DeCoursey and Ligeti 2005). 
Evidence for the critical role of dephosphorylation has come from studies in activated 
neutrophils using PKC inhibitors and phosphatase inhibitors. Activity of NADPH oxidase, in 
NOX2
p
2
2
p
h
o
x
Ser
p67phox
p47phox
p40phox
cytochrome b558
GDP
Rho-
GDI
Rac
NOX2
p
2
2
p
h
o
x
Ser
p67phox
p47phox
p40phox
Pi
GTP
Rac
RESTING ACTIVATED
PKC
 
Chapter 1  36 
 
membrane fractions (Yamaguchi, Sasaki et al. 1993) or polymorphonuclear leukocytes 
(Kawakami, Takemasa et al. 1999), that has been inhibited can be reconstituted with the 
protein phosphatase inhibitors, okadaic acid and calyculin A. Ding and Badwey 
demonstrated that production of O2
 in stimulated neutrophils was terminated along with 
the loss of phosphate from p47phox, with the addition of PKC inhibitors, by constitutively 
active phosphatases. This effect was abolished by antagonists to protein phosphatase 2A 
and 1 (okadaic acid or calyculin)(Ding and Badwey 1992). Curnutte et al found that PKC 
inhibition in activated neutrophils resulted in disassembly of the active NADPH oxidase 
complex in a phosphatase dependent manner (Curnutte, Erickson et al. 1994). The 
respiratory burst in activated neutrophils is prolonged by pre-treatment with okadaic acid 
(Lu, Takai et al. 1992; Harbecke, Liu et al. 1997), suggesting that O2
 production was 
terminated by phosphatase-mediated inactivation of NADPH oxidase.  
These studies showing attenuation of NADPH oxidase activity have been in neutrophils. 
There is also evidence that NO, the endogenous activator of sGC attenuates NADPH oxidase-
dependent O2
 production in endothelial cells using L-NAME to block NO production in 
wild-type and p47phox-knockout mice (Harrison, Drummond et al. 2010) or by exposing 
cultured human umbilical vein endothelial cells to L-NAME or the NO donor DETA-NO 
(Duerrschmidt, Stielow et al. 2006). There was a downregulation of p47phox expression with 
NO production, although the decrease in expression was less than the decrease in O2
 
production suggesting NO also affected activation of NADPH oxidase. In the heart, cGMP 
dependent signalling has been found to be a ROS-suppressing mechanism (Ritchie, Irvine et 
al. 2009). Recently, sGC stimulation with nitroxyl, which has a lack of reactivity with ROS, 
prevented Ang II-induced cardiomyocyte hypertrophy and suppressed NADPH oxidase in 
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neonatal rat cardiomyocytes. The suppressive effects were seen both on O2
 generation 
and Nox 2 expression after exposure to nitroxyl for 48 hours (Lin, Irvine et al. 2012). These 
studies involved prolonged exposure to the experimental conditions for at least 24 hours 
during which time the effects on transcription may dominate even in the presence of effects 
on NADPH oxidase activation. As cGMP dependent signalling can stimulate multiple 
enzymes including protein phosphatases (Francis, Busch et al. 2010), acute exposure to sGC 
agonists has the potential to modulate NADPH oxidase activity and its downstream 
oxidative modifications. 
1.6 Soluble guanylyl cyclase 
1.6.1 Structure of sGC 
Guanylyl cyclase is the enzyme that catalyses the conversion of guanosine triphosphate, 
GTP, into cGMP. It is also referred to as guanylate cyclase and guanyl cyclase. The reaction is 
divalent metal bound GTPcGMP + PPi, with the metal cofactor being Mg2+ under 
biological conditions. However, after tissue homogenates are subjected to a non-ionic 
detergent, Mn2+ is also a suitable cofactor. In the presence of detergent, guanylyl cyclase 
with different kinetic properties and tissue distributions is obtained from the particulate 
fraction and the soluble fraction (Kimura and Murad 1974; Chrisman, Garbers et al. 1975). 
This led to the separation of distinct particulate forms (pGC) and soluble forms (sGC) of the 
enzyme which are traditionally accordingly named. These are now appreciated, after 
identification of cDNAs that encode individual enzymes, as having single membrane 
spanning subunits and soluble subunits respectively. 
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The minimal catalytic guanylyl cyclase unit is a dimer (Thompson and Garbers 1995; Liu, 
Ruoho et al. 1997). The particulate forms are homodimers or homotrimers of 7 membrane-
spanning subunits known as GC-A, GC-B, GC-C, GC-D, GC-E, GC-F and GC-G. The membrane-
spanning forms have an amino-terminal extracellular ligand-binding, transmembrane, kinase 
homology, dimerization and carboxyl-terminal catalytic domains (Potter 2011) (Fig. 1.5). It is 
to the extracellular ligand-binding domain that the peptide activators like atrial natriuretic 
peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and 
guanylyl cyclase activator proteins (GCAPs) bind to the particulate forms of GC. pGC are 
located in the subsarcolemmal space and hence the second messenger produced, cGMP, 
while the same as that for sGC, produces different physiological effects due to the different 
compartmentalisation of cGMP (Su, Scholz et al. 2005; Stangherlin, Gesellchen et al. 2011). 
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Figure 1.5 Schematic of structure of mammalian guanylyl cyclases. 
Particulate (pGC) or transmembrane guanylyl cyclase is represented on the left. 
The pGCs have an amino-terminal extracellular ligand-binding domain, 
transmembrane domain, kinase homology domain, dimerization domain and 
carboxyl-terminal catalytic domain. Soluble guanylyl cyclase (sGC) is represented 
on the right. The sGC catalytic unit contains an amino-terminal haem binding 
domain, carboxyl-terminal catalytic domain and a dimerization domain that 
contains two domains, the Per/Arnt/Sim (PAS) and coiled-coil domains (CC). 
Abbreviations: ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; 
CNP, C-type natriuretic peptide; CO, carbon monoxide; CO2, carbon dioxide; 
HCO3, bicarbonate; GCAPs, guanylyl cyclase activator proteins; Gn, guanylin; Hb, 
haemoglobin; NO, nitric oxide; Sta, heat-stable enterotoxin; Uro, uroguanylin. 
Adapted from (Potter 2011; Derbyshire and Marletta 2012) 
 
In contrast, the soluble members are heterodimers that are largely cytosolic enzymes. 
Mammals have 4 soluble subunits : α1, α2, β1 and β2, with catalytic activity requiring both 
the larger α and smaller β subunit (Koesling, Böhme et al. 1991). The best characterised 
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heterodimers are α1β1 and α2β1 (Zabel, Weeger et al. 1998; Mayer and Koesling 2001). The 
sGC catalytic unit contains an amino-terminal haem binding domain, carboxyl-terminal 
catalytic domain and a dimerization domain (Fig 1.5). This dimerization domain contains two 
domains, the Per/Arnt/Sim (PAS) and coiled-coil domains. This latter domain is unique to 
sGC with no significant homology to other proteins (Derbyshire and Marletta 2012). Studies 
suggest that these two central regions mediate protein-protein interactions and are 
important in the formation of functional catalytic dimers (Rothkegel, Schmidt et al. 2007; 
Ma, Sayed et al. 2008; Möglich, Ayers et al. 2009). sGC is primarily activated in vivo by NO 
and it is the haem moiety that serves as a receptor for NO (Gerzer, Böhme et al. 1981). This 
haem-binding domain, which can bind NO and CO but not O2, is part of a conserved family 
of proteins variably termed haem-nitric oxide binding, sensor of nitric oxide and haem-nitric 
oxide and oxygen binding (H-NOX) (Derbyshire and Marletta 2012). There is some evidence 
that the NO mechanism of activation of the sGC is by relief of an inhibitory interaction by 
the H-NOX domain on the catalytic domain (Winger and Marletta 2005; Haase, Haase et al. 
2010). The crystal structure of the catalytic domain derived from cyanobacteria contains a 
central seven-stranded β sheet surrounded by several α helices in a wreath like structure 
(Rauch, Leipelt et al. 2008). No structure of an active mammalian cyclase has been solved to 
date.  
1.6.2 NO-sGC-cGMP signalling pathway 
sGCs are signal transduction enzymes that are widely distributed across tissues. They 
catalyse the conversion of GTP to cGMP in response to various cellular stimuli. The primary 
endogenous activator of sGC is NO, originally described as endothelium-derived-relaxing 
factor.  
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Nitric oxide synthases (NOS) catalyse the synthesis of NO by converting the amino acid L-
arginine to NO and L-citrulline (Ignarro, Cirino et al. 1999; Bryan, Bian et al. 2009). There are 
three families of NOS: inducible NOS (iNOS), neuronal NOS (nNOS) and endothelial NOS 
(eNOS). The NO produced is a key signalling molecule in biological and physiological 
processes. It is the primary messenger in the NO-sGC-cGMP pathway. The prosthetic haem 
moiety bound to the amino-terminal haem binding domain of sGC, by interaction with the 
axial ligand histidine-105, (Schmidt, Schramm et al. 2004) is the receptor for NO. On binding 
of NO, the sGC has a 100-200 fold increase in activation (Ignarro, Degnan et al. 1982; 
Derbyshire and Marletta 2009). A prerequisite for activation of sGC by NO is the presence of 
the haem moiety in the reduced Fe2+ form (Ignarro, Adams et al. 1986; Foerster, Harteneck 
et al. 1996). Hence not only does the removal of the haem moiety render the enzyme 
insensitive to NO, but the oxidation of the central ferrous iron, which is coordinated 
between the four haem nitrogens and the axial ligand histidine-105, to the ferric state (Fe3+) 
by ODQ, methylene blue or ferricyanide similarly results in the formation of an NO-
insensitive form of sGC (Schrammel, Behrends et al. 1996; Hwang, Wu et al. 1998; Olesen, 
Drejer et al. 1998; Zhao, Brandish et al. 2000). The redox state of sGC can also be influenced 
by endogenous radicals such as O2
 and ONOO (Stasch, Schmidt et al. 2006).  
Synthesis of the second messenger, cGMP, from GTP by sGC initiates the cGMP signalling 
pathway which has three major intracellular effectors: 1) cGMP dependent protein kinases I 
and II (PKG I and PKG II), 2) cGMP gated ion channels and 3)cGMP regulated 
phosphodiesterases (PDE) (Francis, Busch et al. 2010). The cGMP levels are a balance of 
guanylyl cyclase activity and that of the PDE families (PDE 1,2,3,5,6,9,10,11) that catalyse 
the breakdown of cGMP (Beavo 1995). The role of this pathway has been documented in 
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multiple processes including gastrointestinal motility, blood flow, neuronal plasticity, 
vascular function and cardiac protection (Francis, Busch et al. 2010). Its significance in 
cardiovascular disease is discussed in detail in Section 1.6.3. 
1.6.3 NO-sGC-cGMP pathway in cardiovascular disease 
Reduced bioavailability of NO or impaired responsiveness to endogenous NO has been 
implicated in the development of cardiovascular diseases. The alteration of NO-sGC-cGMP 
signalling has been implicated in a wide range of studies and hence the signalling pathway is 
an attractive target for therapeutic intervention (Evgenov, Pacher et al. 2006).  
Arterial hypertension 
Impaired NO-sGC-cGMP signalling, unrelated to a decreased bioavailability of substrate for 
NO production, has been seen in human studies of arterial hypertension (Panza, Casino et 
al. 1993; Taddei, Virdis et al. 1996; Schlaich, Parnell et al. 2004). The use of sGC agonists 
have been studied in rat models of hypertension. These have produced a significant 
reduction of mean arterial pressure (Rothermund, Friebe et al. 2000), a markedly improved 
survival with dose-dependent vasodilatation (Stasch, Becker et al. 2001; Stasch, Dembowsky 
et al. 2002), attenuated cardiac fibrosis and hypertrophy (Zanfolin, Faro et al. 2006), and 
reduced cardiac and renal end organ damage and fibrosis (Sharkovska, Kalk et al. 2010). 
There is also evidence that sGC agonists can exert end organ protection independent of 
haemodynamic effects. In the absence of an antihypertensive effect, sGC agonists in rat 
models of hypertension have been shown to attenuate cardiac fibrosis (Masuyama, Tsuruda 
et al. 2006) and inhibit angiotensin converting enzyme synthesis (Masuyama, Tsuruda et al. 
2009).  
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Atherosclerosis and restenosis and thrombosis 
Reduced bioavailability of endothelial NO and reduced levels of sGC have been shown to 
contribute to the development of atherosclerotic lesions in animal models (Melichar, Behr-
Roussel et al. 2004; Lubos, Handy et al. 2008). sGC agonists have reduced bleeding time, 
reduced neointimal development after intimal injury and decreased atherosclerosis in 
animal models (Teng, Wu et al. 1997; Tulis, Durante et al. 2000; Wu, Chang et al. 2004). sGC 
activation in in-vitro studies has been shown to inhibit platelet aggregation and adhesion, 
tissue factor expression and pro-coagulant activity in human monocytes and endothelial 
cells (Stasch, Schmidt et al. 2002; Tulis, Bohl Masters et al. 2002; Sovershaev, Egorina et al. 
2009). These antiplatelet effects have yet to be demonstrated in humans (Stasch, Pacher et 
al. 2011). Nonetheless, the anti-inflammatory and antiproliferative effects of sGC agonists 
and their in vitro antiplatelet effects make the NO-sGC-cGMP pathway an attractive 
therapeutic target for ongoing investigation.  
Pulmonary hypertension 
Pulmonary hypertension is characterised by increased pressure in the pulmonary arterial 
vasculature as a result of pulmonary vasoconstriction. In normal pulmonary vascular 
endothelium, the production of NO causes a local increase in cGMP synthesis which leads to 
pulmonary vasodilatation to match alveolar ventilation. This production of NO and other 
endogenous vasodilators is impaired in pulmonary hypertension (Machado, Londhe Nerkar 
et al. 2004). Inhaled NO has been used to produce pulmonary vasodilatation which only 
persists for a short duration after the NO administration is discontinued and is further 
limited by the development of methaemoglobinemia, dose-related tolerance and the lack of 
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response in some patients. The vasodilatory effects are mediated by the NO-sGC-cGMP 
pathway, hence this pathway has been targeted for therapy.  
PDE inhibition with sildanefil, to increase cGMP by a reduction in degradation, has been 
used successfully and approved for treatment of chronic pulmonary hypertension. However, 
this treatment is dependent on endogenous NO production, a reduction of which is often 
present in these patients. This leads to a lack of response. sGC stimulators to raise cGMP 
levels have been studied in various animal models of pulmonary hypertension. These have 
largely been positive with beneficial effects seen including pulmonary vasodilation, 
improved arterial oxygenation, reduced intrapulmonary shunting, reduced right ventricular 
systolic pressure, reduced right ventricular hypertrophy and pulmonary vascular 
remodelling (Stasch, Pacher et al. 2011). Clinical studies have now been done using the 
orally bioavailable sGC stimulator, riociguat (BAY 63-2521). The study populations have 
included patients with primary pulmonary arterial hypertension, pulmonary hypertension 
resulting from interstitial lung disease and chronic thromboembolic pulmonary 
hypertension. These have showed promising results with improvement in clinical 
parameters: a reduction in pulmonary arterial pressure, an improvement in all pulmonary 
haemodynamic parameters, improved exercise capacity and functional class, reduction in 
pulmonary vascular resistance, increased cardiac output and increased 6 minute walking 
distance (Grimminger, Weimann et al. 2009; Ghofrani, Hoeper et al. 2010; Frey, Mück et al. 
2011; Hoeper, Halank et al. 2012).  
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Heart Failure 
The endothelial and myocardial dysfunction seen in heart failure involves the dysregulation 
of the NO-sGC-cGMP signalling pathway (Mitrovic, Jovanovic et al. 2011). With the oxidative 
stress of heart failure, there is a decreased production of NO. In addition, there is an 
increased degradation and neutralisation of NO by ROS leading to an overall NO deficit 
(Pacher, Schulz et al. 2005). There is a further decrease in stimulation of the signalling 
pathway by the oxidation of sGC, making the enzyme insensitive to the limited NO with an 
overall reduction in production of the second messenger cGMP.  
The main mechanistic focus of the potential benefits of sGC modulators in heart failure has 
been related to its haemodynamic effects from vasodilatation and changes to vascular 
resistance. The reduction in preload and afterload could improve cardiac output and renal 
blood flow. In a dog model of pacing-induced heart failure, the sGC activator, cinaciguat 
decreased blood pressure and unloaded the heart (Boerrigter, Costello-Boerrigter et al. 
2007). Initial proof-of-concept studies with intravenous short-term use of cinaciguat in 
patients with acute decompensated heart failure were promising with the drug potently 
unloading the heart with improvement in hemodynamic response (Lapp, Mitrovic et al. 
2009). However, in the phase IIb randomised, placebo-controlled studies, short-term use of 
intravenous cinaciguat in acute decompensated heart failure decreased blood pressure 
without improving dyspnoea or cardiac index (Gheorghiade, Greene et al. 2012). Despite 
this, it is conceivable that a different sGC modulator may achieve a different clinical result. 
Also, similar to the divergent effects of the use of angiotensin-converting enzyme inhibitors 
and beta-blockers in acute versus chronic stable heart failure, sGC activators/stimulators 
could show clinical benefit when administered long term to patients with heart failure with 
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improvement of endothelial and myocardial function, myocardial and renal preservation 
and improved cardiac remodelling; potentially by modulation of oxidative signalling as 
opposed to short term alteration of haemodynamics (Masuyama, Tsuruda et al. 2009; 
Gheorghiade, Greene et al. 2012; Voors and van Veldhuisen 2012) 
1.6.4 Soluble Guanylyl Cyclase stimulators and activators 
There are two classes of compounds that act directly on sGC to increase activity. These are 
sGC stimulators and sGC activators which differ in their mode of action.  
sGC stimulators 
sGC stimulators maintain the enzyme in its active form by stabilising the nitroxyl-haem 
complex , thus sensitizing the enzyme to the bioavailable NO. These compounds are termed 
haem-dependent as their activity depends on the reduced haem moiety. They are NO 
independent in their action as they can stimulate sGC in the absence if NO. They do, 
however, work in synergy with NO with their potency increased by 1 to 2 orders of 
magnitude in the presence of NO (Evgenov, Pacher et al. 2006). The first compound, that 
was light insensitive, which was discovered to be a NO-independent, haem dependent 
stimulator of sGC, was an indazole derivative, 3-(5’-hydroxymethyl-2’-furyl)-1-
benzylindazole, more commonly known as YC-1 (Ko, Wu et al. 1994). This compound, which 
has been the most studied of the sGC stimulators, increases the activity of purified sGC by 
approximately 10 fold and the effect is increased to about 200 fold in the presence of NO 
and/or carbon monoxide. It also inhibits one of the cGMP metabolizing phosphodiesterases, 
PDE5, with a concentration giving half maximal inhibition (IC50) of 10μM (Galle, Zabel et al. 
1999), thus potentiating the increase in cGMP. The exact mechanism of direct YC-1 induced 
effects on sGC is still uncertain. It is thought that it may bind to the catalytic domain of sGC, 
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involving both subunits (Stasch, 2009). Apart from indazole derivatives, pyrazolopyridine 
related structures, BAY 41-2272 and BAY 41-8543, have also been developed as sGC 
stimulators. Riociguat (BAY 63-2521), a pyrimidine derivative, is an orally bioavailable sGC 
stimulator that has been studied intensively for use in pulmonary hypertension. These BAY 
compounds, like YC-1, are NO-independent, haem-dependent sGC stimulators that work in 
synergy with NO. They do, however have a higher potency than YC-1 and do not inhibit 
cGMP-dependent phosphodiesterases. Acrylamide analogues have also been discovered as 
sGC stimulators (Evgenov, Pacher et al. 2006; Stasch, Pacher et al. 2011).  
sGC Activators 
These compounds activate sGC when it is in an oxidized or haem-free state. Its effect is 
additive, rather than synergistic, with bioavailable NO (Evgenov, Pacher et al. 2006). These 
compounds are NO-independent and haem-independent. BAY 58-2667 or cinaciguat was 
the first such compound discovered by high throughput screening a decade ago. The 
compound binds to the sGC haem-binding site, mimicking the haem moiety and also 
protecting the haem-free sGC from oxidation induced degradation. If the haem moiety is 
present it has to be in the ferric state to be replaced by BAY 58-2667 due to the reduced 
affinity of the oxidized haem for the sGC haem-binding domain (Stasch, Schmidt et al. 2002). 
Reduced sGC is virtually unresponsive to BAY 58-2667 (Stasch, Pacher et al. 2011). 
Anthranillic acid derivatives, HMR-1766 (ataciguat) and the chemically related S-3448, have 
also been developed and may be able to activate both haem-containing and haem-deficient 
sGC (Schindler, Strobel et al. 2006). BAY 60-2770, another haem-independent, NO-
independent sGC activator is also in preclinical studies (Pankey, Bhartiya et al. 2011; 
Mendes-Silverio, Leiria et al. 2012).  
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1.6.5 Protein phosphatases 
One of the main intracellular effectors of the NO-sGC-cGMP pathway is cGMP-dependent 
protein kinase, PKG. These are serine/threonine kinases that are encoded by two genes, 
PKGI and PKGII, with PKGI being the primary isoform in the cardiovascular system (Takimoto 
2012). The number of identified physiological substrates phosphorylated by PKGI is large 
and ever increasing and includes phosphatases and phosphatase inhibitor 1 with the 
identification of potential PKGI phosphorylation sites being confounded by the fact that PKA 
and PKG have similar consensus sequences (Francis, Busch et al. 2010).  
Protein phosphatases are often implicated in PKG-mediated signalling (Zhou, Ruth et al. 
1996; White 1999; Moreno, de Miera et al. 2001). Specifically, protein phosphatase 2A 
(PP2A) has been shown to be activated by PKG in cells from bovine tracheal smooth muscle 
((Zhou, Ruth et al. 1996). This has also been demonstrated in neuronal cells from anoxia-
tolerant Drosophilia flies (Dawson-Scully, Armstrong et al. 2007; Dawson-Scully, Bukvic et al. 
2010), consistent with the demonstration that PKG activation is protective for cell survival 
during anoxia in mammals (Caretti, Bianciardi et al. 2008).  
As previously discussed, reversible protein phosphorylation is an important regulatory 
mechanism of cell activities. While the focus has traditionally been on protein kinases and 
their regulation in signal transduction with phosphatases being viewed as “housekeeping 
enzymes”(Sontag 2001), the role of dephosphorylation by phosphatases is being increasing 
recognized in cell cycle control and cellular signalling (Nguyen, Matallanas et al. 2012). 
Dysregulation of protein phosphatases are now clearly linked to cancer, diabetes and 
Alzheimer’s disease, making them targets for therapeutic manipulation (Liu, Grundke-Iqbal 
et al. 2005; Vander Mierde, Scheuner et al. 2007; Pereira, Vasconcelos et al. 2011).  
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Proteins can be reversibly phosphorylated on serine, threonine, tyrosine, histidine, arginine, 
lysine, aspartate and glutamate. Serine/threonine and tyrosine are by far the most 
predominantly phosphorylated residues in eukaryotes. Of the protein phosphatase 
superfamily, most belong to the protein tyrosine phosphatase (PTP) family. These are 
structurally apart from the serine/threonine specific phosphatases (PPs) which share the 
common property of relying on the nucleophilic attack of the phosphorous atom by a metal 
activated water molecule to catalyse dephosphorylation of their target protein (Barford 
1996).  
The PPs traditional nomenclature, which is still largely used, classified PP enzymes based on 
their preferred dephosphorylation of the β or α subunit of phosphorylase kinase and their 
inhibition by protein inhibitors 1 and 2. The prototypical mammalian types are types 1, 2A 
and 2B phosphatases with type 2C described early (Cohen 1997). Type 1 are characterized 
by their inhibition by protein inhibitors 1 and 2 and their preferential dephosphorylation of 
the β subunit of phosphorylase kinase. Type 2 PP are not inhibited by protein inhibitors 1 
and 2 and preferentially dephosphorylate the α subunit of phosphorylase kinase. PP2B, also 
known as calcineurin, requires Ca2+ and calmodulin for activity, while PP2C requires Mg2+ for 
activity (Shenolikar and Nairn 1991; Herzig and Neumann 2000). 
This traditional nomenclature does not reflect the developmental origins of the enzymes 
nor does it take into account the more recently discovered “novel phosphoprotein 
phosphatases” (PP3-7). The PP family includes 3 families: phosphoprotein phosphatases 
(PPPs), metallodependent protein phosphatases (PPMs) and transcription initiation factor 
IIF-stimulated C-terminal domain phosphatases (FCPs). PP2C has been found to be actually 
structurally different to the other PPPs, being monomeric and requiring Mg2+,  and is now 
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classified as PPM1 (enzyme 1 of the PPM family). The holozenzymes of the remaining PPP 
are multimeric with regulatory, structural and catalytic subunits. Based on the structural 
differences of the PPP enzymes derived from the amino acid sequences of the catalytic 
subunits, the remaining PPPs are divided into 5 subfamilies: 1) PPP1; 2) PPP2/4/6 consisting 
of PP2A, PP4, PP6; 3) calcineurin/PP2B, 4) PP5, and 5) PP7. The PTPs, PPMs and FCPs are not 
affected by the naturally occurring toxins that inhibit PPP including okadaic acid which has 
been shown to modulate cell signalling to NADPH oxidase(Ding and Badwey 1992; 
Yamaguchi, Sasaki et al. 1993; Curnutte, Erickson et al. 1994; Kawakami, Takemasa et al. 
1999; DeCoursey and Ligeti 2005), as previously discussed, and to the cardiac sarcolemmal 
Na+-K+ pump (William, Vien et al. 2005).  
In humans, 13 catalytic subunits make up the 7 enzymes of the PPP family. There is a 
common globular domain to all the subunits with a highly conserved amino acid sequence 
responsible for their catalytic activity. This domain constitutes the entire catalytic subunits 
in PP1, PP2A, PP4 and PP6 which interact with one (PP1) or two (PP2A, PP4, PP6) regulatory 
domains while PP3, PP5 and PP7 possess additional amino and/or carboxyl terminal 
domains.  
Protein phosphatases 1 and 2A (PP1 and PP2A, respectively) are responsible for the vast 
majority of all serine/threonine dephosphorylations in the cell. PP2A accounts for as much 
as 1% of total cellular proteins (Cohen 1997; Martin, Kettmann et al. 2010). It plays a role in 
cell-cycle control, regulation of signal transduction pathways, cell mobility, cell mitosis, 
apoptosis, inflammation and cell differentiation (Janssens and Goris 2001). Its dysregulation 
has been seen to contribute to cancer and hence it has become a target of cancer 
therapeutics (Eichhorn, Creyghton et al. 2009). PP2A activity has been linked with multiple 
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peptides important to membrane excitability, excitation, contraction coupling (Ai and 
Pogwizd 2005; Xu, Ginsburg et al. 2010; Wijnker, Boknik et al. 2011) and its altered 
expression and activity has been linked with different cardiac phenotypes including heart 
failure and cardiac dysrhythmias (Terentyev, Viatchenko-Karpinski et al. 2003; Belevych, 
Sansom et al. 2011). Increased PP2A expression and activity has been seen with increased 
oxidative stress in cardiomyocytes (Kohr, Davis et al. 2009) and models of heart failure and 
hypertrophy (Boknik, Fockenbrock et al. 2000). It is unclear if the increased activity observed 
is pathological or part of a compensatory mechanism. There is also an association with 
decreased PP2A activity and cardiac dysfunction (Brewis, Ohst et al. 2000; Belevych, Sansom 
et al. 2011). With the expanding evidence of its role in cardiomyocytes (DeGrande, Little et 
al. 2012), its potential role in modulating the activity of Na+-K+ ATPase warrants 
consideration.  
The PP2A holoenzyme is a heterotrimer consisting of a core dimer, PP2AD consisting of a 36 
kDa catalytic C subunit , PP2AC and a 65 kDa structural A subunit, PP2AA also known as PR65; 
with a third regulatory B subunit, PP2AB.  The structural A subunit is thought to serve as a 
scaffold, undergoing conformational change to bring the other two subunits together, 
allowing the B subunit to direct a specific substrate to the active site of the catalytic subunit. 
(Xing, Xu et al. 2006). In mammals, there are α and β isoforms of subunits A and C with the α 
isoform being much more abundant in both cases. There are at least 16 different isoforms of 
the B subunit allowing for a very large number of combinations of PP2A holoenzymes.  
Regulation of PP2A activity is subject to a multitude of mechanisms and can be considered 
in terms of holoenzyme composition, regulation by binding partners, the specificity of the 
substrates and post-translational modifications (Janssens and Goris 2001; Martin, Kettmann 
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et al. 2010). The composition of the holoenzyme is the most important determinant in 
regulating PP2A function. The isoform of the B subunit modulates the catalytic activity of 
the enzyme and influences its substrate selectivity (Cegielska, Shaffer et al. 1994; Sontag, 
Nunbhakdi-Craig et al. 1996). The subcellular compartmentalisation of PP2A is also 
influenced by its subunit composition (Sontag 2001). There is a large number of binding 
partners that interact with PP2A and can associate with specific PP2A holoenzyme. These 
interacting peptides include viral proteins that can bind and directly inhibit its phosphatase 
activity either by direct competition with substrate for access to the catalytic site, or by 
displacement of structural and regulatory subunits from the holoenzyme (Janssens, Goris et 
al. 2005; Chen, Xu et al. 2007; Cho, Morrone et al. 2007). These interacting peptides may 
also target PP2A to specific regulator functions and cellular domains (Voorhoeve, Hijmans et 
al. 1999; Ito, Kataoka et al. 2000; Yan, Fedorov et al. 2000). Studies in PP2A substrates like 
Tau, Myc and Cdc 25C have shown the regulatory effects of substrate specificity with the 
isomer of a single residue affecting activity. In these PP2A substrates containing a proline-
directed serine/threonine motif, the trans, rather than cis, configuration of the proline 
adjacent to the target phosphorylated serine/threonine residue favours dephosphorylation 
by the phosphatase (Zhou, Kops et al. 2000; Stukenberg and Kirschner 2001; Yeh, 
Cunningham et al. 2004). Crucial to PP2A regulation is post-translational modification of the 
unique carboxyl terminal tail of the catalytic subunit that is positioned at the interface 
between the B and A subunits. There is a highly conserved Th304-Pro-Asp-Tyr-Phe-Leu309 
motif which can undergo methylation, tyrosine phosphorylation and threonine 
phosphorylation. The leucine residue in the motif is subjected to carboxymethylation. It has 
been shown to enhance the affinity of the core dimer to some regulatory subunits, though 
not all, thus regulating holoenzyme selective composition and activity (Gentry, Li et al. 2005; 
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Longin, Zwaenepoel et al. 2007; Nunbhakdi-Craig, Schuechner et al. 2007). Tyrosine 
phosphorylation at position 307 could inhibit interaction of the catalytic subunit with the 
regulatory subunit or prevent methylation of Leu309. Threonine phosphorylation may 
similarly affect recruitment of specific regulatory subunits. An additional potential role for 
serine/threonine kinases in modulating PP2A is phosphorylation of serine residues on the 
regulatory B subunits. Studies have shown that PKA- and cAMP-dependent phosphorylation 
of specific regulatory B subunits can activate PP2A (Usui, Inoue et al. 1998; Ahn, McAvoy et 
al. 2007). PKA and PKG have similar consensus sequences with well documented cases of 
either kinase being able to phosphorylate a particular site (Butt, Abel et al. 1994; Francis, 
Busch et al. 2010). Further, a protein identified in vitro as a substrate for PKA may primarily 
be a PKG substrate in vivo and vice versa (Rodriguez-Pascual, Ferrero et al. 1999; Lincoln, 
Wu et al. 2006). Thus, consistent with studies that have demonstrated PKG activation of 
PP2A discussed previously, these PP2A subunits may be phosphorylated by PKG and hence 
be involved in the sGC/cGMP/PKG pathway of signal transduction to the Na+-K+ ATPase. 
1.6.6 Regulation of Na+-K+ ATPase by protein phosphatases 
Phosphatases have been shown to reverse the effects of protein kinases on the Na+-K+ 
pump. These studies have looked at various tissues and different phosphatases and have 
demonstrated both pump inhibition and stimulation. 
Calcineurin or PP2B has been found to have a role in upregulation of Na+-K+ pump 
expression and activity (Therien and Blostein 2000). PP2B mediated α-AR agonist induced 
stimulation of the Na+-K+ pump in rat proximal collecting tubular cells at least partially by 
increasing the apparent affinity of the Na+-K+ pump for sodium (Aperia, Ibarra et al. 1992). It 
has also found been found to stimulate the Na+-K+ pump in the rest of the kidney (Lea, 
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Sands et al. 1994). PP2B is also found to regulate Na+-K+ pump activity in the brain. 
Noradrenaline-stimulated Na+-K+ pump activity in rat brain was shown to be PP2B 
dependent (Mallick, Adya et al. 2000). PP2B also mediates glutamate induced stimulation of 
the Na+-K+ pump in primary cultures of cerebellar neurons (Marcaida, Kosenko et al. 1996).  
Studies have shown stimulatory effects of PP1 on the Na+-K+ pump inferred by inhibitory 
effects of PP1 inhibitors. Dopamine through the DA1 receptor and isoproterenol via the β-AR 
was found to cause Na+-K+ pump inhibition that was mediated in part by the activation of 
the PP1 inhibitors DARPP-32 and inhibitor-1 via phosphorylation in renal tubular cells 
(Meister, Fryckstedt et al. 1989; Aperia, Hokfelt et al. 1990; Aperia, Fryckstedt et al. 1991) 
and choroid plexus (Fisone, Snyder et al. 1998). Ragolia et al demonstrated that the insulin 
induced stimulation of the Na+-K+ pump in rat skeletal muscle was mediated by PP1 (Ragolia, 
Cherpalis et al. 1997). In contrast to these previous studies, PP1 was reported to have 
inhibitory effects on the Na+-K+ pump activity in guinea pig ventricular myocytes although 
experimental methods used may have introduced some inconsistencies (Gao, Cohen et al. 
1994).  
Studies of PP2A’s effects on the Na+-K+ pump have mostly shown stimulatory effects. 
Vasopressin induced stimulation of Na+-K+ pump recruitment and activity was attenuated by 
inhibition of PP2A (Blot-Chabaud, Coutry et al. 1996). PP2A has been found to mediate 
dopaminergic type 1 receptor mediated stimulation of Na+-K+ ATPase in human 
adenocarcinoma cell lines (Lecuona, Garcia et al. 2000) and to counter the inhibitory effects 
of PKC activation in Sf-9 infected cells (Blanco, Sánchez et al. 1998). In contrast to the above, 
inhibitors of PP2A have been found to stimulate the pump in hepatocytes (Lynch, Mader et 
al. 1994). 
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While these effects on the Na+-K+ pump have been thought to be due to dephosphorylation 
of the catalytic α subunit (Ragolia, Cherpalis et al. 1997; Mallick, Adya et al. 2000; Lecuona, 
Dada et al. 2006), similar to the difficulties with the paradigm of kinase-mediated 
phosphorylation of the Na+-K+ ATPase α subunit, there are no putative PP2A binding 
sequences in the primary structure of the Na+-K+ pump α subunit (Kimura, 2011). While it 
has been reported that protein phosphatase 2A interacts with the α subunit of the Na+-K+ 
pump as evidenced from coimmunoprecipitation experiments from rat renal tissue(Kimura, 
Han et al. 2011) and human alveolar adenocarcinoma cells expressing rat Na+-K+ pump α1 
subunit (Lecuona, Dada et al. 2006), protein phosphatases may exert their effect on the Na+-
K+ pump via its effect on other interacting enzymes within the same signalling domain, such 
as NADPH oxidase. Another potential mechanism of protein phosphatase mediated 
regulation of the Na+-K+ ATPase is the dephosphorylation of the accompanying FXYD 
proteins. Phospholemman has been found to be a substrate for both PP1 and PP2A 
(Neumann, Maas et al. 1999), with enhanced phosphorylation at serine 68 on PLM via 
overexpression of PP1 inhibitor causing increased Na pump currents (El-Armouche, 
Wittköpper et al. 2011). Similar to the difficulties with the paradigm of kinase-mediated 
phosphorylation of FXYD proteins mediating kinase dependent regulation of the Na+-K+ 
pump, the actions of PP1 and PP2A have only been demonstrated in cardiac tissue with an 
absence of putative phosphorylation/dephosphorylation sites in the FXYD 2-7 proteins 
(Geering 2006). Further the results of PP1 inhibitors on the Na+-K+ pump in cardiac tissue 
with increased pump currents (El-Armouche, Wittköpper et al. 2011) is in contrast to the 
findings in other tissues (Aperia, Fryckstedt et al. 1991; Ragolia, Cherpalis et al. 1997; Fisone, 
Snyder et al. 1998). These make a canonical phosphoprotein phosphatase-mediated 
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dephosphorylation of the FXYDs unlikely to account for their modulating effects on the Na+-
K+ pump.  
1.7 Scope of thesis 
The role of Na+-K+ pump in normal and abnormal cardiac function and processes is evident 
while the deleterious effects of receptor mediated pump inhibition, including inhibition 
induced by Ang II, has been established (White, Figtree et al. 2009). The NO/sGC/cGMP 
signalling pathway is important in cardiovascular pathophysiology and there is also an 
increasing role of sGC activators and stimulators in the modulation of cardiovascular 
processes. This includes a potential role in providing a balance against receptor mediated 
inhibition of the Na+-K+ pump.  
1.7.1 Hypothesis 
The hypothesis of this thesis is that stimulation of soluble guanylyl cyclase attenuates the 
effects of receptor-mediated oxidative inhibition of the Na+-K+ pump via its effects on 
NADPH oxidase and the downstream oxidative modification of the Na+-K+  pump subunits. 
1.7.2 Aims 
 The aims of this thesis are to  
1) To examine the effects of sGC stimulation on Ang II induced Na+-K+ pump inhibition. 
2) To examine the effect of sGC stimulation on Ang II related superoxide levels in 
cardiac myocytes.  
3) To examine the molecular mechanism responsible for the effects of sGC stimulation 
on Ang II induced Na+-K+ pump inhibition. 
4) To examine the effects of sGC stimulation on adenylyl cyclase dependent Na+-K+ 
pump inhibition.  
 
Chapter 2  57 
 
CHAPTER 2 
 
METHODS 
 
2.1 Animal Care 
Male New Zealand rabbits weighing between 2.5kg and 3.5kg were used. These were 
sourced from Menugora Rabbit Suppliers then housed and cared for in the Ray Kearnes 
Facility at The Kolling Institute, Royal North Shore Hospital. The rooms that housed the 
rabbits were kept at 22C ± 2C and had 12 hour light dark cycles. Each individual rabbit had 
its own cage. All treatment protocols for the animals were reviewed and approved by the 
Animal Care and Ethics Committee of Royal North Shore Hospital/ The University of 
Technology Sydney.  
2.2 Isolation of ventricular myocytes 
The cell isolation method in this work is a modification of that of Haddad (Haddad et al., 
1988). Rabbits were anesthetized with approximately 80mg/kg of ketamine (Parnell 
Laboratories, NSW, Australia) and 50mg/kg of ilium xylazine (Troy Laboratories, NSW, 
Australia) intramuscularly. Heparin (1000iu) was given intravenously through the marginal 
ear vein.  The lack of a corneal reflex and the lack of hind limb withdrawal to pressure were 
used to confirm deep anaesthesia. Once deep anaesthesia was achieved, an incision was 
made in the left lateral intercostal space at the level of 5th intercostal space that was 
extended to a median sternotomy. Following this, the heart was removed from the thoracic 
cavity at the level of the ascending aorta.  
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To delay tissue hypoxia and to remove the blood, the excised heart was then washed in ice 
cold (2-4°C) Krebs-Henseleit buffer (KHB) solution. This solution contained (in mM); 130 
NaCl, 2.8 KCl, 25.0 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, 10 glucose, 19.9 taurine and had been 
oxygenated using carbogen (95% O2 - 5% CO2) for approximately one hour. Once the heart 
was free of any residual blood, the heart was attached to a Langendorff perfusion apparatus 
(Laboratory Supply, Sydney, Australia) by securing the ascending aorta to a glass cannula 
with silk suture (see Figure 2.1). To ensure adequate perfusion of the coronary arteries, the 
cannula tip was positioned 3-4 mm above the aortic valve. The heart was then perfused 
with the ice-cold KHB solution by attaching an intravenous infusion set to the side arm of 
the Langendorff perfusion apparatus. After 6 minutes, the perfusion solution was switched 
to an identical KHB solution that had been warmed to 35°C. The solution was warmed using 
a thermostatically controlled water bath (Julabo, Seelbach, Germany) A recirculation circuit 
of heated distilled water surrounding the perfusion column was used to hold the 
temperature steady. Perfusion of the warm KHB solution was achieved using a rate 
adjustable peristaltic infusion pump (Cole-Palmer Instrument Co, Chicago, USA). The heart 
was placed within a glass water jacket, also heated by the recirculation circuit. The 
suspended heart was perfused with warm KHB solution for 6 minutes, and subsequently 
with a warmed Krebs solution containing ≈ 220 U/ml of type II collagenase (Worthington 
Biochemical Corp, Freehold, NJ, USA) and ≈ 875 U/ml of hyaluronidase (Sigma-Aldrich Pty. 
Ltd., St Louis, MO, USA). The heart was perfused with the enzyme-containing KHB solution 
for approximately 13 minutes. Physical massaging was undertaken on the heart at 4 minute 
intervals for approximately 30 seconds each time. The enzymatic digestion of the heart was 
considered complete when the heart became globular and enlarged with a glassy, 
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translucent appearance. The heart was cut down from the apparatus using an incision at the 
level of the atrioventricular groove, separating the ventricles from the atria. 
 
Figure 2.1 Langendorff perfusion apparatus. 
The photograph depicts the retrograde cannulation and perfusion of the aortic 
root of the heart of a White New Zealand rabbit, hung to a Langendorff perfusion 
column. 
 
The ventricles were then minced using iridectomy scissors for 30-60 s until a uniform 
suspension was obtained. This mixture was then filtered through a nylon mesh (500μm 
pores) to separate the isolated myocytes from undigested myocardial tissue and connective 
tissue. The resultant filtrate of suspended myocytes was then transferred to 15 ml falcon 
tubes and filled with warm KHB solution. These were centrifuged for 2 mins at 1500 rpm in 
KHB solution. After removal of the supernatant, the pellet was re-suspended in a solution 
containing equal volumes of warm Ca2+-containing KHB (comprising of KHB stated above 
with the addition of 0.5 mM CaCl2 and 2.4 mM EGTA) and KHB. Centrifugation and 
aspiration were repeated and the cells were re-suspended in Ca2+-containing KHB and 
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stored at room temperature until experimentation. This gradual re-introduction of Ca2+ was 
to prevent cellular damage due to calcium paradox when the cells were later exposed to 
calcium containing solutions. Myocytes were used on the day of isolation only. Ventricular 
myocytes were used for experimentation if they were rod shaped and quiescent and had 
clear striations.  The isolation protocol produced variable amount of viable myocytes 
constituting 20-50% of the total yield (assessed microscopically). The water used in all 
experimental work, including cell isolation, was obtained by filtration using a Milli-Q Plus 
system (Millipore Corporation, Bedford MA, USA) with filter change and regular 
maintenance carried out as per manufacturer’s specifications.  
2.3 Whole Cell Patch Clamp Technique 
2.3.1 Rational for the technique 
The whole-cell patch-clamped technique, established by Hamill et al. (1981) (Hamill et al., 
1981) was adapted by Gadsby to measure pump current (Gadsby, Kimura et al. 1985) and is 
a powerful tool in studying the Na+-K+ pump. The technique allows effective control of both 
intracellular and extracellular solutions as well as the membrane voltage (Gadsby, Kimura et 
al. 1985). The technique involves attaching the tip of a solution-filled patch pipette, 
containing an Ag/AgCl electrode, to the membrane surface of a cell. With the application of 
gentle suction to the back of the pipette, the membrane in contact with the tip of the 
pipette is ruptured, providing access to the intracellular milieu of the cell. The membrane 
voltage can then be “clamped” to the desired voltage which then allows the measurement 
of transmembrane currents. The composition of both pipette solutions and superfusate 
solutions can be varied to manipulate the intracellular and extracellular milieu respectively 
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and the effects on the Na+-K+ pump activity can be measured via the electrical current 
arising from the Na+-K+ pump. 
2.3.2 Experimental set-up  
The experimental set up consists of the 350 μL capacity Perspex tissue bath (into which the 
isolated myocytes were placed) that was mounted on the stage of an inverted phase 
contrast microscope (Nikon TE200, Nikon Corporation, Tokyo, Japan). (See Figure 2.2) The 
tissue bath was perfused by a gravity-fed system utilizing intravenous infusion burettes with 
manually controlled flow rates. Superfusate solutions were heated to 35°C prior to entry 
into the tissue bath via an inline heater (Model SH-27B, Warner Instrument Corporation, 
Connecticut, USA) which was attached to an automatic temperature controller (Model TC-
344B, Warner Instrument Corporation, Connecticut, USA), allowing precise control of tissue 
bath temperature. Bath temperatures were monitored continuously using a 
telethermometer (Yellow Spring Instrument Corporation, Ohio, USA) and temperature was 
maintained within range by adjusting the drip rate of the intravenous infusion burettes. 
Rapid manual change between the different superfusates was achieved using a 6 position 
mechanical Teflon rotatory valve (Rheodyne Inc., Cotati, CA, USA).  Superfusate solutions 
exited the tissue bath at the opposite end from the bath entry via a 21G needle that was 
placed under continuous gentle suction, avoiding any flow turbulence in the bath. (See 
Figure 2.3).Flow rates of superfusate solutions were regulated to approximately 5 mL/min 
which allowed perfusion of the cells without turbulence while maintaining the tissue bath 
temperature. The inverted microscope and heat exchange system and were mounted on a 
vibration isolation table (Technical Manufacturing Corporation, Maryland, USA) inside a 
Faraday cage.  
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Figure 2.2 The patch-clamping setup. 
Inverted phase-contrast microscope mounted on a vibration isolation table. The 
entire set-up is contained within a Faraday cage to reduce electrical interference. 
 
2.3.3 Patch Pipettes and Pipette solutions 
For patch clamp experiments, wide-tipped patch pipettes were made from unfilamented 
glass capillaries (Harvard Apparatus, Kent, UK) using a Sutter P-87 pipette puller (Sutter 
Instruments, California, USA) to a tip diameter of 4-5 μm. They were then fire polished 
under 500 × magnification using a microforge (Narishige Scientific Instrument Lab, Tokyo, 
Japan) to ensure a smooth, uniform tip. The use of wide tipped pipettes was to facilitate the 
 
Chapter 2  63 
 
dialysis of the intracellular contents and ensure equal Na+ concentration at cytoplasmic 
pump sites and the solution in the pipettes (Gadsby, Kimura et al. 1985; Mogul, Singer et al. 
1989). Pipettes were stored in a sealed electrode storage container (World Precision 
Instruments, Florida, USA) to prevent dust build-up, which may impair formation of a seal 
between the pipette and the cell.  
For the measurement of steady-state Ip, pipettes were back-filled with a solution containing 
(in mM) 70 K+-glutamate, 1 KH2PO4, 5 N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid 
(HEPES), 5 ethyleneglycol-bis-(β-aminoethylether) N,N,N,’,N’-tetra-acetic acid (EGTA), 2 
MgATP, 10 Na+-glutamate, 80 tetramethylammonium chloride (TMA-Cl) and 0.01 L-Arg. The 
solution was titrated to a pH of 7.22 at 22°C using 1 M KOH. Before filling of patch pipettes, 
pipette solutions were filtered through a 0.1 μm syringe filter (Pall Corporation, Michigan, 
USA). When filled, patch pipettes had a resistance of 0.8-1.1 MΩ. 
2.3.4 Experimental solutions  
Myocytes were initially superfused with modified Tyrodes solution containing (in mM) 140 
NaCl, 5.6 KCl, 2.16 CaCl2, 0.44 NaH2PO4, 10 glucose, 1.0 MgCl2 and 10 HEPES. The solution 
was titrated to a pH of 7.4 at 35°C with NaOH and contained 16 mg/L gentamicin. After the 
whole-cell configuration was established (see section 2.3.5), the superfusate was replaced 
with a modified Tyrodes solution identical to that used above, except that it was nominally 
Ca2+ free and contained 0.2 mM CdCl2 and 2 mM BaCl2. Cd
2+ was included to block Ca2+ 
channel conductance and inhibit Na+-Ca2+ exchange (Gadsby and Nakao 1989). Ba2+ was 
included to block K+ channels. In addition, Na+-containing compounds in this superfusate 
were replaced with N-methyl-D-glucamine chloride (NMG-Cl) to avoid transmembrane influx 
that might cause an increase in the intracellular Na+ concentration and secondary pump 
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stimulation. This Na+-free, Ca2+- free solution contained  (in mM) 14.56 KCl, 140 N-methyl-D-
glucamine chloride (NMG-Cl), 0.44 KH2PO4, 10 HEPES, 1 MgCl2, 10 glucose, 2 BaCl2 and 0.2 
CdCl2. This solution was titrated with HCl to a pH of 7.4 at 35°C. Pump current (Ip) was 
defined as the shift in holding current induced by the exposure of the myocytes to Ca2+-free, 
Ba2+-containing superfusate solution with 100 μM ouabain. 
 
Figure 2.3 Tissue bath.  
Pre-heated solutions flow in to the bath from the right (black arrow) on to the 
cells which would sit in the right hand chamber of the bath. Solutions are 
suctioned from the bath from the left hand syringe (white arrow) 
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2.3.5 Patch Clamp Equipment 
Patch pipettes were backfilled using gentle suction and placed in an electrode holder 
connected to a headstage (gain × 0.01, Axon Instruments, California, USA). The headstage 
was connected to an Axoclamp 2B patch-clamp amplifier (Axon Instruments, California, 
USA). The bath solution was grounded via a Ag/AgCl wire (the reference wire) that was 
placed in a second reservoir, downstream of the tissue bath. The potential offset between 
the reference wire and the Ag/AgCl wire electrode contained within the patch pipette was 
set to zero immediately before the commencement of each experiment.  
The patch pipette was moved into contact with the cell using a hydraulic micromanipulator 
(Narishige Co. Ltd, Tokyo, Japan) until a slight indentation could be seen on the cell surface 
membrane. To facilitate formation of a seal, gentle suction was then applied to the back of 
the pipette via a sidearm of the electrode holder. A 20 mV, 40 ms depolarising, square wave 
pulse was passed from the voltage-clamp amplifier through the pipette at an interval of 
1500 ms. The process of seal formation was monitored by observing the current elicited 
during the plateau phase of the square wave pulse. Once a high resistance seal had formed, 
a brief pulse of gentle suction was again applied to rupture the cell membrane. This resulted 
in low-resistance access to the cell interior through the pipette tip, allowing the whole cell 
to be voltage-clamped, a state termed the “whole-cell configuration”. The myocyte’s 
intracellular compartment could then be perfused with the contents of the patch pipette. 
The myocyte was then lifted from the bottom of the tissue bath. To enable continuous 
visual monitoring of the cell throughout the experiment, a video microscopy camera (CCD72 
series, Dage-MTI Inc, Indiana, USA) and a video monitor (Matsushite Electrical Industrial Co 
Ltd. Osaka, Japan) were connected to the microscope. (See Figure 2.4) 
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Figure 2.4 Rabbit ventricular myocyte attached to a patch pipette as 
viewed through microscope. 
Myocytes were selected for experimentation if they had straight borders, were 
quiescent and had clear striations. The patch pipette was then carefully placed 
on the surface of the cell and gentle suction was applied in order to form a seal. 
 
2.3.6 Measurement of membrane capacitance and access resistance  
After the whole cell configuration was established, access resistance (Ra) and membrane 
capacitance (Cm) were estimated using the “Membrane Test” mode of the Clampex 7 
software. Since Cm is a reliable indicator of cell size (Satoh, Delbridge et al. 1996), Cm was 
measured in order to control for cell-to-cell variability in size. Ra is indicative of the quality of 
the access between the patch pipette and the intracellular compartment and should be kept 
as low as possible to facilitate dialysis of the intracellular contents of the myocyte. Control 
of the concentration of intracellular pump ligands is achieved at access resistances less than 
4 MΩ (William, Vien et al. 2005). Cells were rejected and experiments discontinued if the 
access resistance was measured above 4MΩ. 
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2.3.7 Measurement of steady state pump current  
Myocytes were voltage-clamped at -40 mV in order to inactivate voltage-sensitive Na+-channels 
(Follmer, ten Eick et al. 1987) and L-type Ca2+ channels (Bean 1985; Krafte and Kass 1988). When 
forskolin, the adenylyl cyclase (AC) activator was used in the superfusate, the myocytes were 
voltage clamped at -14mV, the equilibrium potential for Cl-, to take into account the large 
forskolin activated Cl- current (White, Liu et al. 2010). A continuous measurement of the holding 
current (Ih) was recorded with AxoTape Version 2.0.8 software. After a period of Ih stability, the 
superfusate was switched to the Ca2+-free, Ba2+-containing modified Tyrodes to inhibit Na+-Ca2+ 
exchange and K+ channel conductance. This resulted in an inward current shift to a new steady-
state Ih level. The Ih was allowed to once again stabilise at the new level after which the 
superfusate was switched to the Ca2+-free, Ba2+-containing, ouabain-containing modified 
Tyrodes solution. As 100 μM of ouabain results in complete inhibition of the Na+-K+ pump, pump 
current (Ip) was identified by measurement of the ouabain induced shift in Ih. The shift in Ih was 
measured with an electronic cursor at the most stable section of each plateau. Switching of 
superfusates was performed at pre-determined time intervals after the whole cell configuration 
was established to ensure that myocytes were exposed to various superfusates for standardized 
periods of time. Figure 2.5 illustrates a typical current trace and the shifts in Ih induced by the 
various superfusate solutions. The overall pump current is the summation of the current of all 
the functioning pump units in the membrane of the cells. The total number of pump units is 
dependent on the overall cell surface area which is indicated by membrane capacitance. Hence 
the absolute Ip was then normalized for cell size by dividing it by Cm to obtain a standardised 
measure of pump activity that allows direct comparison of pump activity between cells of 
different size. The effect of ouabain on Ip is not reversible within the time frame that stable 
holding currents can be reliably measured (William, Vien et al. 2005; Despa and Bers 2007). 
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Figure 2.5 Typical trace of holding current. 
The trace was obtained after the whole cell patch-clamp configuration was 
established under control conditions and the myocyte was clamped at a voltage 
of -40 mV. The decline in holding current is produced by the ouabain induced 
blockade of the Na+-K+ pump, and thus corresponds to pump current (Ip). 
 
2.4 Data acquisition, analysis and storage  
Recording of membrane currents and holding potentials and passing of current and voltage 
steps were performed using the continuous single electrode voltage-clamp mode of an 
Axoclamp 2B amplifier via a DigiData 1200 series interface (Axon Instruments, California, 
USA). Using a multichannel computerized data acquisition system with 12 bit resolution 
(Axotape Version 2, Axon Instruments), continuous recordings of membrane voltage (Vm) 
and holding current (Ih) were made. Data was stored both digitally and as a hard copy. 
2.5 Imaging of intracellular superoxide by DHE fluorescence 
The oxidative fluorescent dye dihydroethidium (DHE) was used to image intracellular O2 as 
described previously (Kim, Guzik et al. 2005; White, Hamilton et al. 2008).To detect 
intracellular O2
, we loaded isolated myocytes that had been pre-treated with YC-1 (10μM 
for 15 minutes) and/or okadaic acid (10nM for 15 minutes) with DHE (2 μmol/l) in Krebs 
solution for 15 min at 37°C in the dark. Cells were then exposed to Ang II (100 nM for 10 
min) or Forskolin (100nM for 10 min) or control solution. Myocytes were then fixed in 2% 
paraformaldehyde on ice for 4 min. After a wash with phosphate buffered saline, PBS, they 
(Ih)
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were mounted on poly-l-lysine-coated glass slides in VectashieldR. They were examined by 
laser-scanning fluorescent confocal microscopy (Nikon C1) equipped with an Argon-Krypton 
laser. The excitation wavelength was 488 nm and the emission wavelength was 585 nm for 
DHE fluorescence. The fluorescence images were obtained by using constant settings of 
scanning speed, pinhole diameter, and voltage gain. Myocytes (≥6) representative of each 
experimental condition were selected randomly for quantification of average fluorescence 
intensity (Photoshop, Adobe) after exclusion of the nucleus. Experimental conditions were 
coded by numbers and data were decoded after analysis. Only myocytes with clear 
striations and rodlike shape were included in the analysis. The average intensity from  each 
experiment was normalized against its relevant control (100%).  
2.6 Detection of S-Glutathionylated proteins  
To detect S-glutathionylation of specific pump-related proteins, isolated myocytes were 
loaded with biotinylated glutathione (GSH) (5mM) for 1 hour at room temperature then 
treated under various experimental conditions for 15-45 minutes. The biotinylated GSH 
ester was made by mixing 25mM sulfo-NHS-biotin with 25mM GSH ethyl ester (GEE) in 
50mM NaHCO3 at pH 8.5 for 2 hours followed by the addition of 125mM NH4 at pH 8.5 for 1 
hour. Cells were then washed 3 times with cold phosphate buffer, with centrifugation at 
3000rpm for 3minutes between each wash. Cells were then lysed in a solution containing (in 
mM); 50 Tris-HCl, 150 NaCl, 2 phenylmethylsulfonyl fluoride (PMSF), 0.05 diethylene 
triamine pentaacetic acid (DTPA), 1% nonylphenoxylpolyethoxylethanol (NP-40), 10 N-
ethylmaleimide (NEM). After addition of cell lysis buffer, the cells were left on ice for 5 minutes 
before being centrifuged at 14,000rpm for 20 minutes. The biotin-tag was used to precipitate S-
glutathionylated proteins (Adachi, Weisbrod et al. 2004). Extracted protein was mixed with 
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streptavidin-sepharose beads for 1 hour at 4⁰C in a cold room. The beads were washed in 
lysis buffer 5 times, with centrifugation at 10,000 rpm for 3 minutes between each wash. 
The washing solution was similar to the lysis buffer, but excluded NEM and included 0.1% 
sodium dodecyl sulfate (SDS). The final precipitate of beads was incubated for 15 minutes with 
elution buffer to release the S-glutathionylated proteins. The elution buffer was similar to 
the lysis buffer, but excluding NEM and including 20 mM dithiothreitol (DTT). The beads/elution 
buffer mixture was clarified by centrifugation at 10,000rpm for 3 minutes. The GSS-protein 
pulled down by this technique was then separated by gel electrophoresis after the addition of 
Laemmli buffer which contained (5 x stock); 1.5g SDS, 3.75 mL 1M Tris-HCl (pH 6.8), 0.015g 
bromophenol blue, 7.5 mL glycerol, 7.5 mL H2O. Samples were placed in Laemmli buffer at 95° C 
for 5 mins prior to SDS-PAGE. After gel electrophoresis the separated proteins were transferred 
to nitrocellulose membranes and probed with antibodies to the β1 subunit of the Na
+-K+ pump. 
(Upstate Biotechnology). Western blots were quantified by densitometry using a Las-4000 
image reader and Multi Gauge 3.1 software (Fuji Photo Film Co., Ltd.), and normalized against 
the relevant control. Exposure times were adjusted to ensure that the variation in signal 
intensity was in the linear dynamic range.  
2.7 Immunoprecipitation and immunoblotting  
After treatment under various conditions, cells were washed in PBS and then lysed in ice-cold 
RIPA buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 2 mM EDTA, 1% Triton X-100 and 
protease inhibitors. The lysates were clarified by centrifugation at 16,000 g for 20 min and were 
incubated with a monoclonal antibody to the specific protein of interest or control IgGs for 1 – 4 
hours. Protein A/G Plus-Agarose beads (40 μl of 50% slurry) were added to the supernatant for a 
further incubation overnight at 4°C then were washed five times with a RIPA buffer wash. 
Immunoprecipitated proteins were eluted by boiling at 95°C for 5 min in 40 μl Laemmli sample 
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buffer. Immune complexes were analysed by SDS-PAGE and Western blot by probing with 
various antibodies to specific proteins of interest. Western blots were quantified as described in 
Section 2.6.  
2.8 Statistical analysis 
Results are expressed as the mean ±S.E.. One-way analysis of variance was used for analysis 
of co-immunoprecipitation data and Student’s t-test was used for paired data, with a single 
tailed distribution for analysis of differences in DHE fluorescent intensity levels between 
experiments and controls. Patch-clamp data was analysed using the Student’s t-test for 
unpaired data. We used Dunnett’s test when the same control group was used for more 
than one comparison. p<0.05 was considered statistically significant.  
2.9 Chemicals and Reagents 
Product  Source  Location  
adenosine 5- triphosphate 
magnesium salt (Mg.ATP)  
Sigma Chemical Co.  St Louis, Missouri, USA  
Angiotensin II Sigma Chemical Co St Louis, Missouri, USA 
Antibody to p47phox  Santa Cruz Biotechnology  Santa Cruz, California, USA  
Antibody to the α1 subunit of 
Na+-K+ ATPase  
Millipore  Billerica, Maryland, USA  
Antibody to the β1 subunit of 
Na+-K+ ATPase  
Millipore  Billerica, Maryland, USA  
Antibody to phosphoserine Sigma Chemical Co St Louis, Missouri, USA 
barium chloride (BaCl2)  BDH  Australia  
cadmium chloride (CdCl2)  Sigma Chemical Co.  St Louis, Missouri, USA  
calcium chloride dehydrate 
(CaCl2.2H2O)  
Sigma Chemical Co.  St Louis, Missouri, USA  
C6 ceramide (D-erythro-
Sphingosine, N-Hexanoyl- 
Calbiochem La Jolla, California, USA 
diethylene triamine 
pentaacetic acid (DTPA)  
Sigma Chemical Co.  St Louis, Missouri, USA  
dihydroethidium (DHE)  Invitrogen  Carlsbad, California, USA  
dimethyl sulfoxide (DMSO) Sigma Chemical Co. St Louis, Missouri, USA 
dithiothreitol (DTT)  Merck  Darmstedt, Germany  
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ethyleneglycolol-bis-(β-
aminoethlyether)N,N,N’,N-
tetraacetic acid (EGTA)  
Sigma Chemical Co.  St Louis, Missouri, USA  
forskolin Sigma Chemical Co. St Louis, Missouri, USA 
gentamicin  Pfizer  Brooklyn, New York, USA  
glucose anhydrous (C6H12O6)  BDH  Australia  
glutathione ethyl ester (GEE)  Sigma Chemical Co.  St Louis, Missouri, USA  
HEPES (N-2-
Hydroxyethylpiprazine-N-2-
ethenesulphonic acid)  
Sigma Chemical Co.  St Louis, Missouri, USA  
hydrochloric acid (HCl)  Merck  Darmstedt, Germany  
L-Arginine Sigma Chemical Co. St Louis, Missouri, USA 
magnesium chloride 
hexahydrate (MgCl2.6H2O)  
Sigma Chemical Co.  St Louis, Missouri, USA  
magnesium sulphate 
(MgSO4)  
Sigma Chemical Co.  St Louis, Missouri, USA  
monosodium glutamate  Sigma Chemical Co.  St Louis, Missouri, USA  
N-Ethylmaleimide (NEM)  Sigma Chemical Co.  St Louis, Missouri, USA  
NMG (D(-)-methlyglucamin)  Merck  Darmstedt, Germany  
nonyl 
phenoxypolyethoxylethanol 
40 (NP40)  
Merck  Darmstedt, Germany  
okadaic acid Calbiochem La Jolla, California, USA 
ouabain  Sigma Chemical Co.  St Louis, Missouri, USA  
paraformaldehyde  Sigma Chemical Co.  St Louis, Missouri, USA  
phenylmethylsulfonyl 
fluoride (PMSF)  
Sigma Chemical Co.  St Louis, Missouri, USA  
potassium chloride (KCl)  Sigma Chemical Co.  St Louis, Missouri, USA  
potassium dihydrogen 
orthophosphate (KH2PO4)  
BDH  Australia  
potassium hydroxide (KOH)  Sigma Chemical Co.  St Louis, Missouri, USA  
potassium L-glutamate  Sigma Chemical Co.  St Louis, Missouri, USA  
Protein A/G Plus-Agarose 
beads  
Santa Cruz Biotechnxology  Santa Cruz, California, USA  
PP2A Millipore Billerica, Maryland, USA 
sodium chloride (NaCl)  Sigma Chemical Co.  St Louis, Missouri, USA  
sodium dihydrogen 
orthophosphate 
monohydrate 
(NaH2PO4.H2O)  
BDH  Australia  
sodium dodecyl sulfate (SDS)  Sigma Chemical Co.  St Louis, Missouri, USA  
sodium hydrogen carbonate 
(NaHCO3)  
Merck  Darmstedt, Germany  
sodium hydroxide (NaOH)  Sigma Chemical Co.  St Louis, Missouri, USA  
Streptavidin sepharose 
beads  
GE Healthcare Life Sciences  Buckinghamshire, UK  
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Sulfo-NHS-biotin  Calbiochem  La Jolla, California, USA  
taurine Sigma Chemical Co.  St Louis, Missouri, USA  
tautomycin Calbiochem La Jolla, California, USA 
Tetramethylammonium 
chloride (TMA,Cl)  
Fluka Chemicals  Switzerland  
tris-HCl  Sigma Chemical Co.  St Louis, Missouri, USA  
triton X-100  Sigma Chemical Co.  St Louis, Missouri, USA  
VectashieldR  Vector Laboratories Inc.  Burlingame, California, USA  
YC-1 (3-(5’-hydroxymethyl-
2’-furyl)-1-benzylindazole)  
Calbiochem  La Jolla, California, USA  
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CHAPTER 3 
 
STIMULATION OF sGC DECREASES ANGII-INDUCED SODIUM PUMP 
INHIBITION 
 
3.1 Introduction 
Heart failure is associated with activation of the renin-angiotensin-aldosterone system and 
elevation of Ang II levels that are thought to mediate some of the end organ damage in 
heart failure syndromes (Ferrario and Flack 1996). In keeping with this, treatment with Ang 
II receptor blockers and angiotensin converting enzyme inhibitors improves outcomes in 
heart failure (Jong, Demers et al. 2002; MEMBERS, Hunt et al. 2009). Adverse effects of Ang 
II are also indicated by the poorer prognosis associated with elevated levels (Roig, Perez-
Villa et al. 2000).  
Ang II has been shown to induce inhibition of the Na+-K+ pump in rabbit ventricular 
myocytes in our Laboratory (Hool, Gray et al. 1996; Buhagiar, Hansen et al. 2001; White, 
Figtree et al. 2009). To ensure that the effects of Ang II as measured by Ip were not due to 
an Ang II-induced influx of Na+ and pump stimulation arising from an increase in the 
intracellular Na+ concentration, White et al (White, Figtree et al. 2009) performed 
experiments in Na+-free superfusates. These results have been reproduced here as a 
reference for interventions that alter the signalling pathways mediating effects of Ang II on 
the pump (Fig 3.1).  
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Figure 3.1 Effect of Ang II on Na+-K+ pump current (Ip). 
Mean Ip normalized for membrane capacitance measured in superfusates 
containing Na+ at concentrations [Na+] indicated (in mmol/l). Number of 
myocytes in each group is indicated in parentheses. * indicates statistically 
significant difference between means of Ip (p<0.05). 
 
Activation of sGC by NO donor, SNP has been shown to increase Na+-K+ pump activity in 
intact rabbit cardiac myocytes (William, Vien et al. 2005) as measured by increased Ip. As NO 
is involved in other signalling pathways that do not involve the sGC/cGMP/PKG pathway, Dr 
William performed experiments with the sGC stimulator, YC-1. As was the case for a NO 
donor, YC-1 induced an increase in Na+-K+ pump activity that was abolished by inhibitors of 
sGC inhibitor, ODQ, and the PKG inhibitor, KT-5823 (Fig 3.2). 
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Figure 3.2 YC-1 induced pump stimulation and the intervening intracellular 
messenger pathways. 
Patch pipettes contained control solutions or solutions that included YC-1 and 
inhibitors of soluble guanylyl cyclase (ODQ), protein kinase G (KT-5823) or 
protein phosphatase (okadaic acid, OA) as indicated. Numbers in parentheses 
indicate the number of myocytes studied with each set of conditions. * indicates 
statistically significant difference (*P < 0.05) between mean (± S.E.) Ip values of 
myocytes perfused or not perfused with pipette solutions containing YC-1; # 
indicates statistically significant difference (*P < 0.05) between mean (± S.E.) Ip 
values of myocytes perfused with pipette solutions containing YC-1 alone and 
solutions containing both YC-1 and ODQ, KT-5823 or OA (William, Vien et al. 
2005). 
 
With its opposing effect on Na+-K+ pump activity compared to Ang II, stimulation of sGC 
presents an avenue of potential therapy in heart failure. However it is unclear if it is able to 
counterbalance the Ang II-induced reduction in Ip and attenuate the inhibitory effects of Ang 
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II on Na+-K+ pump units. This chapter examines the effects of sGC stimulation on Ang II-
induced inhibition of the Na+-K+ pump.  
3.1.1 Aims 
This chapter aims to examine the effect of sGC stimulation on the reduction in Na+-K+ pump 
activity, as measured by electrogenic pump current- Ip, induced by Ang II in cardiac 
myocytes.  
3.2 Materials and Methods 
3.2.1 Cells 
Single ventricular myocytes were isolated from male White New Zealand Rabbits and the 
whole-cell patch clamp technique was used to measure the electrogenic Na+-K+ current (Ip) 
arising from the 3:2 Na+/K+ exchange ratio. Details of anaesthesia, excision of the heart and 
cell isolation techniques have been described in detail in section 2.2. 
3.2.2 Solutions 
For measurement of Ip, the superfusate was switched to the Ca
2+- free Tyrodes solution 
which contained 100 nm Ang II and 10nM okadaic as noted. Cells were exposed to this 
solution for 10-12 minutes with a stable plateau of the holding current before being 
exposed to ouabain-containing Tyrodes solution. The ouabain-induced shift in membrane 
current identified Ip.  
3.2.3 Measurement of electrogenic Na+-K+ pump current 
Details of this method can be found in section 2.3. Briefly, after the whole-cell configuration 
was established, the cells were exposed to Ca2+-free Tyrodes solution for 10-12 minutes and 
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then to a solution that was identical except it contained 100 μM ouabain. Cells were 
clamped at a holding potential of -40 mV and holding currents before and after pump 
blockade by ouabain were identified. Experiments were only accepted as valid if currents 
before and after exposure to ouabain were stable according to predetermined criteria 
(William, Vien et al. 2005). The Ip that was identified was normalised for membrane 
capacitance and hence cell size. 
3.2.4 Statistical Analysis 
Results are expressed as means ±SE. Student’s t-test for unpaired data was used for analysis. 
Dunnett’s test was used when the same control group was used for more than one 
comparison. p<0.05 is regarded as significant for all comparisons.  
3.3 Results 
3.3.1 Stimulation of sGC decreases Ang II induced inhibition in Na+-K+ pump current. 
Ouabain used to identify Ip cannot be washed off within the time frame that the whole-cell 
configuration can be reliably maintained. Separate myocytes were therefore studied to 
determine Ip with and without stimulation of sGC. To examine the effects of sGC stimulation 
on Ang II-induced pump inhibition, we included 1μM YC-1, the haem-dependent sGC 
stimulator, in the pipette solution while Ang II was included in the superfusate. Traces of 
holding currents recorded of a myocyte exposed to Ang II only and that of a myocyte 
exposed to YC-1 as well as Ang II are shown in Panel A of Figure 3.3. The ouabain induced 
shifts in holding current is greater in the myocyte exposed to additional YC-1 compared to 
the myocyte exposed to Ang II. The mean Ip, normalised for Cm for myocytes exposed to Ang 
II and myocytes exposed to Ang II and YC-1 are shown in Panel B of Figure 3.3. The exposure 
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to YC-1, of myocytes treated with Ang II, induced a statistically significantly higher Ip, 
attenuating the Ang II-induced reduction seen compared to control myocytes.  
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Figure 3.3 Effect of activation of sGC with YC-1 on Ang II-induced inhibition 
of Na+-K+ pump current (Ip). 
The timing of changes in the composition of superfusates and the holding 
current of a myocyte exposed to Ang II and that of a myocyte exposed to Ang II 
with 1μM YC-1 included in the patch pipette are shown in Panel A. The ouabain-
induced current shift is larger in the myocyte exposed to YC-1 compared to the 
myocyte exposed to Ang II only. The mean Ip for a control myocyte not exposed 
to Ang II or YC-1 is included (dashed line) for comparison in panel B. YC-1 induced 
a statistically significant higher Ip compared to myocytes exposed to Ang II only. * 
indicates statistically significant difference (p<0.05) between mean (± S.E.) Ip 
values. The number of myocytes in each group is indicated in parentheses. 
A
Ca2+-Free + Ba2+ + Cd2+ +Ang II
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Ang II
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3.3.2 Effects of YC-1 on Ang II induced inhibition in Na+-K+ pump current  are protein 
phosphatase dependent 
Williams et al (2005) have published that the stimulatory effects of YC-1 on the Na+-K+ pump 
were abolished by the addition of inhibitors to sGC, PKG and protein phosphatase (William, 
Vien et al. 2005). Stimulation of sGC attenuates the Ang II induced decrease in summative 
Na+-K+ pump activity of the cell as measured by Ip. In order to further characterise the 
signalling pathway that mediates the effects of sGC stimulation on Ang II induced pump 
current reduction, myocytes were exposed to okadaic acid in the superfusate at a 
concentration of 10 nM. At this concentration okadaic acid preferentially inhibits PP2A 
rather than PP1 (Bialojan and Takai 1988; Honkanen, Zwiller et al. 1990; Herzig and 
Neumann 2000; Fernandez, Candenas et al. 2002) as indicated by half maximal inhibitory 
concentration (IC50) of okadaic acid for the phosphatases. The results are shown in Figure 
3.4. In myocytes exposed to 10 nM of okadaic acid and 100 nM Ang II, YC-1 did not induce 
any significant increase in Ip, implicating PP2A in the effects of YC-1 to reduce the effects of 
Ang II-induced pump inhibition.  
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Figure 3.4 Effect of YC-1 on Ang II induced inhibition of Na+-K+ pump current 
(Ip) in the presence of okadaic acid.  
10 nM okadaic acid was included in the superfusate while 1 μM YC-1 was 
included in the patch pipette as indicated. Pump current (Ip) was calculated by 
the inward shift in holding current caused by exposure to ouabain. Mean Ip ± S.E. 
are shown. * indicates statistical significance (p<0.05). The mean Ip for a control 
myocyte not exposed to Ang II or YC-1 is included (dashed line) for comparison. 
The number of myocytes in each group is indicated in parentheses. There was no 
significant difference in mean Ip values of myocytes perfused with pipette 
solutions with or without YC-1 in the presence of okadaic acid at a PP2A 
inhibitory dose of 10 nM.  
 
To confirm that the effects of YC1 are mediated by PP2A and not PP1, experiments were 
repeated using a different phosphatase inhibitor. Tautomycin preferentially inhibits PP1 
compared to PP2A with a 10-fold selectivity for PP1 over PP2A (McCluskey, Sim et al. 2002; 
Chatfield and Eastman 2004). As the IC50 of PP1 for tautomycin is 0.3-1nM, the inclusion of 
I p
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10 nM tautomycin, dissolved in dimethyl sulfoxide ,DMSO, should nearly completely inhibit 
PP1 in our myocytes while it is not known to inhibit any signalling activated by Ang II. The 
results are shown in Figure 3.5. Inhibition of PP1 with tautomycin did not reduce the effects 
of YC1 in attenuating the Ang II induced pump inhibition.  
 
Figure 3.5 Effect on YC-1 on Ang II-induced inhibition of Na+-K+ pump current 
(Ip) in the presence of tautomycin. 
10 nM tautomycin was included in the superfusate while 1 μM YC-1 was included in the 
patch pipette as indicated. Pump current (Ip) was calculated by the inward shift in 
holding current caused by exposure to ouabain. Mean Ip ± S.E. are shown. * indicates 
statistical significance (p<0.05). The mean Ip for a control myocyte not exposed to Ang II 
or YC-1 is included (dashed line) for comparison. The number of myocytes in each group 
is indicated in parentheses. There was no significant difference in mean Ip values of 
myocytes perfused with pipette solutions with or without YC-1 in the presence of 
tautomycin at a PP1-inhibitory dose of 10nM.  
I p
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*
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3.3.3 Effects of a PP2A activator, C6 ceramide, parallel that of YC1 
The preceding results indicate that exposure of cells to YC-1 in addition to Ang II results in 
less inhibition of the Na+-K+ pump as evidenced by less reduction in Ip. This effect of YC-1 is 
PP2A- dependent. To confirm the effects of PP2A on the Na+-K+ pump in cells exposed to 
Ang II, we examined the effects of including PP2A in the filling solutions of patch pipettes 
that were used to voltage clamp myocytes. PP2A was added to the pipette solution at a 
concentration of 0.1 units/ml. When the membranes were ruptured, after achievement of 
the whole cell configuration, the dialysis of the intracellular space with the pipette solution, 
repeatedly resulted in cell death. This is likely due to the dilution buffer in which the purified 
PP2A enzyme preparation (Upstate, New York, USA) was in which contained strong 
reductants, including 60 mM 2-mercaptoethanol and 1mM DTT, in addition to 10% glycerol. 
Despite dilution, these compounds are likely to have caused membrane disruption and cell 
death.  
As an alternative to directly including PP2A in patch pipette solutions, we used C6 ceramide, 
to activate PP2A native to the myocytes. C6 ceramide is a naturally occurring membrane 
permeable sphingolipid that interacts with PP2A as a direct allosteric activator and as an 
inhibitor of inhibitor 2 while it has no effect on inhibitor 1 (Dobrowsky, Kamibayashi et al. 
1993; Mukhopadhyay, Saddoughi et al. 2009; Voronkov, Braithwaite et al. 2011). These 
properties may explain its preferential activation of PP2A over PP1.  
C6 ceramide was added to the superfusate to examine effects of PP2A activation on Ip in 
cells exposed to Ang II. Results are shown in panel A of Fig 3.6. Compared to cells exposed to 
Ang II alone, cells exposed to additional C6 ceramide had a significantly higher Ip. This effect 
of C6 ceramide was abolished by the addition of 10 nM okadaic acid, independently 
supporting that PP2A mediates the effect of C6 ceramide. The effects of C6 ceramide parallel 
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those of YC-1 on Ang II-induced Na+-K+ pump inhibition which are summarised in panel B of 
Fig 3.6  
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Figure 3.6 Effect of C6 Ceramide on Ang II induced inhibition of Na+-K+ 
pump current(Ip). 
Panel A: 10nM okadaic acid and 10μM C6 ceramide was included in the superfusates as 
indicated. Pump current (Ip) was calculated by the inward shift in holding current caused 
by exposure to ouabain. Mean Ip ± S.E. are shown. * indicates statistical significance 
(p<0.05). The mean Ip for a control myocyte not exposed to Ang II or C6 ceramide is 
included (dashed line) for comparison. The number of myocytes in each group is 
indicated in parentheses.C6 ceramide significantly increased Ip compared to myocytes 
exposed to Ang II alone. This effect was abolished by 10nM okadaic acid. Panel B: The 
effects of YC-1 on Ang II induced inhibition of Na+-K+ pump currents in the presence and 
absence of preferential inhibitors of PP2A (okadaic acid) and PP1 (tautomycin). The 
effects of C6 ceramide parallel that of YC-1.  
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3.4 Discussion 
The findings presented in this chapter are that activation of sGC with YC-1 results in a 
reduction of the Ang II-induced inhibition of the Na+-K+ pump Ip in a PP2A-dependent 
manner. Activation of PP2A with C6 ceramide similarly resulted in a reduction of the 
inhibition of the pump.  
3.4.1 YC-1 attenuates the effects of Ang II 
Despite the firmly established Ang II-induced NADPH oxidase activation (Williams and 
Griendling 2007) and multiple studies from different laboratories indicating the inhibitory 
effects of oxidant stress on the Na+-K+ pump (Shattock and Matsuura 1993; Bogdanova, 
Petrushanko et al. 2006; White, Hamilton et al. 2008; Fuller, Tulloch et al. 2012), studies of 
the effects of Ang II on the Na+-K+ pump have had conflicting results. Ang II has been 
reported to cause stimulation of the Na+-K+ pump in human endothelial cells (Muscella, 
Marsigliante et al. 1997) rat astrocytes (Muscella, Aloisi et al. 2000), rat thyroid cells 
(Marsigliante, Muscella et al. 2003), vascular smooth muscle (Isenovic, Jacobs et al. 2004) 
and rat proximal tubule cells (Javkhedkar, Lokhandwala et al. 2012). Inhibitory effects of Ang 
II have been reported by others. In proximal tubule cells, the Na+-K+ pump has a biphasic 
response to Ang II with stimulation at lower doses and inhibition at higher concentrations. 
(Bharatula, Hussain et al. 1998; Banday and Lokhandwala 2008). Ang II has been found to 
inhibit the Na+-K+ pump in intestinal cells (Marsigliante, Muscella et al. 2001). Even within 
proximal tubule cells, Fekete et al (Fekete, Rosta et al. 2008) demonstrated that while Ang II 
increased transcription of Na+-K+ pump subunits in the proximal tubule cells of diabetic rats, 
they were in the cytosolic fraction with increased translocation of subunits from the 
membrane thus resulting in decreased functioning Na+-K+ pump units. Ang II has also been 
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reported to attenuate the stimulatory effects of other compounds including insulin-like 
growth factor 1 (IGF-1) in vascular smooth muscle (Isenovic, Meng et al. 2004). 
We have previously shown Ang II induced inhibition of Na+-K+ pump in cardiac myocytes. 
This inhibition was abolished with the addition of polyethylene glycol-conjugated 
superoxide dismutase, apocynin- an inhibitor of NADPH oxidase of variable specificity, 
gp91ds peptide and εPKC inhibitory peptide.(White, Figtree et al. 2009). These results 
indicate that Ang II-induced Na+-K+ pump inhibition is NADPH oxidase dependent. 
There are several possible reasons for the divergent reported results of the effects of Ang II 
on the Na+-K+ pump, including tissue-specific differences in its regulation and the difference 
in methodology of measurement of Na+-K+ ATPase activity. Of importance is the ability of 
Ang II to affect non-pump membrane currents and increase Na+ influx, that could lead to an 
increase in pump activity secondary to increased intracellular Na+. Ang II has been reported 
to increase renal Na+ absorption and decrease Na+ excretion in an aldosterone independent 
manner (Beutler, Masilamani et al. 2003; Zhao, Seth et al. 2009). Sun et al(Sun, Yue et al. 
2012) reported that Ang II caused an increased Na+ influx, in a PKC-dependent manner, into 
cortical collecting duct cells of rats by increasing the activity of epithelial Na+ channels 
(ENaC) as measured by channel numbers and open probability. Ang II has been shown to 
stimulate Na absorption and to increase the transcription of ENaC in the colon (Hatch and 
Freel 2008). Ang II also has been reported to activate other co-transporters including the 
Na+/HCO3
- co-transporter in cat cardiac myocytes that can potentially lead to an increase in 
the intracellular Na+ concentration (Aiello and De Giusti 2012). An additional confounder to 
the effects of Ang II on intracellular Na+ and hence assessment of Na+-K+ pump activity, is 
that ROS have been reported to have stimulatory or inhibitory effects on the Na+/H+ 
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exchanger, Na+-K+-2Cl- co-transporter and ENaC in a tissue specific manner(Juncos and 
Garvin 2005; Juncos, Hong et al. 2006; Yu, Bao et al. 2007; Lazrak, Iles et al. 2009). Hence, 
the Ang II induced production of ROS via NADPH oxidase may be another mechanism of Ang 
II induced stimulation of non-pump membrane currents. Thus, an Ang II-induced increase in 
Na+ influx may have contributed to some apparent stimulatory effects on the Na+-K+ pump 
reported by others. To reduce the effects of the confounders described above and ensure 
any increase in Ip  seen was correctly attributed to the effects of cell signalling from the 
activation of sGC and not due to increased substrate of intracellular Na+ loading, all 
experiments presented in this chapter were performed in Na+ free superfusates.  
Another explanation for the divergent reported effects of Ang II on the Na+-K+ pump is the 
differing contributions of other signalling pathways that may reduce the effects of Ang II, 
including that mediated by the activation of sGC presented here. Our Laboratory has 
previously shown that sGC activation either by a NO donor or YC-1 (the latter to avoid the 
non-sGC dependent consequences of NO) results in stimulation of the Na+-K+ pump. This 
effect was dependent on PKG and protein phosphatases (William, Vien et al. 2005). Studies 
of the effect of NO donors on Na+-K+ pump activity have also had conflicting results with 
inhibition seen in kidney cells (Liang and Knox 2000), the renal medulla (McKee, Scavone et 
al. 1994) and epithelial cells of the eye (Shahidullah and Delamere 2006). In contrast, 
stimulation has been seen in rabbit aorta (Gupta, McArthur et al. 1994) and the smooth 
muscle of the corpus cavernosum (Gupta, Moreland et al. 1995). Tissue-specific differences 
in Na+-K+ pump regulation, differences in methodology used to study the Na+-K+ pump and 
variable delivery of NO and its bioactive derivatives by the donor compounds may have 
contributed to the conflicting results between studies. In addition, NO can contribute to the 
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formation of ROS/RNS (Joshi, Ponthier et al. 1999) which our recent findings have shown are 
inhibitory of the Na+-K+ pump (White, Hamilton et al. 2008). Studies examining the effects of 
sGC stimulators on the Na+-K+ pump have been more consistent in reporting stimulation of 
the pump, including via non-cGMP mediated pathways. YC-1 induced relaxation of human 
mesenteric arteries in part by stimulation of the Na+-K+ pump (Slupski, Szadujkis-Szadurski et 
al. 2007). Another sGC stimulator, BAY-41-2272, has been found to stimulate the Na+-K+ 
pump in bovine pulmonary artery, with effects seen even after inhibition of sGC 
(Bawankule, Sathishkumar et al. 2005). 
Our study demonstrates that activation of sGC with YC-1 attenuated the Ang II-induced 
inhibition of the Na+-K+ pump. Exposure to Ang II decreased Ip to 0.35±0.04 pA/pF compared 
to control cells which had an Ip of 0.5±0.03 pA/pF. The addition of YC-1 in the patch pipette 
in cells exposed to Ang II resulted in a significant increase in Ip to 0.51±0.06 pA/pF compared 
to cells without YC-1, consistent with restoration of Na+-K+ pump activity.  
3.4.2 Identification of protein phosphatase mediating the effects of YC-1 
The signalling pathway of sGC from its activation by YC-1 to the Na+-K+ pump in myocytes 
with no other experimentally activated pathway has been examined in our lab by Dr Maged 
William (William, Vien et al. 2005). The stimulatory effects of YC-1 were abolished with 
addition into the patch pipette of ODQ (inhibitor of sGC), KT-5823 (inhibitory of PKG), or 
okadaic acid. These results with the use of pharmacological inhibitors implicated cGMP and 
PKG. The role of cGMP was directly supported by the YC-1 induced Na+-K+ pump stimulation 
being reproduced with exposure of voltage clamped myocytes to the cGMP analogue 8-
pCPT-cGMP or with inclusion of activated PKG in patch pipette solutions. In experiments 
performed by William et al (William, Vien et al. 2005), okadaic acid was included in the 
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patch pipette at a concentration of 100 nM. Okadaic acid is highly membrane permeable. 
Thus, while it would inhibit both PP1 and PP2A according to their IC50 in concentration used 
in the pipette solution, the intracellular concentration of okadaic acid is likely to have been 
considerably lower as its high membrane permeability causes it to diffuse out into the 
extracellular space. Hence, it is uncertain if okadaic acid in the intracellular compartment of 
the voltage clamped myocytes reflects the concentration in the patch pipette solution. To 
eliminate this uncertainty, okadaic acid was added to the superfusate instead of the pipette 
solution in the series of experiments presented here when examining if the effects of YC-1 
on the inhibitory effects of Ang II on the Na+-K+ pump were phosphatase dependent. The 
results implicated PP2A that is inhibited by okadaic acid at a much lower concentration than 
PP1 that was implicated in results reported by William et al (William 2005). 
Unfortunately, the selectivity of protein phosphatase inhibitors is not absolute with some 
degree of cross selectivity. There is, however, a useful difference in relative selectivity based 
on the IC50 of different compounds against different phosphatases. Okadaic acid is useful as 
its IC50 against the different protein phosphatases differs by orders of magnitude. The IC50 
for the dominant phosphoprotein phosphatases are PP1: 20-42 nM; PP2A: 0.2-1 nM, 
PP2B:5000 nM.(Bialojan and Takai 1988; Honkanen, Zwiller et al. 1990; Fernandez, 
Candenas et al. 2002). Thus, at 10 nM, okadaic acid has relative selectivity for PP2A. In 
contrast, tautomycin is more selective for PP1 with IC50 for the various dominant 
phosphoprotein phosphatases being PP1: 0.3-0.7 nM; PP2A: 30 nM, PP2B: 80,000. 
(MacKintosh and Klumpp 1990; Hardie 1999). In experiments presented here, the addition 
of okadaic acid at a PP2A-inhibitory dose of 10 nM to the superfusate abolished the 
attenuating effects of YC-1 on Ang II-induced pump inhibition. In contrast, in the presence of 
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tautomycin at a PP1-inhibitory dose, YC-1 remained able to attenuate the inhibitory effects 
of Ang II. Thus, use of okadaic acid implicated PP2A rather than PP1 in the effects of sGC 
activation to reduce Ang II-induced pump inhibition. The role of PP2A was supported by the 
use of a PP2A activator, C6 ceramide. Similar to YC-1, the inclusion of C6 ceramide in the 
patch pipette attenuated the Ang II-induced decrease in an okadaic acid sensitive manner.  
These results presented in this chapter indicate that stimulation of sGC reduces the 
inhibitory effects of Ang II on Na+-K+ pump activity as seen by the effects on Ip. This effect of 
sGC stimulation may be from a signalling pathway to the pump that is completely separate 
to that of Ang II, with the final Ip being the final summation of two counterbalancing effects 
on pump activity. While this effect of stimulation of sGC in principle could be due to an 
effect on a sGC-dependent pathway shared with Ang II-dependent signalling, no such shared 
signalling is known to exist. There could also be an interaction between separate signalling 
pathways linking sGC and Ang II to Na+-K+ pump regulation. The results presented in this 
chapter do not allow a distinction to be made. It will be further explored in Chapters 4 and 
5. However, the results do indicate a role of dephosphorylation by PP2A in attenuating the 
inhibitory effects on the Na+-K+ pump of Ang II. With increased Ang II activity seen in heart 
failure, and compounds that inhibit the Na+-K+ pump being associated with a worse 
prognosis in heart failure (Galougahi, Liu et al. 2012), modulation of PP2A activity by 
upstream regulators of NO signalling hence presents a potential therapeutic approach. sGC 
activation may potentially, via PP2A, reduce the phosphorylation of p47phox and hence 
NADPH oxidase activity which may explain the ameliorating effects of sGC stimulation on 
Ang II-induced inhibition of Na+-K+ pump current. We further examine this hypothesis in 
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Chapter 4, by assessing the effects of YC-1 on Ang II-induced intracellular O2
 production 
and NADPH oxidase activation. 
3.5 Conclusion  
Stimulation of sGC with YC-1 attenuates the effects of Ang II-induced inhibition of the Na+-K+ 
pump in cardiac myocytes in a PP2A-dependent manner. 
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CHAPTER 4 
 
EFFECTS OF STIMULATION OF sGC ON NADPH OXIDASE AND SUPEROXIDE-
SENSITIVE FLUORESCENCE IN ANG II-STIMULATED CELLS 
 
4.1 Introduction 
Increased oxidative stress is implicated as being part of the pathophysiology of chronic heart 
failure in humans as well as in animal models (Zhang and Forman 2012). Consistent with this 
is the increase in ROS levels seen with failing hearts in both humans and animal studies (Ide, 
Tsutsui et al. 2000; Anilkumar, Sirker et al. 2009). While there are several potential sources 
of ROS in cardiac myocytes, such as mitochondrial respiratory chain enzymes, xanthine 
oxidases, lipoxygenases, myeloperoxidases, uncoupled nitric oxide synthase, and NADPH 
oxidase proteins, there is a large body of evidence suggesting that NADPH oxidase is 
involved in the redox signalling regulation of cardiac function and development (Zimmet and 
Hare 2006; Burgoyne, Mongue-Din et al. 2012). 
As described in Chapter 1, activation of Nox 2 involves serine phosphorylation of p47phox and 
increased colocalisation of p47phox with membrane bound p22phox. While this was initially 
described in neutrophils, increased serine phosphorylation of p47phox and p47phox membrane 
translocation with increased NADPH oxidase activity has also been described in endothelial 
cells (Li and Shah 2003; Li, Fan et al. 2005) and cardiomyocytes (Ribé, Sawbridge et al. 2008).  
Ang II has been found to activate NADPH oxidases in fibroblasts (Cifuentes, Rey et al. 2000), 
endothelial cells (Zhang, Schmeisser et al. 1999; Lang, Mosfer et al. 2000), vascular smooth 
muscle (Griendling, Sorescu et al. 2000; Schieffer, Luchtefeld et al. 2000; Nguyen Dinh Cat, 
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Montezano et al. 2012) and cardiomyocytes (Bendall, Cave et al. 2002). Increased ROS via 
NADPH oxidase is implicated in the adverse phenotypes of heart failure, hypertension and 
left ventricular hypertrophy associated with elevated Ang II levels.  
Despite the evidence linking elevated ROS with heart failure, trials examining the use of 
antioxidants, specifically vitamins, in the treatment of heart failure have had disappointing 
results (Yusuf, Dagenais et al. 2000; Cook Nr and et al. 2007; Sesso Hd and et al. 2008). 
Hence, it appears that the relationship between oxidative stress and congestive heart failure 
or its antecedent conditions is more complex than initially perceived. The effects of ROS 
may be highly dependent upon their source, location, local concentration, and perhaps even 
nature of the ROS species that is generated. Thus, strategies to reduce the effects of ROS 
might be more successful if targeted at the microdomains for receptor mediated 
transduction of oxidant signalling.  
Our Laboratory has previously demonstrated that Ang II induces a PKC-dependent activation 
of NADPH oxidase and an increase in O2
-sensitive DHE fluorescence, implicating an 
increase in O2
 production (White, Figtree et al. 2009). A mechanism of modulating the Ang 
II-induced NADPH oxidase activity can potentially be a mechanism of attenuating its 
inhibitory effects on the Na+-K+ pump.  
4.1.1. Aims 
This chapter examines the effects of stimulation of sGC on Ang II-induced O2
 levels in 
cardiac myocytes as indicated by DHE fluorescence. The effects of sGC activation on Ang II 
activation of NADPH oxidase will also be examined.  
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4.2 Methods and Materials  
4.2.1 Cells 
Single ventricular myocytes were isolated from male White New Zealand Rabbits. Details of 
anaesthesia, excision of the heart and cell isolation techniques have been described in detail 
in section 2.2. 
4.2.2 Imaging of intracellular superoxide levels by DHE fluorescence 
The oxidative fluorescent dye, DHE, was used to image intracellular O2
 as outlined in 
Section 2.5. Myocytes were exposed to 100 nM Ang II for 10 minutes after having been 
preincubated with 10 μM YC-1 or control solutions for 30 minutes. Cells were then fixed. A 
separate set of experiments were performed with similar protocols except that cells were 
coincubated, in addition to 10 μM YC-1 or control solutions, with a protein phosphatase 
inhibitor, okadaic acid, at a PP2A-inhibiting dose of 10 nM The average intensity for cells 
from each experiment was normalized against its control (100%). 
4.2.3 Detection of protein co-immunoprecipitation and serine phosphorylation.  
Cells pre-incubated for 15 minutes with 10 μM YC-1 or control solutions were exposed to 
100 nM Ang II or not for 15 minutes at 37 °C. Cells were subsequently lysed in ice-cold 
buffer as described in Section 2.7. Immunoprecipitated proteins were eluted by boiling at 
95°C for 5 min in 40 μl Laemmli sample buffer. Immune complexes were analysed by SDS-
PAGE and Western blot by probing with antibodies to p47phox, the α1-subunit of Na
+-K+-
pump and to phosphoserine. Data are presented for at least three different experiments for 
each condition. 
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4.2.4 Statistical analysis 
Results are expressed as means ±S.E.. One-way ANOVA was used for analysis of 
immunoprecipitation data and Student’s t-test was used for paired data, with single-tailed 
distribution for analysis of differences in DHE fluorescence intensity levels between 
experiments and controls. p< 0.05 was regarded as significant in all comparisons.  
4.3 Results 
4.3.1 Stimulation of sGC in Ang II exposed cells results in a phosphatase-dependent 
decrease in intracellular superoxide levels  
We examined whether YC-1 decreases fluorescence of cardiac myocytes loaded with O2
-
sensitive dye, DHE, in cells that have been exposed to Ang II. Incubation of cells with 10 μM 
YC-1 for 15 minutes prior to exposure to 100 nM Ang II for 10 minutes decreased DHE 
fluorescence compared with control cells. Since the sGC/cGMP/PKG pathway activates PP2A 
(Zhou, Ruth et al. 1996; Dawson-Scully, Armstrong et al. 2007; Dawson-Scully, Bukvic et al. 
2010), and  stimulates the pump in a PP2A-dependent manner as discussed in chapter 3, we 
examined the role of PP2A in the effects of YC-1 on DHE fluorescence in Ang II-exposed cells. 
Incubation of cells with okadaic acid at a concentration of 10 nM abolished the YC-1 induced 
decrease in DHE fluorescence in Ang II-exposed cells. Representative micrographs are 
shown in Panel A of Figure 4.1 while the results of the fluorescence studies are summarised 
in Panel B of Figure 4.1.  
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Figure 4.1 Effect of stimulation of sGC by YC-1 on O2
-sensitive DHE 
fluorescence in Ang II stimulated cells.  
Myocytes were loaded with the O2
-sensitive dye DHE and examined by 
fluorescent confocal microscopy. Ang II was used to activate NADPH oxidase. In 
some experiments, myocytes were pre-incubated with the phosphoprotein 
phosphatase inhibitor okadaic acid at a PP2A-inhibiting dose of 10 nM. 
Representative micrographs are shown in panel A. The mean fluorescence 
intensity for each condition, after the subtraction of baseline fluorescence, is 
shown in panel B. YC-1 induced a significant decrease in fluorescence versus 
control. This decrease was abolished by okadaic acid. * indicates statistical 
significance between means (±S.E.) of fluorescence intensity (p<0.05). The 
number of experiments in each group is indicated in parentheses. 
 
4.3.2 Effect of a PP2A activator, C6 ceramide, on intracellular superoxide levels, parallel 
that of YC1 in Ang II-stimulated cells 
The preceding results indicate that the effects of YC-1 in attenuating Ang II-induced increase 
in intracellular O2
 levels, as indicated by O2
 sensitive DHE fluorescence, are PP2A-
dependent. To confirm the effects of PP2A the experiments were repeated using the PP2A 
activator C6 ceramide. Incubation of cells with 10μM C6 ceramide for 15 minutes prior to 
exposure to 100nM Ang II for 10 minutes decreased DHE fluorescence compared with 
control cells. In parallel with the effects of YC-1, the decrease in DHE fluorescence was 
okadaic acid-sensitive at a PP2A-inhibiting dose. Representative micrographs are shown in 
Panel A of Figure 4.2 while the results of the fluorescence studies are summarised in Panel B 
of Figure 4.2. 
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Figure 4.2 Effect of stimulation of PP2A activator, C6 ceramide on O2-
sensitive DHE fluorescence in Ang II stimulated cells.  
Myocytes were loaded with the O2
-sensitive dye DHE and examined by 
fluorescent confocal microscopy. Ang II was used to activate NADPH oxidase. In 
some experiments, myocytes were pre-incubated with the phosphoprotein 
phosphatase inhibitor okadaic acid at a PP2A inhibiting dose of 10nM. 
Representative micrographs are shown in panel A. The mean fluorescence 
intensity for each condition, after the subtraction of baseline fluorescence, is 
shown in panel B. C6 ceramide, induced a significant decrease in fluorescence 
versus control. This decrease was abolished by okadaic acid. These effects of C6 
ceramide parallel that of YC-1. * indicates statistical significance between means 
(±S.E.) of fluorescence intensity (p<0.05). The number of experiments in each 
group is indicated in parentheses. 
 
4.3.3 Stimulation of sGC results in decreased serine phosphorylation of p47phox in both 
cells exposed and not exposed to Ang II.  
Serine phosphorylation of p47phox is necessary for the activation of NADPH oxidase, 
including activation of Nox 2 oxidase in non-neutrophil cells (Li and Shah 2003; Ribé, 
Sawbridge et al. 2008). We examined the effects of sGC stimulation and Ang II on serine 
phosphorylation of p47phox . Cell lysates were immunoprecipitated with p47phox and then 
immunoblotted for phosphoserine. As shown in Figure 4.3, sGC stimulation resulted in a 
decrease in serine phosphorylation of p47phox while Ang II resulted in an increase in serine 
phosphorylation. We next examined if sGC stimulation attenuated the Ang II-induced 
increase in p47phox phosphorylation. As seen in Figure 4.4, preincubation of cells with 10 μM 
YC-1 significantly decreased serine phosphorylation of p47phox compared to cells exposed to 
100 nM Ang II alone. This is consistent with sGC stimulation attenuating Ang II induced 
activation of NADPH oxidase.  
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Figure 4.3 Effect of YC-1 and Ang II on baseline p47phox serine 
phosphorylation.  
Myocytes were exposed to control solutions or to YC-1 (10 μM). Myocytes 
exposed to 100nM Ang II was included as a positive control. Cell lysates were 
immunoprecipitated (IP) with p47phox antibody and then immunoblotted (IB) for 
p47phox and phosphoserine (upper panel). The histogram (lower panel) shows 
mean densitometry (±S.E.) of immunoblots from 3 experiments standardised to 
the value from control samples. * indicates significant difference compared with 
control (p<0.05).  
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Figure 4.4 Effect of YC-1 on NADPH oxidase activation in Ang II-exposed 
cells.  
Myocytes were exposed to 100 nM Ang II with or without preincubation in 
solutions containing 10 μM YC-1. Cell lysates were immunoprecipitated with 
p47phox antibody and then immunoblotted for p47phox and phosphoserine (upper 
panel). The histogram shows the mean densitometry (±S.E.) of immunoblots 
from 3 experiments standardised to the value from control samples from Ang II 
exposed cells (lower panel). * indicates significant difference (p<0.05).  
 
4.3.3 Stimulation of sGC causes a decreased interaction of p47phox and the α1 subunit of 
the Na+-K+ pump in control cells and cells exposed to Ang II.  
Activation of Nox 2 involves the translocation of cytosolic p47phox subunits to the membrane 
to bind to the p22phox subunit of the membrane bound cytochrome b558 as discussed in 
Chapter 1. Consistent with this is increased co-immunoprecipitation of p47phox and p22phox 
seen with NADPH oxidase activation (Lassègue, San Martín et al. 2012) including that 
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induced by Ang II in cardiomyocytes (White, Figtree et al. 2009) and endothelial cells (Li and 
Shah 2003; Li and Shah 2004). To further confirm the effect of sGC stimulation on NADPH 
oxidase activation, we attempted to examine the effects of YC-1 on membrane translocation 
of p47phox by studying the effects of YC-1 on co-immunoprecipitation of p47phox and p22phox. 
Unfortunately, we were unable to consistently detect p22phox in whole cell lysates or 
immunoprecipitates obtained from isolated rabbit cardiac myocytes during the duration of 
this research using the commercially available monoclonal and polyclonal antibodies to 
p22phox (Santa Cruz Biotechnology, Santa Cruz, California, USA). This was unexpected as we 
have previously demonstrated increased coimmunoprecipitation of p47phox and p22phox with 
Ang II using these commercial antibodies (White, Figtree et al. 2009). It is possible that the 
different lots that were used may have had a different affinity compared to that previously 
used.  
The α1 subunit of the Na
+-K+ pump is membrane bound. We have previously shown that 
p22phox co-immunoprecipitates with the α1 subunit of the Na
+-K+ pump and this association 
is unaffected by various signalling cascades initiated by Ang II binding (White, Figtree et al. 
2009). It has also been shown that just as Ang II increases the co-immunoprecipitation of 
p47phox and p22phox consistent with the membrane translocation of the cytosolic p47phox 
subunits, Ang II increases the co-immunoprecipitation of p47phox and the membrane 
associated α1 subunit of the Na
+-K+ pump. This association reflects both the membrane 
translocation of p47phox with activation and the translocation of this crucial NADPH oxidase 
subunit to the microdomain of the Na+-K+ pump. Hence, we examined the effects of YC-1 on 
p47phox/α1 interaction in both unstimulated cells and in Ang II stimulated cells. Incubation 
with YC-1 did not cause a significant decrease in co-immunoprecipitation of p47phox and α1 
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subunit in resting cells (Panel A, Fig 4.5). However, in myocytes exposed to Ang II, YC-1 
attenuated the Ang II-induced increase in co-immunoprecipitation of p47phox and α1, 
consistent with a decrease in Ang II-induced NADPH oxidase activation. ( Panel B, Fig 4.5) 
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Figure 4.5 Effect of YC-1 on co-immunoprecipitation of p47phox with α1 subunit of 
the Na+-K+ pump.  
A: Myocytes exposed to control solutions or solutions containing YC-1 (10 μM) or 
Ang II (100 nM). Cell lysates were immunoprecipitated (IP) with p47phox antibody 
and immunoblotted (IB) for p47phox and α1 subunit of the Na
+-K+ pump (upper 
panel). The histogram shows the mean (±S.E.) densitometry of immunoblots 
from 3 experiments standardized to the value of control samples (lower panel). 
YC-1 induced a decrease in p47phox/α1 co-immunoprecipitation, while Ang II 
induced an increase in p47phox/α1 co-immunoprecipitation compared to control. 
B: Myocytes were exposed to 100 nM Ang II. Cells were preincubated in control 
solutions or solutions containing 10 μM YC-1. Cell lysates were 
immunoprecipitated with p47phox antibody and then immunoblotted for p47phox 
and α1. The histogram shows the mean (±S.E.) densitometry of immunoblots 
from 3 experiments standardised to the value from control samples from Ang II-
exposed cells. YC-1 induced a significant decrease in p47phox/α1 co-
immunoprecipitation compared to Ang II-exposed controls. * indicates significant 
difference compared with control (p<0.05).  
 
4.4 Discussion 
We examined the effects of sGC on oxidant signalling in cardiac myocytes as a potential 
mechanism for the attenuation of Ang II-induced Na+-K+ pump inhibition described in 
Chapter 3. Our findings presented in this chapter are that stimulation of sGC with YC-1 
reduces intracellular superoxide levels in Ang II exposed cells as estimated by O2
 sensitive 
DHE fluorescence. This is in keeping with a reduction in NADPH oxidase activation implied 
by p47phox immunoprecipitation experiments. Further, the effects of YC-1 on O2
-sensitive 
DHE fluorescence in Ang II stimulated cells is PP2A dependent.  
4.4.1 Stimulation of sGC reduces intracellular superoxide levels in Ang II stimulated cells 
in a PP2A dependent manner. 
Dihydroethidium (DHE) is a widely used probe for detecting intracellular O2
 (Zhao, 
Kalivendi et al. 2003). The reaction between O2
 and DHE results in the formation of 2-
hydroxyethidium (2-OH-E+) which causes a red fluorescence. (Zielonka and Kalyanaraman 
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2010). However, red fluorescence also results from the two-electron oxidation product of 
DHE, E+, which is formed from oxidation by other non-O2
 ROS. Consequently, DHE 
fluorescence, while O2
 sensitive, is a qualitative, not a quantitative indicator of 
intracellular O2
 (Kalyanaraman, Darley-Usmar et al. 2012). It still is of utility in the 
assessment of relative levels of ROS and we have previously confirmed that the increase 
DHE fluorescence in rabbit ventricular myocytes stimulated with Ang II is abolished with the 
addition of superoxide dismutase. This is consistent with the DHE fluorescence being O2
-
sensitive and Ang II-induced increase in NADPH oxidase activity increasing intracellular O2
 
(White, Figtree et al. 2009). 
Due to the variability in yield of viable cells in our freshly isolated cardiac myocytes, it is 
important that a cell is identified as viable before its O2
 levels are included in the data set. 
The method of DHE fluorescence combined with confocal microscopy allows us to first 
determine the viability of the myocyte from its morphology and then measure its DHE level. 
Alternative techniques that may be more quantitative, such as combining fluorescence 
measurements with HPLC could be difficult to interpret due to the inclusion of ROS from 
dying/dead cells in the measurements.  
Hence, despite the above delineated limitations, the technique of DHE fluorescence is a 
reasonable technique to be utilized to image and compare the relative levels of intracellular 
O2
 between different conditions of experiments as done here. Pre incubation with YC-1 
reduced the Ang II induced increase in O2 sensitive DHE fluorescence in a PP2A dependent 
manner. The effects of PP2A in the signalling from stimulation of sGC to O2 production 
were independently demonstrated by the use of a PP2A activator, C6 ceramide, which 
paralleled the effect of YC-1 on DHE fluorescence.  
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These results support the hypothesis that stimulation of sGC is able to reduce  NADPH 
oxidase activity as evident by its effect on intracellular O2
. The actions of the 
NO/sGC/cGMP signalling pathway in reducing NADPH oxidase activity has also been 
demonstrated by others. NO has been reported to suppress vascular inflammation by 
attenuation of NADPH oxidase-dependent O2
 production (Harrison, Drummond et al. 
2010). Duerrschmidt et al (2006) have demonstrated, that increased NO by use of the NO 
donor DETA-NO, reduces O2
 production and downregulates NADPH oxidase expression 
(Duerrschmidt, Stielow et al. 2006). The NO-mediated regulation of NADPH oxidase has not 
only been demonstrated in endothelial cells, but also in cardiomyocytes. A large amount of 
work has been targeted at the anti-hypertrophic effects of cGMP signalling. Hypertrophic 
stimuli to cardiomyocytes such as Ang II, endothelin and catecholamines all have been 
shown to increase cardiomyocyte production of ROS (Nakamura, Fushimi et al. 1998; 
Tanaka, Honda et al. 2001; Liu, Cheng et al. 2004; Laskowski, Woodman et al. 2006). ROS, in 
particular O2
, have been recognized as important triggers of left ventricular hypertrophy 
both in vitro and in vivo (Adiga and Nair 2008; Ritchie 2009). Thus, the negative regulation 
of cardiomyocyte O2
 generation by cGMP signalling is a potential therapeutic target. 
(Ritchie, Irvine et al. 2009). To avoid the confounding effects of conventional NO donors 
with which O2
 can rapidly react to form the RNS ONOO, while also limiting NO availability, 
the effects of sGC activation has also been examined. Recently, sGC activation with nitroxyl, 
HNO, which has a lack of reactivity with ROS, prevented Ang II-induced cardiomyocyte 
hypertrophy in neonatal rat cardiomyocytes (Lin, Irvine et al. 2012). In keeping with our 
results, Lin et al demonstrated that increased sGC activity suppressed Ang II induced NADPH 
oxidase derived cardiomyocyte superoxide generation. The same group have demonstrated 
similar effects of sGC activation with the NO-independent sGC activator BAY-58-2667. The 
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activator inhibited endothelin-1-induced cardiomyocytes’ O2
 generation as detected by 
lucigenin-enhanced chemiluminescence (Irvine, Ganthavee et al. 2012).  
The dependence of YC-1 on PP2A in its attenuation of Ang II-induced O2
-sensitive DHE 
fluorescence is consistent with the inhibitory effects of Ang II and O2
 (White, Figtree et al. 
2009) on Ip and the reduced inhibition with the addition of YC-1 as described in Chapter 3. 
The role of PP2A in reducing NADPH oxidase activity was independently supported by 
experiments performed with C6 ceramide which similarly attenuated Ang II-induced O2
--
sensitive DHE fluorescence in an okadaic acid-sensitive manner. While the information from 
these experiments cannot identify the target of desphosphorylation by PP2A, plausible 
targets are the serine residues on the AIR of p47phox shown to undergo PKC-dependent 
phosphorylation as part of NADPH oxidase activation.  
As discussed, the imaging of O2
 by DHE fluorescence is qualitative and there is possibility 
of confounding effects of ROS from non-NADPH oxidase sources. Hence, we looked directly 
at the effects of YC-1 on the p47phox subunit of NADPH oxidase.  
4.4.2 Stimulation of sGC reduces activation of NADPH oxidase in Ang II stimulated cells. 
Nox 2 and Nox 4 are the NADPH oxidase isoforms expressed in cardiac myocytes (Nauseef 
2008). Nox 2 activation involves the membrane translocation of p47phox whereas this 
cytosolic subunit is not a component of the constitutively active Nox 4. The PKC dependent 
phosphorylation of p47phox is a crucial step in the activation of Nox 2 (DeCoursey and Ligeti 
2005; Sumimoto 2008; Lassègue, San Martín et al. 2012). This enables the translocation of 
p47phox, with the other associated dormant cytosolic subunits (p67phox and p40phox), and 
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binding of p47phox to the membrane bound cytochrome b558 complex, specifically to the 
p22 phox subunit.  
In keeping with Ang II’s firmly established role in activating NADPH oxidase (Williams and 
Griendling 2007), Ang II increases serine phosphorylation of p47phox subunits in hepatic cells 
(Bataller, xF et al. 2003), human vascular smooth muscle cells (Touyz, Yao et al. 2003) and 
endothelial cells (Li and Shah 2003). Results in this chapter demonstrate that YC-1 induces a 
reduction in serine phosphorylation of p47phox in cardiac myocytes both at basal resting 
conditions and with Ang II stimulation. We have yet to examine if the effects of YC-1 on 
serine phosphorylation of p47phox are dependent on the dephosphorylating action of protein 
phosphatases. However, as presented in the previous chapters, the effects of PP2A in 
attenuating the consequences of Ang II-induced NADPH oxidase activation, namely 1) Na+-K+ 
pump inhibition and 2)O-sensitive DHE fluorescence, make the dephosphorylation of 
p47phox subunits a likely downstream consequence of sGC stimulation. The role of PP2A in 
reducing p47phox phosphorylation and thus Nox 2 activation has been demonstrated in 
neutrophils (Ding and Badwey 1992), consistent with the proposed mechanism in 
cardiomyocytes. Further evidence of the attenuating effects on NADPH oxidase activation 
by YC-1 is the effect on p47phox/α1 subunit co-immunoprecipitation. Consistent with 
previous results by White et al (White, Figtree et al. 2009), we demonstrated that Ang II 
stimulation of NADPH oxidase resulted in increased co-immunoprecipitation of p47phox/α1 
subunit. Stimulation of sGC with YC-1 decreased the co-immunoprecipitation of p47phox and 
the membrane bound α1 subunit of the Na
+-K+ pump in Ang II-exposed cells with a similar 
trend in cells not exposed. This suggests that sGC stimulation induces a decrease in 
translocation of p47phox both to the membrane and to the microdomain of the Na+-K+ pump. 
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This may account for its reduction in both Ang II-induced NADPH oxidase activity and Ang II-
induced Na+-K+ pump inhibition. The decrease interaction of NADPH oxidase with the α1 
subunit of the Na+-K+ pump is consistent with stimulation of sGC resulting in a decrease in 
oxidant signalling to the Na+-K+ pump. This is expected to be reflected by changes in 
oxidative modifications of the Na+-K+ pump, examined in chapter 5.  
4.5 Conclusion 
We conclude that stimulation of sGC with YC-1 reduces Ang II-induced O2
 levels in a PP2A-
dependent manner, in keeping with a reduction in activation of NADPH oxidase. There is 
also a reduction in the colocalisation of NADPH oxidase and Na+-K+ pump subunits (α1) 
which is consistent with a reduction of oxidant signalling to the Na+-K+ pump.  
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CHAPTER 5 
 
EFFECTS OF STIMULATION OF sGC ON OXIDATIVE MODIFICATION 
OF THE NA+-K+ PUMP 
 
5.1 Introduction 
Strategies to reduce the effects of elevated oxidative stress in heart failure are being 
developed as therapeutic weapons against the disease. As discussed in Chapter 3, 
stimulation of sGC attenuates Ang II-induced inhibition of the cardiac sarcolemmal Na+-K+ 
pump in a PP2A-dependent manner. Stimulation of sGC also attenuates Ang II-induced 
activation of NADPH oxidase as discussed in Chapter 4 which presents a likely mechanism of 
its effect on Ip. The demonstration of the effects of stimulation of sGC on the molecular 
regulatory changes to the Na+-K+ pump subunits would help confirm its modulation of 
oxidant signalling to the Na+-K+ pump.  
While the PKA- and PKC-dependent regulation of the Na+-K+ pump has been previously 
attributed to phosphorylation of the pump subunits, this paradigm has some inconsistencies 
including the lack of conserved, kinase-accessible putative phosphorylation sites (Sweadner 
and Feschenko 2001). As an alternative, it has been proposed that kinase-dependent 
phosphorylation of FXYD 1 protein stimulates the pump. This is not readily reconciled with 
the increase in Ip that has been reported with PKA- or PKC-dependent signalling with β1 AR 
blockers or ACE inhibitors (Hool, Whalley et al. 1995; Fry, Garcia et al. 2012) or the beneficial 
effect (Bristow 2011) of β1 AR blockers and ACE inhibitors in heart failure.  
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Oxidative posttranslational modifications can affect structure and function in a manner 
analogous to phosphorylation. Of the possible oxidative modifications, formation of a 
disulphide bond between cysteine residues on the cytosolic tripeptide glutathione (GSH) 
and a protein is of particular interest because it is stable, yet reversible (Pimentel, Haeussler 
et al. 2012). Our Laboratory has previously examined if receptor-coupled activation of 
oxidative signalling and glutathionylation of the Na+-K+ pump contribute to pump regulation. 
Ang II-induced activation of oxidative signalling was associated with glutathionylation of the 
β1 subunit of the Na
+-K+ pump (Figtree, Liu et al. 2009). Mutational studies of Na+-K+ pumps 
expressed in Xenopus oocytes identified cysteine 46 (C46) as the reactive residue in the β1 
subunit (Figtree, Liu et al. 2009), and, consistent with the NADPH oxidase-dependence of 
Ang II-induced inhibition of Ip in cardiac myocytes (White, Figtree et al. 2009), there was a 
causal relationship between β1 subunit glutathionylation and pump inhibition (Figtree, Liu et 
al. 2009). Thus, a decrease in β1 subunit glutathionylation would be confirmatory that 
stimulation of sGC modulates redox regulation of the Na+-K+ pump.  
5.1.1 Aims 
This chapter examines the effects of stimulation of sGC on basal and Ang II-induced 
oxidative modifications of the Na+-K+ pump, specifically the glutathionylation of the β1 
subunit and the co-immunoprecipitation of the α1/β1 subunits.  
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5.2 Methods and Materials 
5.2.1 Cells  
Single ventricular myocytes were isolated from male White New Zealand Rabbits. Details of 
anaesthesia, excision of the heart and cell isolation techniques have been described in detail 
in section 2.2. 
5.2.2 Immunodetection of S-glutathionylated proteins  
To detect S-glutathionylation of the β1 Na
+-K+ pump subunit, myocytes were loaded with 
biotinylated GSH for 1 hour, as outlined in Section 2.6, prior to treatment with different 
experimental conditions. The precipitated GSS-protein was separated by gel 
electrophoresis, transferred to a membrane and probed with antibodies to the Na+-K+ 
pump’s β1 subunit.  
5.2.3 Detection of protein co-immunoprecipitation  
Cells were exposed to control solutions or 100 nM of Ang II for 15minutes after having been 
preincubated with 10 μM YC-1 or control solutions for 15 minutes at 37 °C. They were 
subsequently lysed in ice-cold buffer as per Section 2.7. Immunoprecipitated proteins were 
eluted by boiling at 95°C for 5 min in 40 μl Laemmli sample buffer. Immune complexes were 
analysed by SDS-PAGE and Western blot by probing with antibodies to the β1 subunit and  
the α1-subunit of Na
+-K+-ATPase. 
5.2.4 Statistical analysis 
Each presented immunoblot is representative of at least three separate experiments. Data 
are expressed as the mean ±S.E.. One-way ANOVA was used for analysis of 
immunoprecipitation data and Student’s t-test was used for paired data, with single-tailed 
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distribution for analysis of differences compared to controls. P<0.05 is regarded as 
significant for all comparisons.  
5.3 Results 
5.3.1 Stimulation of sGC reduces baseline β1 subunit glutathionylation in a PP2A 
dependent manner. 
Since stimulation of sGC with YC-1 has been shown to result in an increase in Na+-K+ pump Ip 
(William, Vien et al. 2005), we first examined if this stimulatory effect under basal conditions 
was mediated by a decrease in β1 subunit glutathionylation. Myocytes loaded with biotin-
GSH were exposed to control solutions or solutions containing 10 μM YC-1, in the presence 
or absence of 10 nM okadaic acid, for 15 minutes at 37C. Cells that were not exposed to 
okadaic acid were exposed to the equivalent concentration of DMSO to control for any 
reducing effects of the solvent. After cell lysis, the biotin-tagged glutathionylated protein 
sub-fraction (GSS-protein) was precipitated by streptavidin beads as per Section 2.6. We 
performed immunoblotting on this glutathionylated subfraction for the β1 subunit of the 
pump. Figure 5.1 shows that YC-1 reduced the baseline glutathionylation of the β1 subunit 
of the Na+-K+ pump. This reduction was abolished with the addition of okadaic acid at a 
PP2A-inhibiting concentration of 10 nM, implying that the effects of YC-1 are mediated by 
PP2A.  
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Figure 5.1 Glutathionylation of the Na+-K+ pump’s β1 subunit after exposure 
to YC-1 and okadaic acid. 
Glutathionylation of the β1 Na
+-K+ pump subunits detected by the biotin-GSH 
technique at baseline and after exposure of myocytes to 10 μM YC-1 in the 
presence and absence of 10 nM okadaic acid (OA). YC-1 induced a significant 
reduction in β1 subunit glutathionylation, compared to control, that was 
abolished by 10 nM okadaic acid. Representative immunoblots after 
immunoprecipitation with β1 subunit antibody are shown. The histogram shows 
mean (±S.E.) densitometry of blots from 3 experiments, each normalized against 
control. * indicates statistical significance (p<0.05). 
 
5.3.2 Ang II induces an increase in β1 subunit glutathionylation 
Ang II induces a PKC-dependent activation of NADPH oxidase and would hence be expected 
to increase the oxidative modification of glutathionylation of the β1 subunit of the pump. 
This was reconfirmed as seen in Fig. 5.2.  
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Figure 5.2 Glutathionylation of the Na+-K+ pump’s β1 subunit after exposure to 
Ang II. 
Glutathionylation of the Na+-K+ pump β1 subunits detected by the biotin-GSH 
technique at baseline and after exposure of myocytes to 100 nM Ang II. Ang II 
induced a significant increase in β1 subunit glutathionylation compared to control 
that was abolished by 10 nM OA. Representative immunoblots after 
immunoprecipitation with β1 subunit antibody are shown. The histogram shows 
mean (±S.E.) densitometry of blots from 3 experiments, each normalized against 
control. * indicates statistical significance (p<0.05). 
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5.3.3 Stimulation of sGC attenuates the Ang II-induced β1 subunit glutathionylation in a 
PP2A-dependent fashion if cells are preincubated rather than coincubated with YC-1 
From the results presented in Chapters 3 and 4, stimulation of sGC with YC-1 was able to 
attenuate Ang II-induced NADPH oxidase activity and the Ang II-induced inhibition of the 
Na+-K+ pump. We examined if the effects of YC-1 on Ang II-induced NADPH oxidase 
translated to a decrease in glutathionylation of the β1 subunit that would account for its 
effect on the Na+-K+ pump as assessed by Ip (see Figure 3.3 and Figure 3.4). Initial 
experiments were performed where biotin-GSH loaded myocytes were coincubated with 
100 nM Ang II and 10 μM YC-1 with or without 10 nM okadaic acid for 15 minutes at 37C 
prior to lysis. The glutathionylated protein sub-fraction was precipitated and then 
immunoblotted for β1 subunit of the pump. YC-1 did not have an effect on β1 
glutathionylation when coincubated with Ang II as seen in Fig 5.3A. A separate set of 
experiments were performed where biotin-GSH loaded myocytes were preincubated with 
10 μM YC-1 and/or 10nM okadaic acid for 15 minutes prior to exposure to 100nM Ang II for 
15 minutes at 37 C. As seen in Fig 5.3B, preincubation with YC-1 decreased β1 
glutathionylation in myocytes exposed to Ang II. This attenuation of β1 glutathionylation was 
abolished with the addition of okadaic acid at PP2A-inhibiting dose of 10nM.  
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Figure 5.3 Glutathionylation of the Na+-K+ pump’s β1 subunit after exposure 
to YC-1 and okadaic acid in Ang II-stimulated cells.  
Glutathionylation of the β1 Na
+-K+ pump subunits detected by the biotin-GSH 
technique in Ang II (100nM) stimulated myocytes exposed to 10 μM YC-1 in the 
presence and absence of 10 nM okadaic acid (OA). A: Myocytes were 
coincubated with YC-1 ± OA and Ang II. There was no significant difference in β1 
subunit glutathionylation between any of the experimental conditions. B: 
Myocytes were preincubated with YC-1 ± OA for 15 minutes prior to exposure to 
Ang II for 15 minutes. YC-1 induced a significant reduction in Ang II-induced β1 
subunit glutathionylation that was abolished by 10 nM OA. Representative 
immunoblots after immunoprecipitation with β1 subunit antibody are shown. 
The histogram shows mean (±S.E.) densitometry of blots from 3 experiments, 
each normalized against control. * indicates statistical significance (p<0.05). 
5.3.4 Stimulation of sGC increases α1/β1- Na
+-K+ subunit co-immunoprecipitation in 
unstimulated cells and Ang II-stimulated cells.  
In keeping with the heterodimer of the catalytic α subunit and the regulatory β subunit 
being necessary for Na+-K+ pump function, alteration of subunit interaction has been shown 
to be associated with a change in pump function. Our Laboratory has previously shown that 
conditions that increase oxidant stress, including exposure to Ang II, and increase β1 
glutathionylation are associated with a reduction in α1/β1- Na
+-K+ pump subunit co-
immunoprecipitation (Figtree, Liu et al. 2009). We examined the effects of stimulation of 
sGC with YC-1 on α1/β1- Na
+-K+ pump subunit co-immunoprecipitation, using Ang II as a 
positive control. Cells were exposed to control solutions or 10 μM YC-1 or 100 nM Ang II for 
15 minutes prior to lysis in ice-cold buffer as per Section 2.7. Immunoprecipitated proteins 
were eluted by boiling at 95°C for 5 min in 40 μl Laemmli sample buffer. Immune complexes 
were analysed by SDS-PAGE and Western blot by probing with antibodies to the α1 subunit 
and the β1 subunit of the pump. As shown in Fig 5.4, YC-1 induced an increase in α1/β1- Na
+-
K+ pump subunit co-immunoprecipitation in contrast to the decrease induced by Ang II (A). 
In keeping with the effects on β1 subunit glutathionylation, preincubation with 10 μM YC-1 
attenuated the Ang II-induced decreased interaction of α1/β1-Na
+-K+ pump subunits (B). 
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Figure 5.4 Effect of YC-1 on co-immunoprecipitation of α1 and β1 subunits 
of the Na+-K+ pump in basal and Ang II-exposed cells.  
A: Myocytes exposed to 10 μM YC-1, 100nM Ang II (positive control) or control 
solutions were lysed prior to co-immunoprecipitation. β1 immunoprecipitate (IP) 
was immunoblotted (IB) for α1 and β1 subunits of the Na
+-K+ pump. YC-1 induced 
a significant increase in α1/β1- Na
+-K+ pump subunit co-immunoprecipitation, 
while Ang II induced a significant decrease. B: Myocytes exposed to 100 nM Ang 
II after preincubation with 10 μM YC-1 or control solutions were lysed prior to 
co-immunoprecipitation. Compared to Ang II controls, YC-1 significantly 
increased α1/β1- Na
+-K+ pump subunit co-immunoprecipitation The histogram 
shows mean (±S.E.) densitometry of immunoblots from 3 experiments. * 
indicates significant differences compared with relevant control (p<0.05). 
5.4 Discussion 
The findings presented in this chapter are that stimulation of sGC with YC-1 reduces baseline 
glutathionylation of the β1 subunit of the Na
+-K+ pump in a PP2A-dependent manner. 
Similarly, preincubation with YC-1 reduces Ang II-induced β1 glutathionylation and again this 
effect is abolished by okadaic acid at a PP2A-inhibiting dose. Coincubation of cells with both 
YC-1 and Ang II, however, did not have an effect on Ang II-induced β1 glutathionylation. 
Since interventions expected to increase intracellular O2
 levels increase glutathionylation 
of the β1 subunit of the pump (Figtree, Liu et al. 2009; White, Figtree et al. 2009) and 
glutathionylation of the β1 subunit is causally related to inhibition of the Na
+-K+ pump, these 
results are concordant with the YC-1 attenuation of Ang II-induced DHE fluorescence , 
NADPH oxidase activation and pump inhibition demonstrated in functional studies in 
Chapters 3 and 4. Stimulation of sGC with YC-1 also resulted in an increase in baseline α1/β1- 
Na+-K+ pump subunit co-immunoprecipitation and an attenuation of the Ang II-induced 
reduction in α1/β1- Na
+-K+ pump subunit co-immunoprecipitation. This too is concordant 
with our functional correlates with YC-1 stimulating the Na+-K+ pump and attenuating the 
Ang II-induced oxidant down-regulation of the Na+-K+ pump. 
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5.4.1 Stimulation of sGC decreases baseline oxidative modification of the Na+-K+ pump 
subunits 
YC-1 decreased the baseline β1 glutathionylation to 0.48 ± 0.09 fold compared to controls. 
Reduction of baseline β1 glutathionylation has only been previously demonstrated with the 
use of β3-AR agonists. Bundgaard et al (Bundgaard, Liu et al. 2010) used CL316,243 (10 nM 
and 1000 nM ) to activate the β3-AR in cardiac myocytes. This demonstrated a concentration 
dependent decrease in β1 glutathionylation that was NOS dependent as indicated by the 
effect of the NOS inhibitor, NG-nitro-l-arginine methyl ester (L-NAME) to abolish the 
decrease in glutathionylation. The β3-AR agonist also induced an increase in α1/β1- Na
+-K+ 
subunit co-immunoprecipitation, with concordant functional correlates of Ip measurements. 
β3-AR stimulation is increasingly recognized to increase NO production in the cardiovascular 
system (Moens, Yang et al. 2010). In addition, the NOS/NO- dependence of the effect of β3-
AR agonist on oxidative modification and activity of the Na+-K+ pump implicates the 
sGC/cGMP/PKG signalling pathway in view of NO being the endogenous activator of sGC. 
The results presented in this chapter implicate PP2A to mediate the downstream signalling 
from PKG to the Na+-K+ pump to effectuate a reduction in oxidative molecular changes to 
the Na+-K+ pump. Increasing the activity of sGC, either by direct stimulators/activators, or 
upstream receptor-coupled activation from β3-AR activation, is a potential route of 
attenuating baseline oxidant signalling and deleterious modifications. 
To strengthen its therapeutic potential in modulating redox-dependent regulation of the 
Na+-K+ pump in disease states, we examined the effects of YC-1 in the face of Ang II-induced 
increased NADPH oxidase activity.  
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5.4.2 Stimulation of sGC decreases Ang II-induced oxidative modification of the Na+-K+ 
pump subunits 
Our Laboratory has previously demonstrated that exposure to Ang II, which results in a PKC-
dependent activation of NADPH oxidase, results in an increase in glutathionylation of the β1 
pump subunit. This was reproduced here by an independent set of experiments. It has also 
been previously demonstrated that the preincubation with SOD, catalase or ebselen to 
eliminate the reactive species, O2
, H2O2 and ONOO
 respectively, abolished Ang II-induced 
β1 glutathionylation. SOD was also shown to be able to reverse β1 glutathionylation (Figtree, 
Liu et al. 2009). This previous data demonstrates that the removal of reactive species is able 
to attenuate β1 glutathionylation in the face of oxidant stimuli. The data in this chapter 
demonstrates attenuation of Ang II-induced β1 glutathionylation in a more physiological 
manner with stimulation of upstream signalling from stimulating sGC. (see Fig 5.5). This 
effect of YC-1 on the oxidative modification of the Na+-K+ pump, in concordance with our 
functional correlates on Na+-K+ pump Ip, was PP2A-dependent.  
Of note, the effects of YC-1 were only demonstrable when the cells were preincubated with 
the sGC stimulator prior to Ang II exposure, but not when they were coincubated with YC-1 
and Ang II. Similar differences with coincubation and preincubation have been seen in our 
Laboratory with the use of the upstream activator of sGC, the β3-AR agonist, CL316,243 
(unpublished data). The decreased β1 glutathionylation seen with YC-1 preincubation can be 
attributed to one of two possibilities: 1) increased rate of deglutathionylation and 2) 
decreased rate of glutathionylation. Deglutathionylation requires the breakage of a 
disulphide bond in the protein-SSG that occurs via a double displacement mechanism to 
GSH catalysed by glutaredoxin 1 (Grx1) in most mammalian cells. This results in the 
formation of protein-SH and GSSG (Gallogly and Mieyal 2007). Grx1 is a cytosolic enzyme 
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whose activation is poorly understood but thought to be related to translocation of it to its 
targets and influenced by the cellular redox status (Gallogly and Mieyal 2007). Its 
distribution in different subcellular compartments which have different pH and thus 
different redox potentials for the N-terminal cysteine of Grx can also affect its activity 
(Ströher and Millar 2012). Grx1 gene expression is positively regulated by redox-sensitive 
NF-κB (Aesif, Kuipers et al. 2011). NO/sGC/cGMP signalling is not known to influence any of 
these processes.  
An alternative explanation for the results presented in this chapter are that stimulation of 
sGC results in decreased oxidant signalling and hence decreased β1 glutathionylation while 
basal deglutathionylation is unchanged. Results presented in chapter 4 implicate decreased 
NADPH oxidase activity in mediating the down regulation of Ang II-induced oxidant effects 
by YC-1. The okadaic acid-sensitive nature of YC-1’s effects, as delineated in previous 
chapters by measurement of Ip, O2
-sensitive DHE fluorescence, baseline and Ang II induced 
β1 glutathionylation, indicate the critical role of PP2A in YC-1’s effects. While the data 
presented in this thesis does not allow us to define the precise PP2A dependent step in YC-
1’s modulation of redox signalling, the reduction of serine phosphorylation of p47phox seen 
with YC-1 makes this a possible candidate. A scheme of the proposed signalling pathway of 
stimulation of sGC modulating Ang II induced redox regulation of the Na+-K+ pump is 
illustrated in Fig 5.5. The signalling steps from Ang II and sGC converge with opposing effects 
on NADPH oxidase activity. Stimulation of sGC while decreasing p47phox phosphorylation and 
hence NADPH oxidase activation, acts like a “braking” signal to the oxidant signalling from 
Ang II. Thus the degree of β1 glutathionylation, which is downstream from NADPH oxidase 
would depend on the redox balance created by these two opposing signalling pathways. The 
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absence of attenuation of β1 glutathionylation by YC-1 when it is coincubated with Ang II 
may be a result of the Ang II signalling pathway overwhelming the attenuating effects of YC-
1 on the oxidant signal. 
 
Figure 5.5 Proposed signalling pathway of sGC modulation of Ang II 
induced effects on the pump. 
The results presented in this Chapter are illustrated to the right of the panel. Ang 
II induces increased glutathionylation of the β1 subunit of the pump which is 
inhibitory to its activity (represented by the red arrow head). Stimulation of sGC 
attenuates this process resulting in a decrease in glutathionylation of the β1 
subunit. The proposed signalling pathway from the findings presented in 
previous chapters is that sGC via the action of PP2A reduces the Ang II-induced 
phosphorylation-dependent activation of NADPH oxidase (blue arrow), 
potentially by a reduction in serine phosphorylation of p47phox. AT1 R, 
angiotensin II receptor type 1. 
 
In addition, sGC is itself susceptible to oxidation by radicals like O2
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addition, when the haem moiety is oxidised to the Fe3+ form, the enzyme becomes 
insensitive to NO, which YC-1 works synergistically with to increase cGMP production. (Ko, 
Wu et al. 1994; Stasch, Schmidt et al. 2006; Stasch and Hobbs 2009). Thus, coincubation 
with Ang II is likely to result in oxidation of sGC rendering YC-1 ineffective before sufficient 
stimulation occurred to reduce NADPH oxidase activity. In contrast, preincubation with YC-1 
permits sufficient downstream activation from sGC before increased O2
 renders it 
insensitive to YC-1 and NO. This is consistent with the results of Irvine et al which 
demonstrated that in neonatal rat cardiomyocytes, the NO independent sGC activator that 
preferentially targets Fe3+-oxidized sGC, BAY-58-2667, decreased endothelin-1-induced 
NADPH-derived O2
 generation. In contrast, sGC stimulator that targets sGC in the reduced 
Fe2+-haem containing state, BAY-41-2272, did not have this effect.(Irvine, Ganthavee et al. 
2012). 
5.4.3 Limitations of detection of glutathionylated proteins  
The techniques available for the detection of glutathionylated proteins are far behind those 
for the identification of phosphoproteins, which rely mostly on immunological techniques. 
The main drawback of techniques based on the incorporation of labelled GSH (such as we 
use in this Thesis) is that we may be unable to study or identify all basally glutathionylated 
proteins that may not incorporate any further GSH when exposed to oxidative stress 
(Gianazza, Eberini et al. 2009). 
5.5 Conclusions 
Stimulation of sGC with YC-1 reduces the basal glutathionylation of the β1 subunit in a PP2A-
dependent manner while increasing the co-immunoprecipitation of the α1/β1 subunits of 
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the Na+-K+ pump. Preincubation with YC-1 similarly attenuates the Ang II-induced increase in 
similar oxidative modifications of the Na+-K+ pump. This modulation of the Ang II-induced 
inhibitory molecular changes on the Na+-K+ pump confirms that stimulation of sGC 
modulates redox regulation of the Na+-K+ pump.  
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CHAPTER 6 
 
STIMULATION OF sGC DECREASES ADENYLYL CYCLASE- MEDIATED OXIDANT 
SIGNALLING TO THE NA+-K+ PUMP 
6.1 Introduction 
The pathophysiology of heart failure is associated with increased β-adrenergic signalling 
with increased circulating levels of catecholamines (Rundqvist, Elam et al. 1997; Deschamps 
and Spinale 2006). The firmly established utility of beta blockers in the treatment of chronic 
heart failure supports the pathophysiological role of β-adrenergic signalling (MEMBERS, 
Hunt et al. 2009). The binding of catecholamines to β1/β2 ARs, which are coupled to G 
proteins, activates adenylyl cyclase which synthesizes 3'-5'-cyclic adenosine monophosphate 
(cAMP) (Robinson and Sutherland 1971; Ho, Yan et al. 2010). cAMP then activates protein 
kinase A (PKA). It is well established that this pathway has adverse effects in heart failure 
(Bristow 2011), and it is a useful therapeutic target, a notion supported by the therapeutic 
benefit of beta blockers (Doi, Yano et al. 2002; Reiken, Wehrens et al. 2003; Shan, 
Betzenhauser et al. 2010). 
The phosphorylation targets of PKA in cardiac myocytes include several that are important 
for Ca2+ homeostasis such as the L-type Ca2+ channel, the ryanodine receptor, 
phospholamban and troponin I (Kamp and Hell 2000; Kushnir and Marks 2010; Walker, 
Walker et al. 2011). PKA-dependent regulation of the Na+-K+ pump is also important in Na+ 
homeostasis and, due to Na+-Ca2+ exchange, in Ca2+ homeostasis and excitation contraction 
coupling. Most studies of PKA-dependent regulation of the Na+-K+ pump in non-cardiac 
tissues have reported inhibition (Poulsen, Morth et al. 2010) while PKA-dependent 
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stimulation usually has been reported in cardiac myocytes, mostly attributed to 
phosphorylation of FXYD1 (Fuller, Tulloch et al. 2012). As previously discussed in section 
1.3.4, the lack of a conserved PKA consensus motif on the Na+-K+ pump or FXYD proteins 
other than FXYD1, makes regulation of the pump by PKA-dependent phosphorylation a 
difficult paradigm to accept.  
Our Laboratory has previously examined the effects of adenylyl cyclase activation, and thus 
PKA activation, using a direct activator, forskolin (White, Liu et al. 2010) A direct adenylyl 
cyclase activator was used rather than the more physiologically relevant use of β-AR 
agonists, to avoid the confounding affects from poor selectivity of available agonists against 
the three different β-AR subtypes (Hoffmann, Leitz et al. 2004). White et al, demonstrated 
that adenylyl cyclase activation results in inhibition of the Na+-K+ pump via activation of 
phospholipase C (PLC) which is known to be activated by PKA (Gomes and Soares-da-Silva 
2002; Yao, Fan et al. 2008). This then leads to PKC-dependent increase in NADPH oxidase 
activity. This adenylyl cyclase-dependent signalling pathway contributes to Na+-K+ pump 
inhibition with adrenergic stimulation seen in heart failure. Conversely, it is reversed by 
treatment with selective β1 AR antagonists (Fry, Garcia et al. 2012). 
Beta blockers should attenuate the effects of adenylyl cyclase activation in heart failure by 
inhibiting the upstream signal in the pathway. However, just as there is aldosterone escape 
seen with chronic angiotensin converting enzyme inhibition in chronic heart failure patients 
(Cicoira, Zanolla et al. 2002; Jorde, Vittorio et al. 2002), there is adrenergic escape 
demonstrated in heart failure patients on chronic beta blocker therapy irrespective of beta 
blocker agent used or dose equivalent and it is not identifiable by heart rate.(Frankenstein, 
Zugck et al. 2009). Thus a non-beta blocker dependent pathway to modulate the inhibitory 
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signalling pathway from adenylyl cyclase activity to the Na+-K+ pump has potential 
therapeutic benefit.  
Stimulation of sGC attenuates the effects of Ang II-induced oxidant signalling and its Na+-K+ 
pump inhibition as described in the preceding chapters. Ideally, for this to have greater 
therapeutic relevance, stimulation of sGC should be able to modulate an alternate receptor-
mediated oxidant signalling. This chapter examines this possibility by examining the 
modulation of the effects of adenylyl cyclase activation, downstream from β1/β2 AR 
signalling, by stimulation of sGC.  
6.1.1 Aims 
This chapter aims to examine the effects of stimulation of sGC with YC-1 on adenylyl cyclase 
induced effects in cardiac myocytes, specifically 1) forskolin-induced Na+-K+ pump inhibition 
and 2) forskolin-induced intracellular O2
 as assessed by DHE fluorescence.  
6.2 Methods and Materials 
6.2.1 Cells 
Ventricular myocytes were isolated from White New Zealand Rabbits and the whole-cell 
patch clamp technique was used to measure the electrogenic Na+-K+ current (Ip) arising from 
the 3:2 Na+/K+ exchange ratio. Imaging of intracellular O2
 levels with DHE fluorescence was 
also performed on myocytes. Details of anaesthesia, excision of the heart and cell isolation 
techniques have been described in detail in section 2.2. 
 
Chapter 6  133 
 
6.2.2 Imaging of intracellular superoxide levels by DHE fluorescence 
DHE, was used to image intracellular O2
.- as outlined in Section 2.5. Myocytes were exposed 
to 100 nM forskolin for 10 min after preincubation with 10 μM YC-1 or not (control) for 30 
mins. Cells were then fixed. A separate set of experiments were performed with similar 
protocols except that cells were additionally coincubated with a protein phosphatase 
inhibitor, okadaic acid, at a PP2A-inhibiting dose of 10 nM The average fluorescence 
intensity for cells from each experiment was normalized against its control (100%). 
6.2.3 Solutions 
For measurement of Ip, the superfusate was switched to the Ca
2+-free Tyrodes solution 
which contained 100 nM forskolin and 10 nM okadaic acid as noted. Cells were exposed to 
this solution for 10-12 minutes with a stable plateau of the holding current before being 
exposed to ouabain-containing Tyrodes solution. The ouabain-induced shift in membrane 
current identified Ip. Pipettes were filled with control solutions or solutions containing 1 μM 
YC-1 as noted. A separate set of experiments were initially performed where the modified 
Tyrodes solution was not Na+- free but contained NaCl in place of N-methyl-D-glutamine 
chloride (NMG-Cl). Myocytes were voltage clamped to a holding potential of -14mV for this 
series of experiments.  
6.2.4 Measurement of electrogenic Na+-K+ pump current 
Details of this method can be found in section 2.3. Briefly, after the whole-cell configuration 
was established, the cells were exposed to Ca2+free Tyrodes solution for 10-12 minutes and 
then to a solution that was identical except it contained 100 μM ouabain. Cells were 
clamped at a holding potential of -14 mV and currents before and after pump blockade by 
ouabain were identified. Experiments were only accepted as valid if currents before and 
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after exposure to ouabain were stable according to predetermined criteria (William, Vien et 
al. 2005). The Ip that was identified was normalised for membrane capacitance and hence 
cell size. 
6.2.5 Statistics 
Results are expressed as means ±S.E.. Student’s t-test for unpaired data was used for 
analysis of patch clamp data, while Student’s t test was used for paired data, with single tail 
distribution for analysis of difference in DHE fluorescence intensity levels between 
experiments and controls. p<0.05 is regarded as significant for all comparisons.  
6.3 Results 
6.3.1 Stimulation of sGC in cells exposed to forskolin results in a phosphatase-dependent 
decrease in intracellular superoxide levels 
We examined whether YC-1 decreases fluorescence of cardiac myocytes loaded with DHE in 
cells exposed to forskolin to activate adenylyl cyclase. Incubation of cells with 10 μM YC-1 
for 15 minutes prior to exposure to 100 nM forskolin for 10 minutes decreased DHE 
fluorescence compared with control cells. We examined whether PP2A had a role in the 
effects of YC-1 on DHE fluorescence in cells exposed to forskolin, as we had for the Ang II-
exposed cells described in Chapter 4. Incubation of cells with 10 nM okadaic acid abolished 
the YC-1-induced decrease in DHE fluorescence in cells exposed to forskolin. Representative 
micrographs are shown in Panel A of Figure 6.1 while the results of the fluorescence studies 
are summarised in Panel B of Figure 6.1.  
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Figure 6.1 Effect of stimulation of sGC by YC-1 on O2
-sensitive DHE 
fluorescence in cells exposed to forskolin.  
Myocytes were loaded with the O2
-sensitive dye, DHE, and examined by 
fluorescent confocal microscopy. 100 nM forskolin was used to activate adenylyl 
cyclase and downstream, NADPH oxidase. In some experiments, myocytes were 
pre-incubated with the phosphoprotein phosphatase inhibitor, okadaic acid at a 
PP2A-inhibiting dose of 10 nM. Representative micrographs are shown in panel 
A. The mean (±S.E.) fluorescence intensity for each condition, after the 
subtraction of baseline fluorescence, is shown in panel B. YC-1 induced a 
significant decrease in fluorescence versus control. This decrease was abolished 
by okadaic acid. * indicates statistical significance (p<0.05). The number of 
experiments in each group is indicated in parentheses. 
 
6.3.2 Stimulation of sGC decreases forskolin induced inhibition of the Na+-K+ pump.  
To examine the effects of sGC stimulation on forskolin-induced pump inhibition, we 
included 1 μM YC-1 in the pipette solution and 100 nM forskolin in the superfusate 
solutions. The ouabain-induced shifts in holding current is greater in myocytes exposed to 
additional YC-1 compared to myocytes exposed to forskolin alone. The mean Ip, normalised 
for Cm for myocytes exposed to forskolin and myocytes exposed to forskolin and YC-1 are 
shown in Fig 6.2. Exposure of myocytes treated with forskolin to YC-1 induced a statistically 
significant higher Ip, attenuating the forskolin-induced reduction seen compared to control 
myocytes.  
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Figure 6.2 Effect of activation of sGC with YC-1 on forskolin induced Na+-K+ 
inhibition of pump current (Ip). 
10 nM okadaic acid was included in the superfusate while 1 μM YC-1 was 
included in the patch pipette as indicated. Pump current (Ip) was calculated by 
the inward shift in holding current caused by exposure to ouabain. Mean Ip ± S.E. 
are shown. The mean Ip for a control myocyte is included (dashed line) for 
comparison. YC-1 induced a statistically significant higher Ip compared to 
myocytes exposed to forskolin (Fsk) only. There was no significant difference in 
mean Ip values of myocytes perfused with pipette solutions with or without YC-1 
in the presence of okadaic acid at a PP2A-inhibitory dose of 10 nM. * indicates 
statistical significance between means (±S.E.) of Ip (p<0.05).  The number of 
myocytes in each group is indicated in parentheses. 
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6.4 Discussion 
6.4.1 Stimulation of sGC attenuates forskolin-induced effects on O2
 and Ip. 
We examined the effects of stimulation of sGC with YC-1 on the effects of adenylyl cyclase 
activation with forskolin and its downstream effects of increase in intracellular O2
 and 
inhibition of the Na+-K+ pump. Findings presented in this chapter are that stimulation of sGC 
with YC-1 attenuates the forskolin-induced O2
-sensitive DHE fluorescence in a PP2A 
dependent manner. Concordant with its effect on oxidant signalling, YC-1 attenuates the 
forskolin-induced inhibition of the Na+-K+ pump in a PP2A-dependent manner.  
White et al (White, Liu et al. 2010) have previously demonstrated that forskolin increases 
DHE fluorescence in cardiac myocytes. This increase was abolished by preincubation of 
myocytes with pegylated SOD, consistent with the O2
-sensitivity of DHE fluorescence. The 
increase was also abolished with preincubation with the NADPH oxidase inhibitor, apocynin 
and also εPKC inhibitory peptide, implicating PKC-dependent activation of NADPH oxidase, 
the source of increased O2
 in forskolin-exposed cells. Similar to its effect in Ang II-exposed 
myocytes, stimulation of sGC attenuates forskolin-induced DHE fluorescence in a PP2A 
dependent manner.  
The functional effect of stimulation of sGC seen on the Na+-K+ pump in cells exposed to 
forskolin are consistent with its attenuation of oxidant signalling seen with the DHE 
fluorescence studies. YC-1 attenuates the forskolin induced inhibition of the Na+-K+ pump in 
a PP2A-dependent manner. Activation of adenylyl cyclase with its consequent increase in 
cAMP can activate cAMP-dependent Cl- currents (Sorota 1999). This can lead to a change in 
intracellular Cl_ and hence the electrochemical driving force for the Na+/K+/2Cl- co-
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transporter which then can alter the ouabain-sensitive current that defines Ip (Mihailidou, 
Buhagiar et al. 1998). To avoid this, cells were clamped at -14 mV, the calculated equilibrium 
potential for Cl-, which we have previously demonstrated to eliminate a net change in 
cAMP-dependent Cl- channel fluxes (White, Liu et al. 2010).  
6.4.2 Potential mechanisms of PP2A-mediated effects on adenylyl cyclase induced 
oxidant signalling 
The effects induced by adenylyl cyclase activation with forskolin and the effects of Ang II on 
both O2
 sensitive DHE fluorescence and Ip are similarly attenuated in a PP2A-dependent 
manner by the stimulation of sGC with YC-1. PKC- and cAMP-dependent inhibition of the 
cardiac Na+-K+ pump has been previously demonstrated to share a downstream oxidative 
signalling pathway involving NADPH oxidase activation and the oxidative modification of 
glutathionylation of the β1 subunit of the pump (White, Figtree et al. 2009; White, Liu et al. 
2010). The results in this chapter do not allow us to identify the PP2A-dependent step in the 
effects of sGC on adenylyl cyclase-mediated oxidant signalling. However, in view of the 
downstream oxidative signalling pathway that adenylyl cyclase shares with Ang II-induced 
PKC activation, it is likely that PP2A attenuates NADPH oxidase activity, potentially by 
decreasing serine phosphorylation of p47phox as described in Chapter 4. Other potential 
mechanisms by which stimulation of sGC modulates adenylyl cyclase-mediated oxidant 
signalling include 1) crosstalk between cGMP and cAMP signalling pathways and 2) PP2A 
effects on PKC activation.  
cGMP signals, including via β3-AR coupled signalling, have opposing effects on cAMP levels 
via their microdomain specific effect on different cyclic nucleotide-hydrolysing 
phosphodiesterases (PDEs) (Mongillo, Tocchetti et al. 2006; Zaccolo and Movsesian 2007; 
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Stangherlin, Gesellchen et al. 2011). Of the cAMP hydrolysing PDEs in the heart, PDE2 is of 
interest as it is potently stimulated by cGMP. cGMP is also hydrolysed by PDE2, however, 
the binding of cGMP to a regulatory domain on PDE2 results in an allosteric modification of 
PDE2 that lowers the apparent Km for cAMP and results in activation of the cAMP-
hydrolysing activity of the enzyme more than its competitive inhibition of it (Beavo, 
Hardman et al. 1971; Martinez, Beavo et al. 2002). Thus, stimulation of sGC with the 
resultant increase in cGMP could cause a decrease of cAMP and its downstream oxidant 
signals by increasing cAMP hydrolysis. Since cGMP binds directly to PDE2 to affect its 
activity, independent of any phosphorylation/dephosphorylation step, it is unclear where a 
potential PP2A step in such a mechanism would be.  
The molecular mechanisms of inactivation of PKC are still not well understood. The 
dephosphorylation of the turn motif (TM) and hydrophobic motif (HM) has been 
demonstrated to be involved in the inactivation and degradation of the α and βII isoforms of 
PKC enzyme. PP2A has been found to be associated with PKC (Lee, Lim et al. 2008). PP2A 
and PP1 have been shown to dephosphorylate PKC α and βII in vitro (Gysin and Imber 1997; 
Boudreau, Garduno et al. 2002). However, similar PP2A-dependent dephosphorylation of 
PKC has yet to be demonstrated in cardiac myocytes. There is evidence indicating that PP2A 
is involved in reversing the PKA mediated phosphorylation that is involved in the regulation 
of L-type Ca2+ channels in cardiac myocytes, though not specifically the dephosphorylation 
of protein kinases (Herzig and Neumann 2000; Dai, Hall et al. 2009). Further study is needed 
to ascertain the specific PP2A mediated role in modulation of both PKA and PKC mediated 
oxidant signalling to the Na+-K+ pump. 
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6.5 Conclusion  
Stimulation of sGC is able to the attenuate adenylyl cyclase-mediated increase in 
intracellular O2
 levels and downstream inhibition of the Na+-K+ pump in a PP2A-dependent 
manner.  
 
Chapter 7  142 
 
CHAPTER 7 
 
SUMMARY 
 
Data presented in this Thesis demonstrates the effects of stimulation of soluble guanylyl 
cyclase on oxidant signalling to the Na+-K+ pump and the signalling pathway and post 
translational modifications that lead to its attenuation of the effects of oxidant signalling on 
the Na+-K+ pump. This has important implications as a potential therapeutic strategy in heart 
failure which is characterised by increased oxidant stress, including from increased Ang II 
levels and increased β-adrenergic signalling to adenylyl cyclase, and decreased Na+-K+ pump 
activity.  
7.1 Novel Findings 
The following findings presented in this Thesis had not previously been described at the 
time this research was performed.  
1. Stimulation of sGC with YC-1 attenuates the effects of Ang II-induced inhibition of the 
Na+-K+ pump. 
2. The effect of YC-1 on Ang II-induced inhibition of the Na+-K+ pump is dependent on PP2A 
and is reproduced by activation of PP2A with C6-ceramide.  
3. Stimulation of sGC with YC-1 reduces Ang II-induced superoxide generation in a PP2A-
dependent manner. This correlates with a reduction in Ang II-induced NADPH oxidase 
activation and a reduction in interaction between NADPH oxidase and Na+-K+ pump subunits 
(α1).  
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4. The stimulation of sGC with YC-1 reduces baseline and Ang II-induced glutathionylation of 
the β1 subunit of the Na
+-K+ pump in a PP2A-dependent manner.  
5. The stimulation of sGC with YC-1 reduces adenylate cyclase-mediated increased 
superoxide levels and downstream inhibition of the Na+-K+ pump in a PP2A-dependent 
manner.  
These findings and their relevance to modulation of the Na+-K+ pump are summarized in 
Figure7.1 
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Figure 7.1 Schematic diagram summarising the findings of this Thesis. 
Stimulation of sGC attenuates Ang II-induced inhibition of the Na+-K+ pump (1) 
via PP2A (2). This results in a reduction of NADPH oxidase activity (3) with a 
reduction in cellular O2
 content. Stimulation of sGC attenuates Ang II- induced 
serine phosphorylation of p47phox and its colocalisation with the α1 subunit of the 
Na+-K+ pump, and the glutathionylation of the β1 subunit of the pump (4). sGC 
has similar attenuating effects on adenylyl cyclase-mediated increased O2
 levels 
and downstream inhibition of the Na+-K+ pump (5).  
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7.2 Overview 
Increased oxidative stress, including via receptor-mediated signalling from Ang II or β1/2-AR, 
is implicated as part of the pathophysiology of heart failure (Ferrario and Flack 1996; 
Rundqvist, Elam et al. 1997). Downstream deleterious effects of oxidant signalling include 
increased myocyte hypertrophy and fibrosis (Burgoyne, Mongue-Din et al. 2012) and 
inhibition of the Na+-K+ pump (White, Hamilton et al. 2008; Fuller, Tulloch et al. 2012). A 
mechanism to modulate oxidant signalling to attenuate these adverse effects would be 
useful as a strategy for treating heart failure. 
The increased activity of the nitric oxide signalling pathway by increased NOS activity or NOS 
substrates has been shown by some to attenuate the effects of oxidant stress in arterial 
hypertension (Fu, Qian et al. 2011), atherosclerosis (Wohlfart, Xu et al. 2008), left 
ventricular hypertrophy (Fraccarollo, Widder et al. 2008; Westermann, Riad et al. 2009; 
Ruiz-Hurtado and Delgado 2010) and pulmonary hypertension (Hagan and Pepke-Zaba 
2011). However, due to the potential of high levels of nitric oxide reacting with O2
 to form 
peroxynitrite and contribute to the oxidative stress in the cell, opposing effects of increased 
NOS activity have been reported (Ruiz-Hurtado and Delgado 2010). To circumvent the 
confounding effects of non-sGC dependent effects of NO, such as peroxynitrite formation, 
we directly studied the effects of stimulation of sGC. The results presented in this Thesis 
demonstrate that stimulation of sGC attenuates the inhibitory effects of Ang II on the Na+-K+ 
pump in cardiac myocytes via inhibition of NADPH oxidase activity and the downstream 
oxidative modification of glutathionylation of the Na+-K+ pump. This effect of sGC on the 
Na+-K+ pump and cellular O2
 content are PP2A-dependent and was similarly seen with 
adenylyl cyclase-mediated oxidant stress. These results also contribute to our further 
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understanding of phosphorylation/dephosphorylation dependent events regulating the Na+-
K+ pump, shifting the paradigm from the traditional emphasis on 
phosphorylation/dephosphorylation of the pump, to phosphorylation/dephosphorylation of 
the upstream targets leading to a change in oxidant signalling and hence oxidative 
modification of the pump.  
7.3 Future directions 
Further experiments that may be helpful in understanding the regulation of the Na+-K+ 
pump and the development of novel therapies for heart failure and other cardiovascular 
disease are discussed below 
7.3.1 PP2A and NADPH oxidase 
The results presented in this Thesis have demonstrated a critical role of PP2A in the effect of 
YC-1 in modulating redox-dependent regulation of the Na+-K+ pump via action on NADPH 
oxidase. However, the exact PP2A-dependent reaction has not been defined. As described in 
Chapter 4 and 6, the potential mechanisms include dephosphorylation-dependent 
inactivation of PKC or PKA and hence decreased NADPH oxidase activity. A more likely 
mechanism is that PP2A results in reduced serine phosphorylation, necessary for Nox 2 
activation, of p47phox. Further experiments to assess this include studying the effects of 
okadaic acid on the reduction of Ang II induced serine phosphorylation of p47phox by YC-1 as 
described in Chapter 4. Coimmunoprecipitation experiments to assess the presence of 
colocalisation of PP2A with p47phox, PKC and PKA, and the effect of YC-1 on this, would help 
delineate the PP2A-dependent steps. Further, while we were unable to assess the effects of 
adding PP2A to cardiac myocytes due to the high reductive effects of its diluent buffer 
 
Chapter 7  147 
 
resulting in cell death, one could study if PP2A is able to affect serine phosphorylation of 
p47phox when added directly to whole cell lysate. The use of a PP2A activator like C6 
ceramide could also be used to assess the effects of PP2A on the phosphorylation of the 
different potential targets.  
7.3.2 Effects of NO-independent, haem-independent sGC activators 
The results presented in this Thesis have been derived with the use of a haem-dependent 
sGC stimulator, YC-1, which sensitises sGC, with its haem moiety in the reduced state, to 
endogenous NO (Ko, Wu et al. 1994). The effects of sGC stimulation presented here have 
been seen with exposure of myocytes to YC-1 prior to exposure to Ang II or forskolin, thus, 
prior to exposure of sGC itself to increased oxidative stress. The effects of co-exposure of 
myocytes to both YC-1 and an oxidant stimulus would be the result of competition between 
stimulation of sGC by YC-1 and oxidation of the haem-moiety of sGC rendering it insensitive 
to YC-1 or NO. In keeping with our results presented in Chapter 5, stimulation of sGC with 
YC-1 concurrently with an oxidant stimulus is thus limited in its ability to attenuate the 
effects of oxidant signalling. On the other hand, NO-independent, haem independent sGC 
activators which currently have limited availability to researchers, such as BAY 58-2667 and 
BAY-60-2770 (Pankey, Bhartiya et al. 2011; Irvine, Ganthavee et al. 2012), activate sGC with 
its haem-moiety oxidised to the ferric state only. Thus, its potential to activate sGC and 
hence modulate redox signalling in the face of ongoing oxidative stress is greater than the 
haem-dependent sGC stimulators. Its use, either alone or in combination with a haem-
dependent sGC stimulator to harness the activity of reduced sGC as well, should result in 
greater attenuation and, potentially, greater reversal of the downstream oxidative 
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modification and inhibition of the Na+-K+ pump and present a more potent therapeutic 
strategy in heart failure.  
7.3.3 In vivo effects of β3-AR agonists, an upstream receptor-coupled activator of sGC 
As discussed in Chapter 5, β3-AR agonist have been shown to reduce both baseline 
(Bundgaard, Liu et al. 2010) and Ang II-induced (unpublished) oxidative modification of the 
Na+-K+ pump with concordant increases in Ip measurements. In vivo studies using a β3-AR 
agonist have been performed in failing and non-failing sheep hearts with acute 
haemodynamic measurements confirming a negative inotropic effect in the normal heart 
but not in the failing heart (Bundgaard, Liu et al. 2010). While confirmed to be NOS-
dependent, it is still to be confirmed if the effects of β3-AR activation on the Na
+-K+ pump 
are PP2A-dependent or even a result of inhibition of NADPH oxidase activity. Others have 
demonstrated that β3 AR activates the nitric oxide/cGMP/PKG pathway (Angelone, Filice et 
al. 2008; Gauthier, Rozec et al. 2011) thus potentially activating the same sGC activated 
redox-modulating reaction cascade presented in this Thesis. Thus, while soluble guanylyl 
cyclase activity can be modulated directly with stimulators and activators, a more 
physiological mechanism of activating this pathway would be activation of an upstream 
receptor, specifically the β3-AR, and assessing its effects in heart failure which is a 
phenotype with increased oxidative stress. A phase IIb, randomised, double blind, placebo-
controlled trial using a β3-AR agonist, mirabegron, in heart failure patients on optimal 
conventional therapy is in development and will help to delineate the clinical effects of the 
signalling pathway presented in this Thesis (BEAT-HF). 
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7.4 Relationship to recently published literature 
7.4.1 cGMP and NADPH oxidase 
Data presented in this Thesis, with stimulation of sGC attenuating NADPH oxidase activity in 
cardiomyocytes, is consistent with that seen by other investigators. As discussed in Chapter 
4, activation of sGC in cardiomyocytes with nitroxyl (Lin, Irvine et al. 2012)or BAY 58-2667 
(Irvine, Ganthavee et al. 2012) has been demonstrated to suppress NADPH oxidase derived 
O2
 generation. YC-1 increases cGMP by stimulating sGC but the compound has also been 
found to be an inhibitor of cGMP-hydrolysing phosphodiesterase type 5 (PDE5). Such PDE5 
inhibition is expected to act synergistically on cGMP levels with the effect to stimulate sGC-
mediated synthesis (Friebe, Mullershausen et al. 1998; Evgenov, Pacher et al. 2006) but it 
might affect the cGMP pool in a different microdomain.  
Elevation of cGMP levels independent of sGC has been shown to attenuate NADPH oxidase 
activity. An increase in cGMP in vascular smooth muscle cells either by the addition of a 
cGMP analogue or activation of pGC has been shown to suppress NADPH oxidase activity 
(Gao, Qian et al. 2009). Sildanefil, a potent inhibitor of PDE5 has been shown to inhibit 
NADPH oxidase activity and O2
 production in vascular smooth muscle cells (Koupparis, 
Jeremy et al. 2005) and the vascular wall in diabetic rats (Luo, Dai et al. 2011). Consistent 
with this, our Laboratory has demonstrated that inhibition of PDE5 with T-1032 stimulates 
the Na+-K+ pump (Hamilton 2011). There is however potential crosstalk between cGMP to 
cAMP due in part to the inhibition by cGMP of PDE3, which preferentially breaks down 
cAMP. Thus, depending on the microdomain it is within, an increase in the pool of cGMP can 
potentially have opposing effects on redox signalling and is the subject of further research in 
our Laboratory.  
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7.4.2 Role of phosphatases and dephosphorylation 
The results in this Thesis demonstrates the role of PP2A in the modulation of redox 
signalling to the Na+-K+ pump by sGC. The effect of stimulation of sGC in attenuating 1) Ang 
II- and forskolin-induced Na+-K+ pump inhibition ,2) Ang II- and forskolin-induced increase in 
O2
-sensitive DHE fluorescence and 3) baseline and Ang II-induced glutathionylation of the 
β1 subunit of the Na
+-K+ pump was demonstrated to be PP2A dependent. The traditional 
paradigm of regulation of the Na+-K+ pump by kinase-mediated phosphorylation of the 
catalytic α-subunit presents a convenient parallel of counter-regulation by PP2A-mediated 
dephosphorylation. However, just as there are no putative phosphorylation sites on the Na+-
K+ pump that are easily accessible to kinases (Sweadner and Feschenko 2001; Galougahi, Liu 
et al. 2012), this paradigm is similarly flawed by the lack of putative PP2A binding sequences 
in the primary structure of the pump. (Kimura, Han et al. 2011). The demonstration of YC-1’s 
effect on Ang II- and forskolin-induced cellular O2
 levels being PP2A dependent is 
consistent with results published by others on the role of protein phosphatases in the 
regulation of NADPH oxidase. Antagonists to protein phosphatases 2A and 1 have been 
shown to potentiate the respiratory burst in neutrophils and macrophages as discussed in 
section 1.5.4. (Yamaguchi, Sasaki et al. 1993; Bengis-Garber and Gruener 1995; Djerdjouri, 
Combadiere et al. 1995; Dorseuil, Quinn et al. 1995; Gay, Raddassi et al. 1997; Forman, Zhou 
et al. 1998). Protein phosphatases have also been shown to attenuate phosphorylation of 
p47phox (Bengis-Garber and Gruener 1995; Yamaguchi, Saeki et al. 1996), reduce the 
membrane translocation of the cytosolic components of NADPH oxidase (Dorseuil, Quinn et 
al. 1995) and result in disassembly of the active NADPH oxidase complex in stimulated 
neutrophils (Curnutte, Erickson et al. 1994).  
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Phosphorylation/dephosphorylation of p47phox has been the predominant focus in the study 
of intracellular signalling pathways involved in NADPH oxidase activation. As indicated from 
these previous studies and from the data presented in this Thesis, PP2A directly or indirectly 
may reduce phosphorylation of p47phox and hence reduce NADPH oxidase activity. 
Dephosphorylation of other NADPH oxidase subunits may also play a role. Egger et al have 
demonstrated that translocation of p67phox from the cytosol to the membrane, which is 
necessary for activation of NADPH oxidase, can be attenuated by a PP1- or PP2A-mediated 
pathway in microglial cells (Egger, Hammer et al. 2001). More recently, in neutrophils, Dang 
et al demonstrated that p67phox is constitutively phosphorylated in a process that is 
antagonized by PP1/PP2A and may play a role in regulation of NADPH oxidase activity (Dang, 
Raad et al. 2011). 
The findings of this Thesis demonstrate a phosphatase-dependent step in the regulation of 
the Na+-K+ pump that is upstream from the pump, at the level of NADPH oxidase activity, 
and reduces the oxidative modification, glutathionylation, of the Na+-K+ pump. 
Glutathionylation as the molecular mechanism mediating oxidative inhibition of the Na+-K+ 
pump is slow to be widely adopted in the Na+-K+ pump field. Kinase-mediated regulation of 
the pump has traditionally been thought to be mediated by direct phosphorylation of amino 
acids residues on the α-subunit of the Na+-K+ pump and more recently published literature 
has focused on phosphorylation of the FXYD1 accessory protein as the endpoint of Na+-K+ 
pump modulation by kinases (Madhani, Hall et al. 2010; Fuller, Tulloch et al. 2012). Recent 
work from our Laboratory has demonstrated that this can be accounted for by the role of 
kinases in activating NADPH oxidase, and that the molecular mechanism that mediates 
pump inhibition is glutathionylation of Cys46 of the β1 pump subunit (Figtree, Liu et al. 
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2009; White, Figtree et al. 2009). The work presented in this Thesis, by demonstrating that a 
mechanism to decrease the inhibitory effects of Ang II-induced oxidative stress on the pump 
is mediated by protein phosphatases decreasing the previously described effects of kinases 
on NADPH oxidase activity and glutathionylation of the β1 pump subunit, further supports 
the key role of glutathionylation as the molecular mechanism mediating oxidative inhibition 
of the Na+-K+ pump. The precise PP2A-mediated reaction may be dephosphorylation and 
hence inactivation of PKA or PKC or dephosphorylation of NADPH oxidase subunits and 
hence inactivation of NADPH oxidase. This requires further investigation.  
7.5 Implications in clinical practice 
The heart failure phenotype is characterised by increased oxidant stress and increased 
cytosolic sodium which is detrimental. The oxidant signalling that inhibits the Na+-K+ pump 
further increases the cytosolic sodium by inhibiting its extrusion by the pump. The 
attenuation of induced oxidant signalling by sGC and the restoration of Na+-K+ pump activity 
thus has implications for cellular sodium handling and treatment of heart failure.  
Studies using sGC stimulators and activators have demonstrated haemodynamic benefits 
with unloading of the heart from its vasodilatory effects and changes to vascular resistance 
in experimental animal models of congestive heart failure. BAY 41-2272 improved cardiac 
output by afterload reduction rather than increased inotropy in a pacing-induced canine 
model of heart failure (Boerrigter, Costello-Boerrigter et al. 2003; Boerrigter and Burnett 
2007). A sGC activator, cinaciguat (BAY 58-2667) similarly decreased blood pressure and 
unloaded the heart in a pacing-induced canine model of heart failure (Boerrigter, Costello-
Boerrigter et al. 2007). These initial studies led to the first human studies in acute 
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decompensated heart failure using cincaciguat as an intravenous sGC activator. While the 
initial studies were promising (Lapp, Mitrovic et al. 2009), the phase IIb randomised 
controlled trial, COMPOSE II, was terminated early as intravenous cinaciguat was found to 
decrease blood pressure without improving dyspnoea or cardiac index (Gheorghiade, 
Greene et al. 2012). These human studies were acute studies using an intravenous 
preparation. It is possible that the effects of cinaciguat on endothelial function rather than 
its effects on redox-dependent regulation of cardiomyocyte function was the predominant 
outcome seen in this acute study at the intravenous doses used. Further, a recent study has 
demonstrated oxidative stress having different effects in different tissues on sGC 
responsiveness to a sGC stimulator compared to a sGC activator (Costell, Ancellin et al. 
2012). Thus, despite COMPOSE II being a negative trial, modulation of sGC activity still 
warrants further investigation as a therapeutic tool in heart failure, with chronic use of oral 
agents to see the effect of long term attenuation of oxidative signalling, or use of a sGC 
stimulator in combination with a sGC activator, or use or an activator of an upstream 
receptor such as the β3-AR agonist which is a trial that is about to be undertaken.  
7.6 Conclusion 
Stimulation of sGC attenuates oxidative inhibition of the cardiac Na+-K+ pump induced by 
Ang II. This effect of sGC is PP2A-dependent and is associated with an attenuation of Ang II- 
induced cellular O2
 levels, NADPH oxidase activation and β1 subunit glutathionylation 
(which is casually related to Na+-K+ pump inhibition). Similar effects are seen when the 
adenylyl cyclase activator, forskolin, is used as the oxidative stimulus. These conclusions 
have important physiological and pathophysiological implications in view of the crucial role 
that the Na+-K+ pump plays in cardiac myocyte homeostasis and function. There is particular 
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relevance in cardiovascular diseases associated with increased oxidative stress, such as 
heart failure, where sGC may act as a brake to, or potentially reverse, the oxidant signal and 
its consequences. Thus, increase in sGC activity either by direct activators and stimulators, 
or by activation of an upstream receptor such as the β3-AR, presents a potential therapy for 
heart failure that warrants further investigation. 
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